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Summary
The complement system has become a therapeutic target due to its involvement in a 
number of inflammatory conditions. Soluble recombinant forms of the membrane- 
associated regulators (CReg) have been created as therapeutics. However, these 
reagents are limited by their short half-lives in vivo and their tendency to 
systemically inhibit complement. To extend their circulating half-lives Fc fusion 
proteins have been generated while targeting reagents to sites of inflammation or 
inhibiting specific parts of complement, such as the terminal pathway, has been used 
to overcome systemic complement inhibition. Many of the reagents generated to 
date are based upon human proteins and are therefore immunogenic in rats, 
preventing their testing in rat models of chronic disease. To enable the testing of 
anti-complement therapeutics in rat models of chronic disease, various CReg-Fc 
containing a rat Fc and different portions of rat Crry were generated in this study. 
Functional analysis of the generated reagents was carried out to identify two different 
Crry-Fc. One would retain full activity while the other would address the issues of 
systemic complement inhibition by having negligible activity in the circulation, due 
to steric hindrance imparted on the Crry by the Fc, but could be cleaved at 
inflammatory sites to unleash an active regulator. A Crry-Fc that retained full 
activity was identified and tested in vivo. This reagent had a long circulating half- 
life, low immunogenicity and markedly reduced disease severity in a rat model of 
myasthenia gravis. Attempts to generate a Crry-Fc that had negligible activity in the 
circulation but could be cleaved at inflammatory sites to unleash anti-complement 
activity were unsuccessful. The generation of the active Crry-Fc reagent paves the 
way to testing anti-complement therapeutics in rat models of chronic disease.
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Chapter 1: Introduction.
1.1 The Complement System
The complement (C) system, discovered as a heat-labile component of blood plasma, 
that “complemented” the action of antibodies, consists of more than 30 proteins in 
plasma or on cell surfaces. The proteins are part of the innate immune system, which 
acts as an early defence against infectious organisms. The C system is a cascade 
mechanism that brings about cell death or damage, opsonisation of pathogens, 
induction of inflammatory responses and clearance of immune complexes. It 
involves three activation pathways, known as the classical, alternative and lectin 
pathways, these all lead into a common terminal pathway. The classical activation 
pathway (CP) is initiated by the binding of the first C component, Clq, to aggregated 
IgG or IgM on a pathogen’s surface. The alternative pathway (AP) proceeds in the 
absence of a specific antibody and is initiated by the target surface itself; this 
pathway can also act as an amplification loop for both the classical and lectin 
pathway. The lectin pathway (LP) is triggered by mannan-binding lectin or ficolins 
binding to sugar residues that are abundant in bacterial cell walls. The terminal 
pathway results in the formation of the membrane attack complex (MAC), a lytic 
pore that brings about osmotic lysis of the cell. The C system is summarised in 
figure 1.1 and the pathways are described in more detail below.
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Classical pathway
IgM or an 
array of IgG
Lectin Pathway 
Microbes/mannose Alternative pathway
MBL/MASPs C3(H20)Bb
Properdin
C3bBC4b2
C3bBbC4b2a
C3b
C5
C4b2a3b C3bBb3b
C5a
C5b
▼
C5b6
Terminal pathway
C6
C l
C5b67 (C5b-7) 
-C8
C5b-8
  Multiple C9
C5b-9 (MAC)
Figure 1.1 The complement system.
A schematic diagram of the activation and terminal pathways of the C system. Activation 
of the C system can occur via three pathways; the classical, alternative or lectin pathway. 
All three activation pathways lead into a common terminal pathway that results in the 
formation of a lytic pore, the membrane attack complex (MAC).
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1.1.1 The classical activation pathway
The binding of C lq to IgM or aggregated IgG activates the CP on target surfaces. 
C lq forms part of C l, a large hetero-oligomeric complex consisting of one molecule 
of Clq, two molecules of C ls and two molecules of C lr non-covalently associated in 
a calcium dependent manner. Clq consists of 18 polypeptide chains (6A, 6B and 6C 
chains) wound together to form a collagen-like tail with six large globular heads 
(Reid and Porter 1976). C lq binds via these heads to the Fc portion of activating 
antibody. When multiple heads of C lq bind a conformational change occurs within 
C lq causes a conformational change in the two attached C lr molecules. This 
conformational change within the C lr molecules enables them to cleave each other at 
a single site close to the N-terminus. The auto-activated C lr then cleaves C ls at a 
single site close to the N-terminus activating this serine protease. C ls enzymically 
cleaves C4 the next component (Gaboriaud, Thielens et al. 2004).
C4 is a large plasma protein containing 3 disulphide-bonded chains; a, p and y 
(Schreiber and Muller-Eberhard 1974). It is cleaved by C ls at a single site near to 
the N-terminus of the a-chain resulting in the generation of a smaller fragment C4a 
(9kDa) and a larger fragment C4b (190kDa). Cleavage of C4 to C4b results in a 
conformational change revealing an internal thioester in C4b, this thioester can 
rapidly react with amine or hydroxyl groups present on activating surfaces. In this 
way C4b becomes covalently bound to the surface (Law and Dodds 1997). 
However, the binding of C4b to target surfaces is inefficient; typically only 10% of 
the C4b generated binds to the target surface. The exposed thioester may be 
hydrolysed by H2O, preventing the binding of C4b to the target surface serving as a 
way of restricting C activation to the vicinity of the activating Cl complex.
In the presence of magnesium, membrane bound C4b acts as a receptor for the next 
component C2. C2 is cleaved by C ls resulting in release of an N-terminal fragment 
C2b. (Nagasawa and Stroud 1977). The larger fragment, C2a remains attached to 
C4b forming the C3 convertase, C4b2a. The C2a within this enzyme cleaves C3 the 
next C component. C3 consists of two disulphide-bonded chains, a  and P, and is 
cleaved in the a-chain releasing C3a (9kDa), a pro-inflammatory peptide (Lambris 
1988). An internal thioester is exposed in C3b, the remaining fragment, which binds 
through the thioester to the C3 convertase to form a C5 cleaving enzyme, C4b2a3b.
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The C3b may also bind to the adjacent membrane (Law and Dodds 1997). The 
coating of membranes with C3b is called opsonisation and mediates interactions with 
phagocytic cells (see section 1.2.1)
C5 is the first component of the terminal pathway and is a two-chain plasma protein 
that binds non-covalently to the C5 convertase. C5 is cleaved by C2a at a single site 
in the a-chain, releasing a small pro-inflammatory fragment C5a (llkDa). The 
larger fragment C5b (181kDa) contains a labile hydrophobic surface binding site and 
a binding site for C6 (Loos 1985) (figure 1.1).
1.1.2 The alternative pathway
The AP is antibody independent and is initiated by the binding of C3b to an 
activating surface. This C3b may arise from the cleavage of C3 through classical or 
lectin pathway activation and in this way the AP serves as an amplification loop for 
these pathways. Alternatively, the C3b may arise due to a process called ‘tickover’. 
In ‘tickover’ the internal thioester of C3 undergoes spontaneous hydrolysis at a slow 
rate, about 1% of the total C3 in plasma per hour. A conformationally altered C3 
arises called C3(H20), a C3b-like molecule. This C3b-like molecule can bind factor 
B (fB; 93kDa) in solution enabling a constitutively active serum protease, factor D 
(fD; 26kDa), to cleave fB (Volanakis and Narayana 1996). Factor B is cleaved at a 
single site resulting in release of a smaller fragment Ba (30kDa) and the generation 
of a larger fragment Bb (63kDa). The cleavage into Bb activates a serine protease 
domain within the molecule which forms a fluid phase C3 convertase, C3(H20)Bb. 
This enzyme can bind and cleave C3 resulting in deposition of C3b on adjacent 
surfaces and AP activation. The generated C3b binds fB in a magnesium dependent 
manner rendering it susceptible to cleavage by fD as before and results in the 
generation of C3bBb, the AP C3 convertase. This convertase is stabilised and its 
lifetime extended by the binding of properdin, the only known positive regulator of C 
(Hourcade 2006). The resultant C3b from this convertase may become surface 
bound acting to recruit more fB, amplifying the C3 convertase formation, or it may 
bind to the C3 convertase to form a C5 convertase, C3bBbC3b. C3bBbC3b can bind 
C5 allowing the cleavage of C5 by Bb and thereby marking the beginning of the 
terminal pathway (Xu, Narayana et al. 2O0l) (figure 1.1).
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1.13 The lectin pathway
The LP is activated when mannan-binding lectin (MBL) or ficolins bind to sugar 
residues in bacterial cell walls. MBL is a serum C-type lectin structurally similar to 
Clq, consisting of multiple copies of a single subunit composed of three identical 
polypeptide chains. The polypeptide chains form a helical collagen-like domain and 
C-terminal carbohydrate recognition domains (CRD). Through the CRD, MBL 
binds carbohydrates in the presence of calcium while it is associated with MBL- 
associated serine proteases (MASPs) through the collagen like domain. Ficolins 
consist of a collagen like domain, through which they are also associated with 
MASPs, and a fibrinogen like domain through which they bind to carbohydrates 
(Endo, Takahashi et al. 2006). There are three MASPs which are associated with 
MBL and ficolins: MASP-1, MASP-2 and MASP-3. MASP-3 is an alternatively 
spliced form of MASP-1 while MASP-2 has an alternatively spliced form, sMAP 
which lacks the serine protease domain and is believed to compete with MASPs for 
binding to MBL and ficolins. The binding of MASPs to MBL or ficolin activates 
MASPs by promoting their auto-activation through cleavage at a single site, 
analogous to the activation of C lr and C ls when bound to Clq. While three MASPs 
exist, MASP-2 is sufficient for LP activation. The function of MASP-1 and 3 remain 
unclear. MASP-2 cleaves C4 and C2, as C ls does in the CP, generating the C3 
convertase (Hajela, Kojima et al. 2002; Sorensen, Thiel et al. 2005). The pathway 
then follows the same cascade as the CP (figure 1.1).
1.1.4 The terminal pathway
All three activation pathways lead into the membrane attack or terminal pathway. 
Whilst still attached to the C5 convertase, C5b binds C6, a single chain protein, 
resulting in a conformational change in C6 that exposes a C7 binding site. Once C7 
attaches to the complex a further conformational change occurs resulting in the 
detachment of C5b67 from the convertase. The fluid phase C5b-7 complex contains 
a transient, high-affinity lipid binding site that is susceptible to inactivation by 
hydrolysis or interaction with other plasma proteins, C5b-7 that does encounter the 
membrane physically associates with it. The next component C8 consists of 3 chains 
(a, P and y). C8 binds to the C5b-7 complex through its P-chain. The C5b-8
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complex can cause slow lysis of erythrocytes as the a-chain of C8 inserts through the 
membrane causing them to become leaky (Schreck, Parker et al. 2000). The final 
component, C9, binds to the a-chain of C8 and unfolds, inserts into the membrane 
and increases leakiness. The unfolding of C9 enables polymerisation of further C9 
molecules which also insert into the membrane forming a pore-like structure called 
the membrane attack complex (MAC) (Podack and Tschopp 1984). The MAC 
increases permeability leading to osmotic lysis of simple cells such as erythrocytes or 
in bacteria it disrupts the outer membrane increasing permeability and inducing lethal 
changes in the inner membrane.
1.2 The physiological roles of C
C not only mediates the killing of invading pathogens either directly through the 
formation of the MAC or indirectly through enhancement of phagocytosis, but is also 
involved in the solubilisation of immune complexes, the induction of humoral and 
cellular immune systems, the clearance of apoptotic cells and the activation of certain 
cell types.
1.2.1 Bacterial killing
C can kill pathogens through the formation of the MAC on the cell surface 
(discussed 1.14) or through the induction of phagocytosis. Pathogens or cellular 
debris opsonised with C3b or its breakdown products, iC3b and C3dg, are recognised 
by phagocytic cells via complement receptors expressed on these cells (Taylor 1983). 
C3a and C5a, released during C activation, enhance phagocytosis by stimulating the 
migration of neutrophils, eosinophils, basophils and monocytes which express 
receptors for these fragments (Hugli 1981). These anaphylatoxins can also activate 
cells increasing vascular permeability, causing smooth muscle contraction and 
histamine release from mast cells and basophilic leukocytes.
1.2.2 Immune complex clearance
Immune complexes, antigen-antibody complexes, become more insoluble as they 
grow resulting in precipitation and inflammation. C plays several roles in clearing
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immune complexes. Firstly, the complex itself can activate C resulting in 
opsonisation of the complex preventing further growth by masking antigenic sites. 
Opsonisation of large immune complexes with C3b can break apart the complex 
resulting in it disaggregating. Secondly, C3b and C4b on the immune complex can 
bind CR1 (CD35), a complement receptor expressed on erythrocytes. Binding to 
erythrocytes via CR1 results in the removal of the complex from the circulation as 
the complexes are carried to the liver and spleen where they are internalised and 
degraded (Schifferli 1996).
1.2 3  Humoral immune response
The discovery that a transient reduction in C3 led to impairment in antibody response 
suggested that C was involved in adaptive immunity (Pepys, Miijah et al. 1976). 
Opsonisation of antigen containing complexes with C3b enhances B cell immunity. 
The complement receptor CR2 (CD21) binds C3b opsonised antigens and forms a 
receptor complex with CD 19 and CD81, the B cell receptor. Co-engagement of 
CD21-CD19-CD81 lowers the threshold for B cell activation (Dempsey, Allison et 
al. 1996). The expression of CR1 and CR2 on follicular dendritic cells (FDCs) 
serves to retain C3-coated antigen within the lymphoid compartment where antigen 
is presented to B and T lymphocytes (Carroll 2004).
1.2.4 Apoptosis
C influences apoptosis in diverse ways. Firstly, C can protect cells from undergoing 
apoptosis. C5a inhibits spontaneous apoptosis in neutrophils while the MAC can 
inhibit apoptosis of cells in the central nervous system by up-regulating anti- 
apoptotic genes and down-regulating pro-apoptotic genes (Lee, Whyte et al. 1993; 
Rus, Niculescu et al. 2001). Secondly, C plays a role in the clearance of apoptotic 
cells. C lq binds apoptotic cells and via specific receptors on phagocytes including 
CD91 and calreticulin it initiates phagocytosis (Ogden, deCathelineau et al. 2001). 
The opsonisation of apoptotic bodies with fragments of C4 and C3 also aids the 
recognition and clearance via interaction of the C fragments with C receptors on 
phagocytes. *
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1.2.5 Cell activation
C activation at a cell surface does not always result in cell death. Cells are protected 
by the expression of regulators (discussed section 1.3), inactivation of C components 
by hydrolysis, proteolysis or phosphorylation at the cell surface, or due to the active 
removal of MAC by a cell. MAC can be removed from cell membranes via shedding 
on membrane vesicles or internalisation and degradation (Hansch, Betz et al. 1984). 
The deposition of MAC on a cell membrane that does not result in cell death is 
referred to as sub-lytic attack. Sub-lytic attack activates phagocytes resulting in 
release of inflammatory mediators such as prostaglandins, thromboxanes, 
leukotrienes and reactive oxygen species. On aortic smooth muscle cells and 
Schwann cells sub-lytic attack stimulates cell proliferation (Niculescu, Badea et al. 
1999; Dashiell, Rus et al. 2000).
13 Complement Regulation
To prevent inappropriate C attack on self-cells an array of C regulators (CReg) exist. 
A group of over 10 proteins regulate either in the fluid-phase or on the membrane of 
host cells. These regulators inhibit the activation pathways and the terminal pathway 
of C. The CRegs found in humans are summarised in table 1.1 and a schematic of 
their sites of action is shown in figure 1.2.
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Regulator Location Ligand Function
Cl-inh Plasma Cl Dissociates the activated Cl complex and acts 
as a chaperone for Cl in plasma preventing 
spontaneous fluid phase activation.
C4bp Plasma C4b Accelerates the decay of the CP convertases 
and acts as a cofactor for the factor 1 mediated 
cleavage of C4b.
Factor H Plasma C3b Accelerates decay of AP convertases and acts 
as cofactor for factor I mediated cleavages of 
C3b.
Factor I Plasma C4b, C3b In conjunction with a cofactor cleaves C3b 
and C4b inactivating them.
CR1
(CD35)
Membrane C4b, C3b, 
iC3b
Possesses decay accelerating activity and 
cofactor activity.
DAF
(CD55)
Membrane C4b, C3b Accelerates decay of the convertases.
MCP
(CD46)
Membrane C4b, C3b Acts as a cofactor for factor I mediated 
cleavages of C4b and C3b.
S-Protein Plasma C5b-7 Binds C5b-7 in the fluid phase preventing 
binding to a membrane.
Clusterin Plasma C5b-7 Binds C5b-7 in the fluid phase masking the 
membrane-binding site.
CD59 Membrane C5b-8 Binds to C5b-8 complex preventing multiple 
C9 from binding and forming the MAC
Rat regulaltors
Rat DAF Membrane C4b, C3b Accelerates decay of the convertases.
Rat MCP Membrane 
(testis 
' specific)
C3b, C4b Can act as a cofactor for factor I but 
expression pattern suggests it has more of a 
role in reproduction.
Rat Crry Membrane C3b, C4b Acts as a decay accelerator of the convertases 
and as a cofactor for factor I.
Rat CD59 Membrane C5b-8 Binds to C5b-8 complex preventing multiple 
C9 from binding and forming the MAC
Table 1.1 Complement regulatory proteins.
A summary of the CReg found in humans as well as the membrane-associated 
regulators found in rats.
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Classical pathway
IgM or an 
array of IgG
Cl-inh  -
Lectin Pathway 
Microbes/mannose Alternative pathway
MBL/MASPs C3(H20)Bb
Factor I
C3bBC4b2
C4b2a C3bBb
MCP
C4b2a3b C3bBb3b
MCP
Factor H 
Factor I
C5b
C6
t
C5b6
Terminal pathway
C7 S-ProteinClusterin
C5b-7 *
C8
C5b-8
CD59 Multiple C9
C5b-9 (MAC)
Figure 1.2 Regulation of C.
A schematic showing the site of action of the CReg on the activation and terminal 
pathways (dashed arrows). Fluid phase regulators are shown in blue in italics, 
whilst the membrane bound are in green.
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1.3.1 Regulation of the activation pathways
Fluid phase regulation o f the activation pathways is carried out by Cl-inhibitor (Cl- 
inh), C4b binding protein (C4bp), factor H (fH) and factor I (fl). Decay-accelerating 
factor (DAF; CD55), complement receptor 1 (CR1; CD35) and membrane cofactor 
protein (MCP; CD46) are membrane-associated regulators.
1.3.1.1 The RCA cluster
Many of the regulators o f C activation have structural similarities and are encoded 
within a gene cluster on chromosome 1, termed regulators o f complement activation 
(RCA) cluster. In humans the members of the RCA cluster that regulate C are fH, 
C4bp, MCP, DAF and CR1. All the RCA proteins interact with the activation 
products o f C3 or C4 and contain compact globular domains known as short 
consensus repeats (SCRs). An SCR contains approximately 60 amino acids with a 
consensus sequence containing four invariant cysteine residues, an invariant 
tryptophan and highly conserved glycine and proline residues (figure 1.3). The 
cysteine residues form 2 intradomain di sulphide bonds that help maintain the six- 
stranded anti-parallel P-sheets o f the SCR (Barlow, Baron et al. 1991; Chou and 
Heinrikson 1997).
:o o h
Figure 1.3 The SCR domain.
A diagram showing the compact globular nature o f an SCR, the disulphide 
bonds (red) maintain the structure of the SCR. Amino acids are shown in 
blue with the cysteine residues labelled (C).
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C4b2a
Factor I
Figure 1.4 Decay acceleration and cofactor activity.
A. CReg that possess decay accelerating ability, such as DAF, accelerate the 
natural decay o f the convertases shown here with the C3 convertase 
dissociating into its constituent proteins, C4b and C2a. The components o f the 
convertase cannot reassemble following dissociation. Without this regulation 
the C3 convertase would form the C5 convertase and C activation would 
proceed.
B. CReg that act as cofactors, such as MCP, promote the inactivation o f C3b and 
C4b by enabling their cleavage by factor I. Here, C3b has been cleaved into 
iC3b and C3f by the action of factor I with MCP.
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1.3.1.2 C4b binding protein
C4bp regulates the CP and LP by accelerating the decay of the preformed C3 
convertase (figure 1.4A), preventing the association of C4b with the convertase 
subunits or by acting as a cofactor for the fl mediated cleavage of C4b (Gigli, Fujita 
et al. 1979). As a cofactor for fl (see below), C4bp binds C4b inducing a 
conformational change that renders C4b susceptible to cleavage and inactivation by 
fl. C4b is cleaved into iC4b and further into C4c and C4d (Seya, Nakamura et al. 
1995) (figure 1.4B). C4bp has an oligomeric structure with isoforms containing 
different compositions of a and p chains. The most common isoform contains seven 
a-chains, each containing 8 SCRs, and one p-chain, containing 3 SCRs. The chains 
are covalently linked at the C-terminus by disulphide bonded cysteine residues 
(Chung and Reid 1985) (figure 1.5A).
1.3.13 Factor H
Factor H, a single chain glycoprotein, consists of twenty SCRs and regulates the AP 
(figure 1.5B) (Ripoche, Day et al. 1988). It prevents the amplification of the AP by 
binding to C3b preventing association with fB, by accelerating the natural decay of 
the C3 and C5 convertases or by acting as a cofactor for the fl mediated cleavage of 
C3b. As a cofactor for fl, fH promotes the cleavage of C3b resulting in the 
formation of inactive C3b (iC3b) and the release of C3f (Harrison and Lachmann 
1980).
1.3.1.4 Cl inhibitor.
Cl-inh, a member of the serine protease inhibitor family (serpin), inactivates several 
different proteases. It inactivates Clr, C ls and MASPs in the C system in addition to 
Factor XII and kallikrein in the contact system, Factor XI and thrombin in the 
coagulation system and tissue plasminogen activator and plasmin in the fibrinolytic 
system. An exposed reactive loop within Cl-inh acts as a pseudo-substrate for the 
protease. Cleavage of this loop by a protease results in a conformational change 
trapping the protease in a complex with Clinh (Bos, Hack et al. 2002). In addition to 
acting as a substrate for Clr, C ls and MASPs resulting in their inactivation, Cl-inh
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acts as a chaperone for Cl in plasma preventing spontaneous activation (Tenner and 
Frank 1986).
13.1.5 Factor I
Factor I is a two-chain serine protease that, in the presence of a cofactor (C4bp, fH, 
MCP or CR1), cleaves C3b or C4b within their a ’-chains thereby inactivating them 
(figure 1.4B) (Tsiftsoglou, Willis et al. 2005). C3b is cleaved into iC3b and C3f 
(Harrison and Lachmann 1980). In the presence of CR1, C3 can be degraded further 
into C3c and C3dg (Ross, Lambris et al. 1982). The cleavage of C4b proceeds via 
iC4b, which is rapidly cleaved to give C4c and C4d (Shiraishi and Stroud 1975; 
Nagasawa, Ichihara et al. 1980)
13.1.6 Complement receptor 1
CR1, a transmembrane protein, regulates both the CP and AP. Four allelic variants 
of CR1 exist; the most common consists of 30 SCRs and has a molecular weight of 
190kDa. Based on a degree of internal homology, all except the two C-terminal 
SCRs are arranged into larger units of 7 SCRs called Long Homologous Repeats 
(LHRs). CR1 serves to clear immune complexes from the circulation (discussed 
1.2.2) and also regulates C by accelerating the decay of the C3 and C5 convertases in 
addition to acting as a cofactor for the fl-mediated cleavages of both C3b and C4b. 
CR1 is the only cofactor in humans to act as a cofactor for the third fl-mediated 
cleavage of C3b into C3dg (Krych-Goldberg and Atkinson 2001).
13.1.7 Decay Accelerating Factor (DAF)
DAF, a 70-80kDa glycoprotein, accelerates the natural decay of the C3 and C5 
convertases of both the CP and AP. DAF consists of four SCRS, a region rich in 
serine, proline and threonine (STP) residues and a GPI-anchor (figure 1.6). SCRs 2 
and 3 regulate the CP while SCRs 2-4 are necessary to regulate the AP (Coyne, Hall 
et al. 1992). A hydrophobic patch between SCRs 2 and 3 appears to be necessary for 
function (Lukacik, Roversi et al. 2004). DAF interacts with the individual 
components of the convertase (i.e. C3b and Bb or C2a) with a much lower affinity
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than for the whole convertase enabling DAF to selectively bind and decay the active 
convertase (Harris, Abbott et al. 2005).
1.3.1.8 Membrane Cofactor Protein (MCP)
MCP is an abundantly expressed cofactor for the fl-mediated cleavage of C3b into 
iC3b and C4b into C4c and C4d (Seya, Turner et al. 1986; Seya and Atkinson 1989). 
MCP is capable of regulating all the activation pathways of C but evidence suggests 
it has a major role in regulating the AP of C and can only act on C3b that is not part 
of a convertase (Barilla-LaBarca, Liszewski et al. 2002). MCP consists of 4 N- 
terminal SCR domains, a heavily glycosylated STP region, a small segment of 12 
amino acids of unknown function followed by a transmembrane region and a 
cytoplasmic domain (figure 1.6) (Lublin, Liszewski et al. 1988). Alternative splicing 
gives rise to 3 different STP regions, A, B and C, as well as different cytoplasmic 
tails including cyt-1 (16 amino acids) and cyt-2 (23 amino acids) (Post, Liszewski et 
al. 1991). C4b binding and cofactor activity has been located to SCRs 2-4 although 
SCR 1 is required for optimal activity while C3b cofactor activity resides in SCRs 2- 
4 with SCRS 3 and 4 binding C3b (Adams, Brown et al. 1991).
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a-chain
p-chain
C4bp
B.
Factor H
Figure 1.5 The structure of fluid phase regulators of complement 
activation that are encoded within the RCA cluster.
A. The structure o f the most common isoform o f C4bp. It consists o f 7 
a-chains (blue) each containing 8 SCRs and 1 p-chain (red) 
containing 3 SCRs covalently linked at the C-terminus by disulphide 
bonded cysteine residues.
B. The structure of fH consists solely o f 20 SCRs (blue circles).
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CR1
LHR-A
LHR-B
LHR-C
DAF MCP
LHR-D
Figure 1.6 The structure of the membrane bound regulators of C activation 
encoded within the RCA cluster.
The structure of complement receptor 1 (CR1), decay accelerating factor (DAF) 
and membrane cofactor protein (MCP). The constituent SCRs (blue circles) are 
shown along with serine/threonine/proline rich regions (STP, yellow box) and the 
mechanism for membrane attachment. Transmembrane domains are shown in red 
while GPI-anchor attachment sequences are shown as arrows. The constituent long 
homologous repeats (LHRs) of CR1 are shown.
35
1.3.2 Regulation of the terminal pathway.
Regulation of the terminal pathway is carried out by S-Protein and Clusterin, fluid 
phase regulators, and CD59, a membrane associated regulator. Regulation of the 
terminal pathway is particularly important to prevent against ‘bystander lysis’, when 
C5b-7 complexes formed in response to a target surface attach to a neighbouring 
‘innocent’ host cell causing lysis of the host cell.
1.3.2.1 S-Protein.
S-Protein, also known as vitronectin, is a 75kDa glycoprotein that binds C5b-7 in the 
fluid phase, masking the membrane binding site and preventing association with the 
membrane (Podack and Muller-Eberhard 1979; Podack, Preissner et al. 1984). The 
complex retains its capacity to bind C8 and C9 forming sC5b-9, soluble MAC which 
is known as the terminal complement complex (TCC). To a lesser extent S-Protein 
can inhibit the incorporation of C9 into membrane bound C5b-8 complexes (Milis, 
Morris et al. 1993)
1.3.2.2 Clusterin
Clusterin, a highly conserved glycoprotein, was believed to regulate C as it was 
present in sC5b-9 complexes (Murphy, Kirszbaum et al. 1988). Its role as CReg has 
been controversial with some studies demonstrating binding to C5b-7, preventing the 
binding of the complex to membranes, while other studies showed that addition of 
Clusterin to C5b6, C7, C8 and C9 enhanced lysis or that physiological concentrations 
of Clusterin did not regulate C (Choi, Mazda et al. 1989; Jenne and Tschopp 1989; 
Hochgrebe, Humphreys et al. 1999). The emerging picture is that Clusterin acts as 
an extracellular chaperone, serving as a hydrophobic ‘sink’ to remove toxic or 
damaged molecules away from cells (Wilson and Easterbrook-Smith 2000). In this 
way Clusterin binds terminal C complexes through their hydrophobic regions 
clearing them from the circulation rather than directly regulating C.
36
13 .2 3  CD59
CD59, a widely expressed GPI anchored membrane glycoprotein, has a variety of 
names including membrane inhibitor of reactive lysis, HRF-20, protectin and MAC 
inhibitory factor. It inhibits MAC formation by binding to the a-chain of C8 within 
the C5b8 complex allowing only a single copy of C9 to bind, preventing the 
unfolding, polymerisation and insertion of C9 into the membrane (figure 1.7) (Meri, 
Morgan et al. 1990; Rollins and Sims 1990). CD59 contains 5 intrachain disulphide 
bonds that maintain the disc shaped structure of the molecule (Sugita, Nakano et al. 
1993; Fletcher, Harrison et al. 1994). Molecular engineering was used to locate the 
active site, which was found to be on the upper face of the disc around a hydrophobic 
groove formed between two anti-parallel ^-sheets (Bodian, Davis et al. 1997).
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MAC
C9 Unfolding Polymerisation
C5b-8
C9
C9
C5b-8
C5b-8
CD59 CD59
Figure 1.7 Mechanism of action of CD59.
A. In the absence o f CD59, C9 binds to the C5b-8 complex, unfolds and 
polymerises with further C9 molecules which unfold to form the MAC.
B. CD59 binds to the C5b-8 complex allowing only one C9 molecule to bind 
preventing the unfolding and polymerisation o f multiple C9 that form the 
MAC.
Modified from a figure kindly provided by Dr Claire Harris, Department o f Medical Biochemistry 
and Immunology, Cardiff University.
38
1.3.3 Rat complement membrane regulators.
In recent years much of the work on CReg has focussed on identifying analogues of 
the human CReg in other species, of particular interest to the work in this thesis are 
the rat CReg.
13.3.1 Rat DAF
Rat DAF is capable of accelerating the decay of the C3 and C5 convertases. Rat 
DAF consists of 4 N-terminal SCRs and an STP region (Hinchliffe, Spiller et al. 
1998). However, two membrane forms of rat DAF exist due to alternative splicing 
of a single gene giving rise to either a GPI-anchored or a transmembrane protein 
(Miwa, Okada et al. 2000). GPI-anchored DAF is widely expressed particularly on 
circulating cells, with the exception of T cells, and on endothelia whilst 
transmembrane DAF is testis specific (Miwa, Okada et al. 2000; Hanna, Spiller et al. 
2002).
1.3.3.2 Rat MCP
Rat MCP consists of 4 N-terminal SCRs, an STP region, a transmembrane region and 
a cytoplasmic domain although alternative splicing within the STP region and 
cytoplasmic domain can give rise to several isoforms. Although expression is 
restricted to the inner acrosomal membrane of sperm, rat MCP does retain the ability 
to act as a cofactor for fl (Mead, Hinchcliffe et al. 1999; Mizuno, Harris et al. 2004). 
Its location on sperm suggests more of a role in reproduction. A study by Inoue et al. 
suggested MCP had a suppressive role in reproduction as MCP deficient mice had 
accelerated acrosome reactions and enhanced fertility (Inoue, Ikawa et al. 2003).
1.3.3.3 Rat Crry
Rat Crry is a widely expressed CReg unique to rodents, Crry was first discovered in 
mice and then two groups identified rat Crry (Wong and Fearon 1985; Quigg, 
Galishoff et al. 1993; Takizawa, Okada et al. 1994). Crry inhibits C activation of 
both the CP and AP, although in vivo data suggests it has a more dominant role in 
regulating the AP (Molina, Miwa et al. 2002). Crry possesses both fl cofactor
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activity and decay accelerating activity, suggesting it was a functional homologue of 
both DAF and MCP in rodents (Kim, Kinoshita et al. 1995). However, the sequence 
more closely resembles human CR1 and so Crry is considered a CR1 homologue 
(Molina, Wong et al. 1992).
Crry consists of SCRs, a transmembrane domain and a cytoplasmic tail. Two forms 
have been identified in the rat, one containing 6 SCRS and the other 7 (Quigg, Lo et 
al. 1995). Although the exact functional site of Crry has not been identified, it is 
believed that function lies within SCRs 1-4 as they are homologous to SCRs 1-4 
within mouse and human CR1 where CReg activity resides (Kalli and Fearon 1994; 
Molina, Kinoshita et al. 1994). SCR 5 of Crry is homologous to SCR 30 of human 
CR1 while the remaining SCRs, 6 and 7, are homologous to SCR 6 in human CR1. 
Crry appears to be the dominant CReg in rodents as Crry deficiency is embyronically 
lethal due to uncontrolled C activation and it has been demonstrated that Crry is 
necessary for the protection of both T cells and erythrocytes in vivo (Xu, Mao et al. 
2000; Hanna, Spiller et al. 2002; Miwa, Zhou et al. 2002). The blocking of Crry by 
monoclonal antibodies in vivo caused increased vascular permeability, 
leucocytopenia and thrombocytopenia (Matsuo, Ichida et al. 1994).
1.3.3.4 Rat CD59
Rat CD59 resembles human CD59 in terms of molecular weight, membrane 
anchorage and stage of C inhibition (Hughes, Meri et al. 1993). It is broadly 
expressed, although it is not expressed on T lymphocytes and platelets, and shows 
44% homology with human CD59 at the amino acid level (Funabashi, Okada et al. 
1994; Hanna, Spiller et al. 2002). All 10 of the cysteine residues are conserved as 
well as several other stretches.
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i1.4 The role of complement in pathology
Under normal conditions CReg provide sufficient protection of self-cells from C 
attack. However, C can be activated to an excessive degree or in an inappropriate 
site and as a result has been implicated in the pathology of a number of inflammatory 
diseases or states. These diseases include immune complex and autoimmune 
diseases such as systemic lupus erythematosus and autoimmune arthritis, ischaemia- 
reperfusion (I/R) injuries, sepsis, multiple trauma and neurodegeneradve disorders 
such as Alzheimer’s disease, multiple sclerosis and Guillian-Barr6 syndrome. 
Diseases involving C and evidence for the role C activation in these diseases are 
given in table 1.2. In autoimmune diseases C can be activated by antibodies that 
recognise self-antigens leading to C deposition and destruction of host cells and 
tissue (Semple and Freedman 2005). In I/R injuries it is believed that C is activated 
by membrane phospholipids and mitochondrial proteins that become exposed due to 
the ischaemia, following reperfusion these serve as neoantigens to activate C 
(Austen, Kobzik et al. 2003; Chan, Ibrahim et al. 2003). In therapeutic interventions, 
exposure of blood to a foreign surface whether that be in dialysis or transplantation, 
can activate C via the AP.
C mediates injury either directly by the MAC or indirectly by the generation of the 
anaphylatoxins C3a and C5a. The MAC causes tissue damage by lysing unprotected 
cells as well as having pro-inflammatory activity, inducing cell activation resulting in 
production of inflammatory chemokines and expression of P- and E-selectins and 
intercellular adhesion molecules (Kilgore, Shen et al. 1995; Kilgore, Schmid et al. 
1997; Tedesco, Pausa et al. 1997). The peptides, C3a and C5a, induce damage 
through their effects upon neutrophils, eosinophils and mast cells (Wetsel 1995). 
C5a acts as a potent chemoattractant in addition it induces the production of a wide 
range of inflammatory mediators. C3a acts as a chemoattractant for eosinophils and 
mast cells and activates these cells to produce inflammatory mediators.
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Disease Evidence References
Rheumatoid arthritis C activation products in synovial fluid and on synovial 
membrane.
Systemic C inhibition or C deficiency suppresses disease in 
various animal models.
Treatment of patients with an anti-C5 antibody lessened disease 
severity.
Brodeur, Ruddy et al. 1991; Kemp, Spragg et 
al. 1992; Wang, Rollins et al. 1995; 
Goodfellow, Williams et al. 2000; Kaplan 
2002
Glomerulonephritis Abundant deposits of C activation products in glomeruli.
C activation products found in urine of patients with glomerular 
disease
C inhibition or deficiency suppresses disease in models.
Davis and Cavallo 1976; Adler, Baker et al. 
1984; Couser, Johnson et al. 1995; Nangaku, 
Pippin et al. 1999; Morita, Ikeguchi et al. 
2000
Multiple sclerosis C activation products in cerebrospinal fluid and around areas of 
demyelination in the CNS.
C inhibition suppresses disease in animal models.
Morgan, Campbell et al. 1984; Compston, 
Morgan et al. 1989; Piddlesden, Storch et al. 
1994; Davoust, Nataf et al. 1999
Alzheimer’s disease C deposition in and around plaques in the CNS. 
Up-regulation of C components in diseased brain. 
Deposited plaques capable of activating C.
Rogers, Cooper et al. 1992; Jiang, Burdick et 
al. 1994; Shen, Li et al. 1997; Terai, Walker et 
al. 1997; Yasojima, Schwab et al. 1999
Myocardial
infarction
Abundant C deposits in and around infarcts.
Reperfusion associated with C activation in ischaemic area. 
C inhibition at time of reperfusion in models reduces infarct 
size.
Reduced serum C levels after myocardial infarction.
Pinckard, Olson et al. 1975; Pinckard, 
O’Rourke et al. 1980; Shandelya, Kuppusamy 
et al. 1993; Mathey, Schofer et al. 1994; 
Vakeva, Agah et al. 1998
Stroke Abundant C deposits in and around affected area.
C deficient animals have reduced infarct size.
C inhibition at time of reperfusion shown to reduce damage.
Davis and Brey 1992; Huang, Kim et al. 
1999; Imm, Feldhoff et al. 2002; Figueroa, 
Gordon et al. 2005
Guillian-Barre
syndrome
C deposition found at nerve and activation products found in 
spinal fluid.
C depletion and anti-C therapy reduces disease severity.
Sanders, Koski et al. 1986; Hartung, 
Schwenke et al. 1987; Jung, Toyka et al. 
1995; Vriesendorp, Flynn et al. 1995; Putzu, 
Figarella-Branger et al. 2000
Table 2.1 continued overleaf
Disease Evidence References
Adult respiratory 
distress syndrome 
(ARDS)
C activation products found in lungs and plasma. 
Anti-C therapy therapeutically effective in condition.
Robbins, Russ et al. 1987; Zilow, Joka et al. 
1992; Zimmerman, Dellinger et al. 2000
Systemic lupus 
erythematosus
C involved in tissue damage with C activation products found in 
lesions and in plasma.
C inhibition in animal models decreases proteinuria in 
associated renal disease.
C also protective as Clq and C4 deficiency predisposes to 
disease development, early stages of C necessary for clearance 
of apoptotic bodies and immune complexes.
Belmont, Hopkins et al. 1986; Helm and 
Peters 1993; Wang, Hu et al. 1996; Stone, 
Williams et al. 2000; Rupert, Moulds et al. 
2002
Myasthenia gravis C activation products on post-synaptic membrane.
C consumption in vivo
C deficiency or inhibition reduces disease severity in animal 
models.
Sahashi, Engel et al. 1978; Sahashi, Engel et 
al. 1980; Engel and Arahata 1987; Christadoss 
1988; Piddlesden, Jiang et al. 1996; Romi, 
Kristoffersen et al. 2005
Cardiopulmonary 
bypass and 
haemodialysis
C activation products in plasma.
Coating circuits found to reduce C activation.
Inhibition of C in vivo inhibits reaction to extracorpeal circuits.
Amadori, Candi et al. 1983; Cheung, Parker et 
al. 1994; Rinder, Rinder et al. 1995; Tamim, 
Demircin et al. 1999
Hyperacute rejection C activation products found in transplanted tissue.
C deficiency and anti-C therapy prolongs graft survival.
Forbes, Pinto-Blonde et al. 1978; Forbes and 
Guttmann 1982; Pruitt and Bollinger 1991; 
Brauer, Baldwin et al. 1995; Abe, Sawada et 
al. 2003
Table 1.2 Complement in pathology.
A summary of some of the diseases associated with C activation along with evidence for the role of C in these disease states.
1.5 Anti-complement therapeutics
Although C is not always the primary cause of many of the diseases listed in table 
1.2 it has been associated with, it does contribute to the resultant pro-inflammatory 
cycle and tissue damage and has therefore become a therapeutic target. Numerous 
agents have been tested as potential anti-complement therapeutics; these include 
polyanionic reagents, peptides, antibodies and recombinant proteins.
1.5.1 Cobra venom factor
Cobra venom factor (CVF) was the first anti-C therapeutic to be tested in models. 
CVF binds fB forming a stabilised AP C3 convertase (CVFBb). Compared to 
C3bBb the complex has an extended half-life, 7 hours compared to 1.5 minutes, and 
is resistant to fluid phase regulation (Vogel, Bredehorst et al. 1996). CVFBb 
continuously activates the AP thereby consuming C3 and obliterating C activity in 
experimental animals for between 24 and 72 hours. The use of this reagent has 
however been limited as it is strongly antigenic resulting in the generation of 
neutralising antibodies. CVF has been a useful proof of principle demonstrating that 
anti-C therapy is relevant to many pathologies. Recently, human C3 was used to 
generate chimeric derivatives of CVF that stabilised the C3 convertase whilst 
reducing the immunogenicity of CVF paving the way to use a CVF-like molecule 
therapeutically (Kolln, Spillner et al. 2004).
1.5.2 Poly anionic agents
A number of polyanionic molecules including heparin, dextran sulphate, polyvinyl 
sulphate, polylysine and suramin have been shown to inhibit C in vitro (Asghar 
1984). Heparin has been shown to inhibit C at various points including inactivating 
Cl, blocking assembly of the C3 convertase and interfering with MAC assembly 
(Baker, Lint et al. 1975; Hughes-Jones and Gardner 1978; Weiler 1983). In vivo, 
heparin is widely used as an anti-coagulant in patients with shock syndromes and to 
coat extracorpeal circuits in dialysis and cardiopulmonary bypass where it serves to 
prevent coagulation and C activation (Ovrum, Mollnes et al. 1995; Heyer, Lee et al. 
2002). Its role as an anti-C therapeutic in vivo has not been extensively addressed.
45
1.5.3 Small molecule inhibitors
A number of natural and synthetic molecules have been shown to inhibit C in vitro as 
well as in vivo. For a summary of these molecules see table 1.3. Whilst the small 
molecule inhibitors are cost-effective, have good tissue penetration and can be 
developed for oral use, they often have non-specific effects affecting more than just 
the C system. They are also limited by their short in vivo half-lives resulting in their 
rapid clearance from the body making them unsuitable for long term anti-C therapy 
in chronic inflammatory conditions.
Molecule Synthetic/
natural
Action and uses References
K76COOH Natural, a
fungal
metabolite
Inhibits C at the C5 stage. 
Effective in vivo in animal 
models.
Konno and 
Tsurufuji 1983; 
Iida, Izumino et 
al. 1987; Yamada, 
Kudoh et al. 1997
FUT-175 Synthetic
organic
molecule
Broad-spectrum serine protease, 
acts as an inhibitor for Cls, fD 
and the C3/C5 convertases. 
Effective in various animal 
models where it proved to be 
anti-inflammatory. Effective in 
glomerulonephritis patients.
Issekutz, Roland 
et al. 1990; Inagi, 
Miyata et al. 
1991; Fujita, 
Inoue et al. 1993
BCX-1470 Synthetic
organic
molecule
Inhibits fD, C ls as well as 
thrombin, factor Xa and trypsin. 
Inhibited development of reverse 
passive Arthus reaction induced 
oedema in rats.
Szalai, Digemess 
et al. 2000
Compstatin Synthetic
cyclic
peptide
Binds C3 and prevents cleavage. 
Effective in an ex vivo model of 
kidney xenotransplantation, 
inhibited C activation on 
extracorporeal circuits and 
abrogated C activation induced 
by heparin-protamine complexes 
in Baboons.
Sahu, Kay et al. 
1996; Nilsson, 
Larsson et al. 
1998; Fiane, 
Mollnes et al. 
1999; Soulika, 
Khan et al. 2000
F-OpdChaWR Synthetic
cyclic
peptide
C5aR antagonist. Effective in 
vivo including inhibiting C5a- 
meditated neutropenia in rats.
Paczkowski, 
Finch etal. 1999; 
Short, Wong et al. 
1999
Table 1.3 Small molecule inhibitors of C.
A summary of the small molecules used to inhibit C with their site of action, uses and 
some key references.
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1.5.4 Regulation of C by therapeutic antibodies
Several antibodies have been developed against C5 that inhibit C by preventing the 
cleavage of C5 (Wurzner, Schulze et al. 1991). Anti-C5 monoclonal antibodies have 
been tested in mouse models of immune complex nephritis and collagen-induced 
arthritis, and a rat model of myocardial I/R injury (Wang, Rollins et al. 1995; Wang, 
Hu et al. 1996; Vakeva, Agah et al. 1998). In all these models anti-C5 antibodies 
proved therapeutically effective. To enable testing of these reagents in humans, a 
humanised antibody was created and a single-chain Fv fragment (scFv) derived from 
the antibody (Thomas, Rollins et al. 1996). The scFv antibody significantly reduced 
C activation and therefore myocardial damage in patients on cardiopulmonary bypass 
(Fitch, Rollins et al. 1999). This reagent, termed Pexelizumab™, is now in advanced 
stages of development for acute conditions such as cardiopulmonary bypass, 
myocardial infarction and stroke, and chronic situations including rheumatoid 
arthritis, nephritis, dermatomyositis and pemphigus (Kaplan 2002; Whiss 2002). 
Phase II trials of Pexelizumab in acute myocardial infarction have been disappointing 
as it did not reduce infarct size or adverse clinical outcomes despite blocking C 
activity in vivo (Mahaffey, Granger et al. 2003). However, the observation that it 
reduced mortality in myocardial infarction patients and patients undergoing 
cardiopulmonary bypass means that it warrants further investigation as a viable anti- 
C therapeutic (Granger, Mahaffey et al. 2003; Sheman, Fitch et al. 2004).
1.5.5 Soluble complement regulators
Many of the fluid phase regulators are at such a high concentration in plasma that 
large quantities would have to be used to see any therapeutic affect. However, Cl- 
inh purified from plasma has been used therapeutically in hereditary angioedema 
(HAE), which results from a Cl-inh deficiency (Donaldson and Evans 1963). By 
inhibiting the activity of Cl and other proteolytic cascades, Cl-inh resolved the 
oedema. Experimental models have also demonstrated the therapeutic benefit of Cl- 
inh in the treatment of septic shock, acute pancreatitis, myocardial infarction and 
liver I/R injuiy (Buerke, Murohara et al. 1995; Niederau, Brinsa et al. 1995; 
Horstick, Heimann et al. 1997; Heijnen, Straatsburg et al. 2006). In murine cerebral 
I/R injuiy, Cl-inh reduced ischaemic volume and neurological deficits by down- 
regulating the expression of adhesion molecules and pro-inflammatory cytokines
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whilst up-regulating protective cytokines (De Simoni, Storini et al. 2003; Storini, 
Rossi et al. 2005). Recently, recombinant Cl-inh has been produced and reached 
phase I clinical trials in HAE (van Doom, Burggraaf et al. 2005).
1.5.6 Recombinant membrane regulators
1.5.6.1 Recombinant soluble CR1
The first and best-characterised soluble recombinant form of a membrane-associated 
regulator is soluble CR1 (sCRl). sCRl is comprised of the extracellular domains of 
CR1 (30 SCRs) and inhibits the formation of the C3 and C5 convertases by acting as 
a decay accelerator and a cofactor for the factor I mediated cleavages of C3b and 
C4b (figure 1.8A). sCRl has been shown to be protective against tissue injury in 
several animal models of acute and chronic inflammatory conditions including 
myasthenia gravis, multiple sclerosis, rheumatoid arthritis, glomerulonephritis and 
I/R injuries (Weisman, Bartow et al. 1990; Piddlesden, Storch et al. 1994; Couser, 
Johnson et al. 1995; Goodfellow, Williams et al. 1997; Eror, Stojadinovic et al. 1999; 
Goodfellow, Williams et al. 2000). sCRl has been tested in human with ARDS and 
in patients on cardiopulmonary bypass where the agent was well tolerated and 
effectively inhibited C activation (Zimmerman, Dellinger et al. 2000; Rioux 2001). 
This reagent is still undergoing development, particularly for males on 
cardiopulmonary bypass as it provided more clinically effective in males than 
females.
Various modifications have been carried out in order to improve the therapeutic 
efficacy of sCRl and its in vivo half-life. Removal of LHR-A (the N-terminal 7 
SCRs) created a regulator specific for the AP of C (figure 1.8B). This reagent has 
been used to dissect the relative contributions of the CP and AP in I/R injuries and 
has the therapeutic advantage of still allowing C activation via the CP and immune 
complex handling (Murohara, Guo et al. 1995; Scesney, Makrides et al. 1996). sCRl 
has also been expressed containing an albumin-binding domain from streptococcal 
protein G at the C-terminus. By enabling the attachment of the protein to albumin in 
the circulation this approach resulted in an increased in vivo half-life of sCRl whilst 
not inhibiting function (Makrides, Nygren et al. 1996). Addition of Siayl Lewis X
48
(sLeX) tetrasaccharide groups to sCRl created a bifunctional molecule that localised 
to sites of inflammation by binding P-, E- and L-selectins where it not only acted as a 
CReg but also inhibited selectin-dependent leukocyte adhesion (Mulligan, Warner et 
al. 1999; Rittershaus, Thomas et al. 1999). Perhaps the most promising sCRl 
modification is APT070, a membrane targeted form of sCRl containing only the 3 
N-terminal SCRs (figure 1.8C). This molecule has been targeted to membranes by 
the addition of a lipid targeting peptide at the C-terminus that contains positively 
charged amino acids that bind the phospholipid membrane and a terminal myristoyl 
group that inserts into the membrane bilayer (Smith and Smith 2001). APT070 
showed an enhanced C inhibitory activity compared to a non-membrane targeted 
form of the protein and is effective in inhibiting disease in models of arthritis and 
renal transplantation (Linton, Williams et al. 2000). Current studies are being carried 
out to assess the role of APT070 in rheumatoid arthritis and renal transplantation 
(Smith 2002). This lipid targeting strategy has been applied to other CReg including 
rat Crry where it increased C inhibitory activity of the molecule and rat CD59 where 
it created a reagent that suppressed disease in a model of rheumatoid arthritis (Fraser, 
Harris et al. 2002; Fraser, Harris et al. 2003).
1.5.6.2 Recombinant forms of other membrane regulators
CR1 is not the only membrane regulator to be expressed as a recombinant form and 
tested for therapeutic efficacy. Soluble forms of both DAF and MCP have been 
expressed and shown to inhibit C activation in vitro as well as in in vivo models 
(Moran, Beasley et al. 1992; Christiansen, Milland et al. 1996). However, the 
effectiveness of sDAF and sMCP is less than sCRl presumably because sCRl 
contains both decay accelerating activity and fl cofactor activity. Studies using 
sDAF and sMCP show that they are much more effective together than alone and 
therefore a hybrid molecule containing 4 SCRs of MCP and 4 SCRs of DAF called 
C-activation blocker-2 (CAB-2) was generated (Christiansen, Milland et al. 1996; 
Higgins, Ko et al. 1997). This molecule was therapeutically effective in a model of 
the Arthus reaction and Forssman shock in vivo and reduced myocardial injury in an 
ex vivo model of I/R injury (Kroshus, Salemo et al. 2000). More recently CAB-2 
was shown to prolong graft survival in pig to primate cardiac xenografts (Salemo, 
Kulick et al. 2002).
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LHR-D
LHR-A LHR-C
C-terminusN-terminus
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terminal SCRs
▼
Figure 1.8 Soluble recombinant forms of CR1.
A diagram showing the recombinant forms o f CR1 generated.
A. sCRl consisting of the 30 amino-terminal SCRs of CR1.
B. Removal o f the 7 N-terminal SCRs (LHR-A) of sCRl generated an AP specific 
regulator.
C. Expression of the 3 N-terminal SCRs from LHR-A of sCRl with a membrane 
targeting peptide tail consisting of positively charged amino acids (+) and a 
myristoyl group (arrow) generated APT070.
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1.5.6.3 Regulator hybrid molecules
Although soluble recombinant forms o f the membrane CReg are effective in vivo 
their therapeutic use is limited by their short circulating half-lives. Therefore to 
extend their in vivo half-life and increase their therapeutic efficacy a number o f  
CReg hybrid molecules have been generated. To target CReg to a specific site, 
antibody CReg hybrids have been created where the Fab antibody arms target the 
CReg to a specific site (figure 1.9A). Hybrid molecules containing either CD59 or 
DAF attached to anti-dansyl antibody fragments at the C-terminus efficiently target 
to dansylated cells and protect against C lysis (Zhang, Yu et al. 1999; Zhang, Lu et 
al. 2001). In vivo this strategy has been used to target rat Crry and rat CD59 to 
kidney tubular epithelia where these reagents reduced tubulointestinal injury (He, 
Imai et al. 2005). CReg have also been targeted to sites o f C activation by generating 
CReg-CR2 fusion proteins. CR2 binds C3 activation fragments including iC3b and 
C3dg, which are present at sites o f C activation. This approach has been used to 
target DAF to sites o f C activation in a mouse model o f lupus nephritis although no 
effect on clinical severity was assessed in this study (Song, He et al. 2003). The 
targeting o f Crry to sites o f C activation in an intestinal I/R injury model using CR2 
significantly reduced C-mediated injury as well as reduced susceptibility to infection 
due to systemic C inhibition (Atkinson, Song et al. 2005).
A second type o f CReg-antibody hybrid molecule utilises the Fc o f an antibody to 
confer a long circulating half-life upon attached molecules (Pugsley 2001). The 
CReg domains replace the Fab arms o f an antibody with the Fc attaching to the C- 
terminus o f the CReg (figure 1.9B). This approach was used to create a mouse Crry 
fusion protein containing the Fc o f mouse IgGl (Quigg, Kozono et al. 1998). This 
reagent had an increased in vivo half-life and was therapeutically effective in 
glomerulonephritis, intestinal I/R injury and traumatic brain injury (Quigg, Kozono 
et al. 1998; Rehrig, Fleming et al. 2001; Leinhase, Schmidt et al. 2006). Both DAF 
and CD59-Fc fusion proteins have been generated containing a human Fc (Harris, 
Williams et al. 2002). These reagents were effective in vitro at inhibiting C and the 
DAF-Fc was shown to inhibit disease in a rat model o f antigen-induced arthritis. 
Such reagents are still undergoing development.
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1.5.6.4 ‘Prodrug’ regulators
DAF-Fc and CD59-Fc reagents were shown to have a reduction in function 
compared to sDAF and sCD59 respectively (Harris, Williams et al. 2002). The 
function was improved by insertion of ‘spacing’ domains between the CReg and the 
Fc and full function was totally restored when the Fc domains were removed with 
papain. Hence, the CReg function was reduced by steric restraint imparted by the Fc. 
This observation resulted in the design of a CReg ‘prodrug’. In the proof-of-concept 
molecule the minimal functional domains of human DAF (3 N-terminal SCRs) were 
fused to the rigid Fc of human IgG2a in order to maximise the steric hindrance of the 
CReg (Harris, Hughes et al. 2003). A short enzyme site was inserted between the 
CReg and the Fc; the enzyme site was specific for either aggrecanase or matrix 
metalloproteinases (MMPs). These enzymes are at high levels in arthritic joints and 
cleave aggrecan, a major component of cartilage that is destroyed during arthritis 
(Little, Hughes et al. 2002). The resultant DAF-Fc ‘prodrug’ had negligible C 
regulatory activity but was cleaved by purified enzymes or enzymes present in 
synovial fluid to release an active CReg. Thus a reagent with little or no systemic 
activity was designed that could unleash powerful anti-C activity at target sites 
(figure 1.9C). This reagent has not been tested therapeutically in vivo.
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Antibody Fab used to target
Antibody Fc
CReg
B.
\ Fab arms o f antibody1 replaced by CReg
Antibody hinge ------------w^
 ' " Antibody Fc
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inflammatory site
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/
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CReg
Figure 1.9 CReg hybrid molecules.
A. CReg-Fab hybrid molecules. The Fab arms of an antibody are used to 
target the CReg to specific sites.
B. CReg-Fc hybrid molecules. The Fc confers an extended half-life upon the 
attached CReg.
C. CReg ‘prodrug’, a sterically hindered CReg-Fc molecule that is cleaved at 
sites of inflammation by specific enzymes resulting in the release of an 
active regulator.
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1.6 Aims of this thesis
The overall aim o f this work was to design and develop better inhibitors o f C for use 
in rats. To date many different anti-C therapeutics have been designed and tested in 
various models o f disease. These reagents all have their own advantages and 
disadvantages with the disadvantages including systemic C inhibition leaving 
individuals prone to bacterial infections and immune complex disease, short half- 
lives resulting in continued administration and immunogenicity in animal models 
preventing the testing o f the reagents in models o f chronic disease over long time 
periods. The specific aims o f this study where therefore:
1. To generate a totally rat CReg-Fc fusion protein using rat Crry and rat Fc 
domains to reduce the immunogenicity o f such reagents in rats.
2. To carry out functional analysis o f rat Crry to locate the functional domains 
and enable the generation o f a rat Crry ‘prodrug’.
3. To test both the active Crry-Fc and ‘prodrug’ in rat models o f disease.
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Chapter 2: Materials and methods.
Unless otherwise stated all chemicals were from Sigma Chemical Company or Fisher 
Scientific UK Ltd.
2.1 Molecular Biology
The cloning of recombinant rat Crry and the Fc of rat IgG2a into expression vectors.
All RNA manipulations were carried out using Diethylpyrocarbonate (DepC) treated 
autoclaved tips and vials. All DNA manipulations were carried out using autoclaved 
tips, vials and solutions. All polymerase chain reactions (PCRs) were carried out 
using a Dyad DNA engine (MJ Research Ltd).
2.1.1 Buffers and Broths
Buffer Contents
lxTAE: 40mM Tris, 40mM acetic acid, ImM EDTA pH 7.2
Agarose gel loading 
buffer:
20% glycerol (v/v) in lOx TAE with bromophenol blue.
Lauria-Bertani (LB) 
broth:
1% tryptone (w/v), 1% NaCl (w/v), 0.5% (w/v) yeast 
extract in water
LB Amp broth: lOOug/ml ampillicin in LB broth cooled to 50°C
LB Amp plates: As LB amp broth except the broth contained 1.5% agar
SOC: 2% tryptone (w/v), 0.5% yeast extract (w/v), 0.05% 
NaCl (w/v) and 2.5mM KC1 at pH 7. After autoclaving 
lOmM MgCL and 20mM glucose was added and the 
solution sterile filtered using a 0.22pM filter
2.1.2 RNA isolation
Rat oligodendroglioma cells (33B; ECACC) were harvested from a T80 tissue 
culture flask, resuspended in 1ml UltraSpec™ RNA (Biotecx) and transferred to a
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DepC treated vial. Following incubation on ice for 5 minutes, 0.3ml chloroform was 
added. Following vortexing to mix, the vial was incubated on ice for 5 minutes. 
Following centrifugation at 12,000g for 15 minutes to separate the DNA and protein 
phase from the RNA phase, the aqueous phase (RNA) was transferred to a fresh tube 
and an equal volume of isopropanol was added to precipitate the RNA. The tube was 
incubated on ice for 10 minutes and then centrifuged at 12,000g for 10 minutes. The 
supernatant was removed and the pellet was washed twice in 70% (v/v) ethanol 
diluted using DepC treated water. The washes involved vortexing the pellet to 
resuspend and centrifugation at 7500g for 5 minutes. The pellet was briefly dried on 
a heated block and dissolved in lOOpl DepC treated water. The concentration of the 
RNA was established using its absorbance at 260nm.
2.1.3 Reverse transcriptase-PCR (RT-PCR)
cDNA was prepared from the RNA isolated from the 33B cells.
The reaction consisted of:
1.5pg RNA,
2pl pdN6 primers (Invitrogen Life Technologies),
1.5pi 25mM dNTPs (Bioline), ^
6pl 5x 1st strand buffer (Invitrogefi Life Technologies),
1.5 pi RNAsin (Promega)
3pi DTT (Invitrogen Life Technologies).
DepC treated dFLO to take the reaction volume to 30pl.
After incubation at 65°C for 10 minutes followed by 10 minutes on ice, 1.5pi 
Superscript II RNase H Reverse Transcriptase (Invitrogen Life Technologies) was 
added. The reaction mix was incubated at 25°C for 10 minutes to allow the primers 
to anneal, 42°C for 2.5 hours to extend the DNA and 99°C for 2 minutes to denature 
the enzyme. The cDNA was stored at -20°C.
2.1.4 PCR
A number of different PCRs were carried out to clone the different proteins for this 
project. PCRs were carried out using either Taq (Bioline) or Vent proofreading
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(New England Biolabs) polymerase. For the cloning of DNA encoding 5 SCRs of rat 
Crry a two step PCR reaction was used, this DNA was then used as a template to 
clone the DNA for the other Crry proteins. Details of which method was used to 
clone each construct as well as the source of DNA used is given in table 2.1. The 
primers used for amplification, screening and sequencing of DNA were obtained 
from Invitrogen Life Technologies. The primers were reconstituted using dFLO to 
achieve a concentration of 1 OOpmol/pl and then diluted to lOpmol/jil. Table 2.2 
describes the primers used in each PCR.
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Product/
Purpose
Primers PCR reaction cDNA source
Fc of rat IgG2a IgG.l and IgG.2 Vent PCR Fc within a pDR2AEFla 
plasmid that had been 
previously made in the 
lab.
5SCR (for Fc 
fusion protein)
Crryl, Crry2, 
CrryA and CrryB
Two stage PCR 
to eliminate a 
BamHl site
Rat oligodendroglioma 
cells.
4SCR (for Fc 
fusion protein)
Crryl and 
4SCRFc
Vent PCR Plasmid containing 
cDNA encoding 5 SCRs 
of Crry
3 SCR (for Fc 
fusion protein)
Crryl and 
3SCRFc
Vent PCR Plasmid containing 
cDNA encoding 5SCRs 
of Crry
4SCR (non-Fc 
fusion protein)
Crryl and SCR4 Vent PCR Plasmid containing 
cDNA encoding 5 SCRs 
of Crry
3 SCR (non-Fc 
fusion protein)
Crryl and SCR3 Vent PCR Plasmid containing 
cDNA encoding 5 SCRs 
of Crry
Bacterial colony 
screening
E F la5 \ EFla3’ 
and IgG3’
Taq PCR Bacterial lysate used as 
templates for PCR.
Table 2.1 The primers, PCR reaction and sources of cDNA used to clone the 
recombinant rat Crry proteins and the Fc of rat IgG2a.
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Primer
name
Primer sequence Modifications/ 
restriction site
Crryl 5 CGCTCT AG AG AGG ACCGCTGT G AGGG3 • Xba-1
CrryA 3’GTAGGCCAAACC AGG AG A TAG 5’ T—»C mutation 
to remove an 
internal BamHl 
site
CrryB 5’CATCCGGTTTGG TCCTCTATC3’ A—>G mutation 
to remove 
BamHl site
Crry2 3 GG AC AC AC ATTGTTC ACT ATCCT AGGCGCs ’ BamHl
4SCRFc 3TCGACGAAGTTCCACTTTAGGCCTAGGGCG5’ BamHl
3SCRFc 3 G AGG AGTC AGTAACTTGAGCC TAGGGCGs ’ BamHl
SCR4 3’GGTTCGACGAAGTTCCACTTTATCCCTAGGGAGs’ BamHl and 
stop codon
SCR3 3’GAGG AGTC ACGT AACTTG AG ATCCCT AGGGCGs ’ BamHl and 
stop codon
IgG.l 5’GCCGG ATCCGCC AGC AGC ACC AAGT GG37 BamHl
IgG.2 3GGATTTCCTACGGTTGTGGATATCATG5’ EcoRV
EFla5’ 5CAAGCCTCAGACAGTGGTTC3’ •
EFla3’ 3’ATGTCTGGATCGGTGCGGGGCs’
IgG 3’ 3 GGG AAG AT GAAGACAGATGs ’
Table 2.2 Primer sequences used in the cloning of the recombinant forms of rat 
Crry and the Fc of IgG2a.
The primer name is shown along side the sequence with any modifications to the 
cDNA or introduced restriction sites shown in the right hand column. Restriction 
sites are shown in the primer sequence in blue, the base mutation to eliminate an 
internal BamHl site in grey and any introduced stop codons in red.
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2.1.4.1 Taq PCR
Where Taq polymerase (Bioline) was used as the enzyme each PCR contained the 
following reagents:
1 OOng template DNA, 
lOpmol of forward primer, 
lOpmol of reverse primer,
2.5pl lOx NH4 buffer (Bioline; 160mM (NH4)2 S0 4, 670mM Tris-HCl, 0.1% (v/v) 
Tween-20), lpl 50mM MgCl2 (Bioline),
5 pi ImM dNTPs (Bioline),
dH20  to take the reaction volume to 24.5pl.
The reaction was heated at 94°C for 3 minutes to denature the DNA and then 0.5pi 
Taq polymerase (Bioline, 5U/pl) was added.
Each PCR consisted of the 30 cycles of:
Denaturation: 95°C for 30 seconds.
Annealing: 58°C for 30 seconds (annealing temperature is dependant upon
the specific primer used).
Extension: 72°C for 2 minutes
Followed by a final extension at 72°C for 15 minutes
2.1.4.2 Vent PCR
In the reactions where Vent polymerase (New England Biolabs) was used the 
reaction consisted of: 
lOOng template DNA,
15pmol of forward primer,
15pmol of reverse primer,
2.5pl lOx ThermoPol reaction buffer (New England Biolabs; lOOmM KC1, lOOmM 
(NH4 )2 S0 4, 200mM Tris-HCl pH 8 .8 , 20mM MgS04, 0.1% (v/v) Triton X-100),
7.5pl ImM dNTPs (Bioline),
dH20  to take the reaction volume to 24.5pl.
The reaction was heated to 94°C for 3 minutes prior to the addition of 0.5pl Vent 
DNA polymerase (New England Biolabs, 2U/pl) to denature the DNA.
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Each PCR consisted of the same steps as the Taq polymerase reaction detailed above 
(section 2.1.4.1).
2.1.4.3 Two step PCR
To clone the DNA encoding the 5SCRs of rat Crry a two step PCR reaction was 
carried out to remove an internal BamHl restriction site that would interfere later 
with the cloning procedure. The cloning strategy is demonstrated in figure 2.1. In 
step 1 the DNA was amplified in two sections following method 2.1.4.1. For section 
1 primers Crryl and CrryA (table 2.2) were used to amplify a 723 base pair fragment 
of DNA. Primer CrryA contained an A —>G base mutation at residue 248 conserving 
the amino acid coded as a glycine but removing the BamHl site. Primer Crryl 
incorporated an Xbal restriction site at the 5’ end. For section 2 primers Crry2 and 
CrryB (table 2.2) were used to amplify a 363 base pair fragment of Crry. The CrryB 
primer was complementary to CriyA and also included the mutation at residue 248. 
Primer Crry2 incorporated a BamHl restriction site.
In step 2, the two DNA sections from step 1 were allowed to anneal through their 
complementary sequence and were used as a template to amplify DNA encoding the 
entire 5 SCRs of Crry. In this reaction 200ng of each of the products from step 1 
were mixed together along with 5pi lOx ThermoPol reaction buffer (New England 
Biolabs), 15jil ImM dNTPs (Bioline) and (IH2 O to bring the reaction volume to 
43.5pl. The reaction was heated to 94°C for 4 minutes and 0.5pl Vent DNA 
polymerase (New England Biolabs) was added.
Five cycles of the following steps were then carried out to enable the fragments to 
come together and the full length DNA be created:
Denaturation: 94°C for 30 seconds
Annealing: 58°C for 60 seconds
Extension: 72°C for 3 minutes
3pi of the Crryl primer and Crry2 primer (both at lOpmol/pl) were then added whilst 
the reaction was held at 94°C. This enabled the cDNA encoding the 5SCRs of Crry 
to be amplified using 30 cycles of the following scheme:
61
Denaturation:
Annealing:
Extension:
94°C for 20 seconds 
58°C for 45 seconds 
72°C for 2 minutes
2.1.5 Agarose gel electrophoresis
DNA fragments and PCR products were visualised by agarose gel electrophoresis. 
1% (w/v) agarose (Invitrogen Life Technologies) in lx TAE buffer was melted in a 
microwave and allowed to cool before the addition of lOOng/ml ethidium bromide 
(final concentration). The agarose was poured into a gel casting tray (Thermo 
Electron Corporation), an appropriate size comb was inserted and the agarose was 
allowed to set. The comb was removed and the gel immersed in lx TAE in an 
electrophoresis tank (Thermo electron corporation). DNA samples containing 10% 
(v/v) agarose gel loading dye were loaded along with DNA standard size markers. 
Gels were run at 60V for 1-2 hours depending on the resolution required. The DNA 
within the gel was visualised using a UV transilluminator (Bio-Rad, Chemi-Doc), the 
images were captured on a digital camera using the Bio-Rad Gel Documentation 
system. To quantify DNA using an agarose gel, the gels were prepared as above 
except that Smart Ladder DNA markers (Eurogentec) were loaded.
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i) Step 1, PCR of segments
Inserted
mutation
Signal peptide i Crry template SCR 5
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fragment 1
fragment2 (Crryl>
ii) Step 2, Join up PCR, followed by amplification
5’ fragment 1 
 ►
Complementary region 3’
fragment2
Figure 2.1 Two step PCR to generated DNA encoding 5SCRs of Crry.
In step 1 of the PCR, two fragments o f DNA were generated. Primers Crryl and 
CrryA were used to amplify fragment 1 whilst primers Crry B and Crry2 were used 
to amplify fragment 2. In step 2 of the PCR, DNA fragments 1 and 2 were allowed 
to anneal to each other through the complementary region. Full length cDNA 
encoding the 5 SCRs o f Crry was generated in a PCR reaction using primers Crryl 
and Crry2
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2.1.6 Purification of PCR products
PCR products were purified using a Qiagen QIAquick® PCR purification kit or 
where plasmid DNA was used as the template from agarose gels using a Geneclean® 
III kit (Q-Biogene). The manufacturer’s protocol was used for the PCR purification 
kit. In brief, the DNA was bound to a silica membrane, washed and then eluted 
using 50pl water. The concentration was determined by the absorbance at 260nm. 
To purify the PCR products from an agarose gel, the product was loaded into a 3% 
(w/v) Nusieve agarose gel (FMC Bioproducts) made up with lx TAE containing 
1 OOng/ml ethidium bromide. Following electrophoresis the gel was placed on a UV 
transilluminator and the bands of interest were excised. The DNA was purified from 
the gel using the manufacturer’s protocol in which the agarose was dissolved in 
sodium iodide, the DNA bound to a silica matrix, washed and eluted into lOpl of 
distilled water. The concentration was determined as above.
2.1.7 Restriction digests
The PCR products and plasmid were digested using the relevant restriction enzymes. 
All enzymes were from G E Healthcare (previously Amersham Biosciences). In 
each digest 5pl of the relevant enzyme was used with 7pl of the corresponding 
buffer, 5pg DNA (PCR product or plasmid) and the reaction volume was taken to 
70pi with distilled water. For BamHl Buffer K was used, for EcoRV Buffer H and 
for Xbal Buffer M along with 7pi 0.1% (w/v) BSA. BamHl digests were incubated 
at 30°C while EcoRV and Xbal digests were incubated at 37°C. All digests were 
incubated for 2 hours. Following each digest the DNA was purified using a 
QIAquick® PCR purification kit and eluted using 60pl distilled water. To quantify 
the DNA yield, the products were loaded onto an agarose gel and run against Smart 
Ladder markers as described previously.
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2.1.8 Ligation
The digested PCR products were ligated into the pDR2AEFla plasmid or the pDR2- 
Fc plasmid using T4 DNA ligase (Promega). The ligation reaction was incubated at 
16°C overnight and consisted of
lOOng plasmid and a 3-fold molar excess of insert calculated by:
3 x (100 x size (kb) of insert)/ size (kb) of vector
along with lpl lOx ligase buffer (Promega, 300mM Tris-HCl pH 7.8, lOOmM 
MgCh, lOOmM DTT and lOmM ATP), lpl T4 DNA ligase and dH2 0  to take the 
reaction volume to lOpl.
Ligations were stored at -20°C until required. The ligated DNA was transformed 
into bacteria directly from the ligation mix.
2.1.9 Transformation
Chemically competent DH5a (Invitrogen Life Technologies) were transformed with 
the ligated DNA by heat shock. Ligated DNA (2pl) was added to 50pl of chemically 
competent DH5a on ice and mixed. The bacteria were left on ice for 20 minutes and 
then incubated at 42°C for 45 seconds. Following this they were incubated on ice for 
a further 2 minutes and 950pl SOC medium was added. The bacteria were allowed 
to recover by incubating at 37°C for 1.5 hours. The bacteria (either 100 or 200pl) 
were then aliquoted onto LB amp plates and incubated overnight at 37°C.
2.1.10 Bacterial colony screening
Bacterial colonies were screened by PCR to detect successful ligation of DNA into 
the plasmid. The primers used in the screening are described in table 2.2. Primers 
EFla5’ and EFla3’ bound to the plasmid either side of the inserted DNA and were 
used to screen the pDR2AEFla plasmid for ligation of DNA encoding the Fc or the 3 
or 4 SCRs of rat Crry for the non-fusion proteins. Primers EFla5’ and IgG3’ were 
used to screen the pDR2-Fc plasmid for the insertion of DNA encoding the 5, 4 or 
3 SCRs of rat Crry. Single colonies were picked with a sterile pipette tip and placed 
in 20pl of dH2<D in a 0.5ml tube. After gentle pipetting to mix, lpl of the mix was 
spotted onto an LB amp plate. The remaining 19pl was boiled for 10 minutes on a
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heating block to lyse the bacteria. The tubes were then incubated on ice for 5 
minutes and the lysed bacteria pelleted by centrifugation at 12,000 g for 5 minutes. 
2pl of the bacterial lysate was used as the template in a Taq PCR reaction as 
described in section 2.1.4.1. Following PCR, 10pl of each reaction was analysed by 
agarose gel electrophoresis and clones that contained inserts of the correct size were 
identified.
2.1.11 Plasmid isolation
Following the PCR screen, a positive colony was picked from the LB amp plate 
using a sterile loop. The colony was transferred to 10ml LB amp broth and 
incubated overnight at 37°C with shaking. The bacteria were pelleted by 
centrifugation at 1300 g for 10 minutes and the supernatant discarded. The DNA 
was isolated from the bacteria using the QIAprep® Spin Miniprep kit (Qiagen) 
according to the manufacturer’s protocol using a microcentrifuge. In brief, the 
bacteria were lysed and the DNA bound to a silica matrix, following a wash, the 
DNA was eluted with 70pl (IH2O and stored at -20°C.
2.1.12 DNA sequencing
The cDNA constructs generated were sequenced using the Big Dye™ Terminator 
Cycle Sequencing Kit (Perkin Elmer). The sequencing reaction contained:
300ng of template DNA,
2.5pmol of either the forward or reverse primer,
lpl Big Dye Premix containing Ampli Taq DNA polymerase,
5pl Better Buffer (Web scientific) and 
dH2 0  to make the reaction volume up to 15pl.
The primers that were used for screening the bacterial colonies were also used in the 
sequencing reaction. For instance EFla5’ and EFla3’ were used to screen for 
insertion of DNA encoding the Fc so in the 5’ sequencing reaction, EFla5’ was used 
while EFla3’ was used in the 3’ sequencing reaction.
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Reactions consisted of 25 cycles of the following steps:
Denaturation: 96°C for 30 seconds,
Annealing: 50°C for 15 seconds
Extension: 60°C for 4 minutes.
Following the reaction, 5pi dFhO was added to the reaction tube and the DNA was 
precipitated by addition of 2pi 3M Sodium acetate pH 5.2 to the reaction tube along 
with 50pl ethanol. After mixing and incubation on ice for 20 minutes, the DNA was 
pelleted by centrifugation at 12,000 g for 25 minutes. The pellet was washed with 
200pl 70% (v/v) ethanol. Sequencing was carried out in house (Central 
Biotechnology Services) using an ABI model 377 DNA sequencer (Perkin Elmer).
2.1.13 Expression vectors
The expression vector used within this project, pDR2AEFla, was a gift from Dr I. 
Anegon (INSERM, U437, Nantes, France) (Charreau, Cassard et al. 1994). This 
vector is a eukaryotic expression vector that contains a multiple cloning site next to 
the Elongation Factor 1 alpha (EFla) promoter, which drives very high levels of 
expression in eukaryotic cells (Mizushima and Nagata 1990). This vector also 
includes an ampillicin and a hygromycin resistance gene allowing for selection in 
both bacteria and eukaryotic cells. When the DNA encoding the Fc of rat IgG2a was 
ligated into this vector it was referred to as pDR2-Fc.
2.2 Eukaryotic expression and cell maintenance
The transfection of CHO cells with the expression plasmids and the maintenance of 
CHO and hybridoma lines.
All tissue culture was carried out under sterile conditions in a flow cabinet using 
sterile flasks, tubes and other equipment. All tissue culture reagents and equipment 
were obtained from Invitrogen Life Technologies unless otherwise stated. All flasks 
were incubated in a humid atmosphere at 37°C, 5% CO2 unless otherwise stated.
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2.2.1 Tissue culture cells and media
Cells Suppliers/ source
Chinese Hamster
Ovary (CHO) cells: Obtained from EC ACC.
Hybridomas: TLD1C11 hybridoma cell line provided by Dr W. F. 
Hickey (Dartmouth College. Hanover, NH, USA).
RPMI-1640 was used as cell culture medium and was supplemented with 50U/ml 
penicillin/streptomycin, lpg/ml amphotericin B, 2mM L-glutamine and ImM 
sodium pyruvate. Depending upon the cell type being cultured different amounts of 
foetal bovine serum (FBS) were added. Transfected CHO cells were cultured in the 
presence of Hygromycin B. Details of the FBS content and Hygromycin B content 
of the cell culture media is given below:
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Media Use FBS and Hygromycin B 
content
Untransfected CHO 
media
Culture of 
untransfected CHO
5% (v/v) FBS
Selection media Selection of 
transfected CHO cells
5% (v/v) FBS, 400jig/ml 
Hygromycin B.
Transfected cell media Culture of transfected 
CHO
5% (v/v) FBS, lOOpg/ml 
Hygromycin B.
Bulk CHO media Culture of CL 
AD1000 flasks, 
section 2.2.4.2
0% (v/v) FBS, lOOpg/ml 
Hygromycin B.
Hybridoma media Culture of hybridoma 
lines
10% (v/v) FBS.
Bulk hybridoma media Culture of CL 1000 
flasks, section 2.2.5.2
No supplements
High density hybridoma 
media
Culture of CL 1000 
flasks, section 2 .2 .5. 2
15% (v/v) Ultra low bovine 
immunoglobulin FBS
Freezing media Freeze cells 10% (v/v) DMSO in foetal 
bovine serum
2.2.2 Transfection of CHO
CHO cells were transfected using LipofectAMINE™ PLUS reagent in T25 tissue 
culture flasks. Transfection was carried out according to manufacturer’s instructions; 
2 jig plasmid DNA was pre-complexed with PLUS reagent in serum free media (opti- 
MEM® with GlutaMAX™) at room temperature for 15 minutes. The pre-complex 
was combined with the LipofectAMINE™ reagent diluted in opti-MEM® and 
incubated for a further 15 minutes at room temperature. The cells were washed twice 
in opti-MEM® and the transfection mix was applied to the cells. The cells were 
incubated with the transfection mix in to 2ml of opti-MEM® for 5 hours at 37°C, the 
mix was then replaced with untransfected CHO medium. The cells were placed in 
selection medium 24 hours later to select for transfected cells. A flask of mock- 
transfected cells (had undergone transfection conditions without plasmid DNA) were
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also placed under selection. When these non-transfected cells had all died, as 
determined by microscopy, the CHO cells were maintained in transfected cell 
medium. The supernatant from the transfected cells was retained for Western blot 
analysis to detect for expression of the protein.
2.2.3 Cloning of CHO cells
In order to isolate high expressing transfected CHO cells, the cells were cloned out 
by limiting dilution in 96-well plates. Cells were harvested from a tissue culture 
flask and resuspended to 1000 cells/ml medium. lOOpl of medium was placed in the 
wells of a 96 well plate. To the first column lOOpl of cells was added, the cells were 
diluted in an 8 -step 1 : 2  serial dilution across the plate to achieve dilution of 
approximately 1 cell per well. After two weeks in culture, the supernatant from the 
wells containing approximately 1 cell per well was screened by ELISA (section 
2.4.9). Cells from the well where the supernatant had the highest level of protein 
were taken on and expanded.
2.2.4 Maintenance of CHO cells
Prior to transfection, an aliquot of CHO cells was taken from frozen stocks, rapidly 
thawed and resuspended in pre-warmed (37°C) untransfected CHO medium. The 
cells were centrifuged at 300g for 5 minutes, resuspended in lOmls of untransfected 
CHO media and transferred to a tissue culture flask. To sub-clone adherent cells, the 
cells were washed twice with sterile saline and lifted from the flask using 1ml 
Trypsin-EDTA. Once the cells had detached from the flask they were diluted in 
fresh medium and transferred to the desired number of flasks. To freeze down CHO 
cells, a T80 flask was trypsinised as before, centrifuged at 300g for 5 minutes and 
resuspended into 1ml freezing medium. The cells were placed in a Cyrovial 
(Greiner) and frozen in a Cyro 1° Freezing Container (Nalgene) to -80°C. The 
container ensured that the temperature would decrease by 1 ° per minute and in 
conjunction with the DMSO within the freezing medium prevented the formation of 
ice crystals within the cells. After 24 hours at -80°C, the cells were transferred to 
liquid N2 for long term storage. After transfection a number of different cell culture 
methods were used to maintain the CHO cells.
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2.2.4.1 T80 flasks
Transfected CHO cells were maintained in T80 flasks (Nunc) using transfected cell 
medium. The cells were sub-cloned and replenished regularly in order to maintain 
cell viability. The supernatant harvested from the cells was kept in sterile bottles for 
purification of the Crry proteins.
2.2.4.2 CELLine flasks
Transfected cells were also maintained in CL AD1000 flasks (Integra Biosciences). 
These are cell culture flasks which consist of two compartments separated by a 
lOkDa semi-permeable membrane (figure 2.2A). In one compartment, containing a 
polyethylene teraphthalate (PET) matrix, the cells were maintained in transfected cell 
medium whilst the other compartment contained bulk CHO medium (described 
section 2.2.1). The cells, cellular products and proteins within the bovine serum 
necessary for cellular growth were retained in the cell compartment by the membrane 
while nutrients and metabolic waste products diffused through the membrane. To 
inoculate the flasks, the membrane was wetted by placing 25ml bulk media in the 
medium compartment while the cell compartment was inoculated with 2.5x10 cells 
in 15ml transfected cell medium. A further 975ml of bulk CHO medium was added 
to the medium compartment. Following inoculation the media in both compartments 
was changed on day 10 and then every seven days. The medium harvested from the 
cell compartment was centrifuged at 900g for 5 minutes and the supernatant retained 
for purification of the Crry proteins. The media from the medium compartment was 
discarded.
2.2.4.3 Fermenter
The CHO cells were also maintained in a BioStat B Plus fermenter (B Braun 
Biotech). This consisted of a stirred glass vessel in which the cells were incubated 
and a control unit which adjusted temperature, pH, p02 levels and stirring speed 
within the glass vessel (figure 2.2B). Cytodex 1 beads (GE healthcare) were swollen 
in PBS as per manufacturer’s instruction; 2g of beads were used per litre of culture.
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The beads were washed in PBS and autoclaved. The beads were washed in
o
transfected cell medium and the relevant number of cells ( 1 . 5 - 2 x 1 0  cells/litre of 
culture) were added. The cells were incubated with the beads to allow their 
attachment to the beads. There were two ways in which the cells were attached to 
the beads. In method one, the beads were autoclaved within the culture vessel, the 
transfected cell medium was added and the vessel stabilised at the culture conditions. 
The cells were inoculated into the culture vessel and the culture stirred for 5 minutes 
every hour for the first 3 hours after which full stirring was commenced. In method 
two, the beads were prepared and autoclaved in a separate siliconised 500ml glass 
bottle. The beads were washed into 200ml transfected cell medium within this bottle 
and the cells added. The cells were incubated with the beads in the bottle overnight 
at 37°C in 5% CO2 . The beads with the cells attached were then added to the culture 
vessel containing 800ml transfected cell medium and the fermentation commenced. 
With both methods the pH and pC>2 meters had previously been calibrated and the 
vessel autoclaved. The fermenter was stirred between 50-60RPM at 37°C, pH 7.4. 
The pH was maintained using CO2 or 0.1M sodium carbonate (autoclaved), sterile 
filtered air was pumped into the system.
To assess cell number and viability a 10ml sample was removed from the culture 
vessel, centrifuged at 300g for 5 minutes, the supernatant was discarded and the 
bead/cell pellet was washed twice with sterile saline. The cells were trypsinised 
from the beads using Trypsin-EDTA and separated from the beads using a 100pm 
cell sieve (Nuncon). The cells were pelleted by centrifugation at 300g for 5 minutes 
and resuspended in 1ml transfected cell medium. The total number of cells were 
counted using a haemocytometer. To establish viability, cells were mixed 1:1 with 
Tiypan blue and the live cells (not stained) were counted. When cell viability or 
number dropped either the fermentation was stopped or a medium change was 
carried out. To change the medium the stirrer was switched off to allow the cells to 
settle, the system pumps were then used to remove expired medium and add fresh 
medium.
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Figure 2.2 Diagrams of the CL AD1000 flask and fermenter system.
A. The CL AD 1000 flask. Cells are placed into the cell compartment containing 
the PET matrix through the cell port. Nutrients pass into the cell 
compartment whilst waste products pass out into the bulk medium 
compartment through the semi-permeable membrane, the cut off of the 
membrane retains cellular products within the cell compartment. Gas enters 
the cell compartment through the gas permeable membrane while the 
medium was gassed via the lid.
B. The fermenter culture vessel. The vessel is surrounded by a water jacket and 
contains a stirrer, a temperature probe, a pH probe and a pC>2 probe. Gas 
enters the culture in fine bubbles through the sparger. The lid of the vessel 
contains inlets and outlets which can be attached to the system pumps to 
change media and add acids or bases to maintain pH.
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2.2.5 Maintenance of hybridoma lines
Cyrovials were removed from liquid nitrogen storage and thawed as CHO cells 
(section 2.2.4) except the cells were washed into hybridoma medium and when 
bought up from storage they were incubated in T25 flasks which had been pre-seeded 
with mouse peritoneal macrophages. To obtain high expressing cells, the hybridoma 
cells were cloned out into 96 well plates pre-seeded with macrophages. The cloning 
was identical to section 2.2.3 other than hybridoma medium was used. Expression 
level was assessed using an ELISA (section 2.4.9).
2.2.5.1 T80 flasks
Hybridoma cells were maintained in T80 tissue culture flasks (Nunc) using 
hybridoma medium. As hybridoma cells are only weakly adherent they did not 
require trypsinisation for sub-cloning but were lifted by gentle knocking of the flask. 
The cells were then split between the required number of flasks. The cells were sub­
cloned and the medium replenished regularly to keep cells healthy and to ensure 
secretion of antibody. The media harvested from the cells were kept in sterile bottles 
for purification of the antibody.
2.2.4.2 CELLine flasks
Hybridoma cells were maintained in CL1000 flasks (Integra Biosciences). These are 
similar to CL AD1000 flasks used to culture CHO cells except that they do not 
contain a PET matrix in the cell compartment. The membrane was wetted by placing 
25ml bulk hybridoma medium in the medium compartment. The cell compartment 
of the flask was inoculated with 2.5x107 cells in 15ml high density hybridoma 
medium and a further 975ml of bulk hybridoma medium was added to the medium 
compartment. The media of both compartments was changed on day 10 following 
inoculation and then every seven days. When harvesting from the cell compartment, 
cells were reseeded by mixing 3ml of the harvest with 12ml fresh high density 
hybridoma medium before re-inoculation. The remaining harvest from the cell 
compartment was centrifuged at 900g for 5 minutes and the supernatant was retained
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for antibody purification. The bulk media from the medium compartment was 
discarded. The cell number was established by diluting the cell harvest 1 in 100 in 
fresh medium and then counting the cells using a haemocytometer. The viability was 
established by diluting the cell harvest in the same manner and then mixing the cells 
1:1 with Trypan blue. The live cells (not stained) were counted.
2.2.5.3 Tecnomouse
A Tecnomouse (Integra Biosciences) hollow fibre culture system was used to culture 
hybridoma cells. The tecnomouse comprises a culture cassette consisting of a 
cultivation chamber for the cells and hollow fibres through which medium is 
pumped. The membrane of the hollow fibres allows nutrients to diffuse into the 
cultivation chamber and metabolic waste products to diffuse out of the chamber into 
the hollow fibres (figure 2.3). Cellular protein products are retained within the 
cultivation chamber. A cassette was prepared by attaching it to the control unit and 
washing the extracellular (EC) space with 1500ml non-supplemented RPMI-1640 
overnight using the system pump. The intracellular space (IC) was flushed with 
50ml high density hybridoma medium. Hybridoma cells (6xl08) were harvested 
from tissue culture flasks, washed and resuspended in 1 0 ml high density hybridoma 
medium. The IC space was inoculated with these cells and 2000ml bulk hybridoma 
medium was circulated in the EC space using the system pump. The cells were 
incubated at 37°C using a thermohood for the Tecnomouse and in 5% CO2 to 
maintain pH. The media was replaced in both compartments every seven days. In 
the harvest, 3 ml from the IC compartment was added to 12ml fresh high density 
hybridoma medium and replaced in the IC space to maintain cell numbers. The 
remaining IC harvest was centrifuged at 900g for 5 minutes and the supernatant 
retained for antibody purification. The medium from the EC space was discarded. 
The cell number and viability was established using the same method as for the 
CELLine flask (section 2.2.5.2).
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Figure 2.3 Diagram of the Tecnomouse cassette.
The cell compartment (intracellular space) is shown in grey, nutrients move into 
this compartment whilst metabolic waste products move out into the hollow 
fibres (extracellular space). Gases diffuse in and out o f the intracellular space 
whilst medium is pumped around the extracellular space (Lukacik, Roversi et al. 
2004).
76
2.3 Protein purification
Purification of recombinant Crry proteins and antibodies from tissue culture 
supernatant.
2.3.1 Buffers
Buffer Contents
Phosphate buffered saline 
(PBS):
8.2mM Na2HP04, 1.5mM KH2P 04,137mMNaCl, 
pH 7.4.
CNBr-activated Sepharose 
Coupling buffer: 0.1M NaHCOs, 0.5M NaCl, pH 8.3
Borate buffered saline (BBS): lOOmM Boric acid, 25mM Sodium Borate, 75mM 
NaCl, pH 8.3
Tris buffered saline (TBS): lOmM Tris, 150mM NaCl, 0.01% (w/v) azide, pH 
7.4
Malonate buffer: 50mM Malonic acid, 37.5mM NaOH, 4mM 
Betaine monohydrate pH 5.4
2.3.2 Clarification of supernatant prior to purification
Prior to any purification technique cell culture supernatant was clarified by 
centrifugation at 6000 g for 15 minutes at 4°C
2.3.3 Protein A and G chromatography
Both protein A and G are bacterial proteins which have been utilised in the 
purification of many antibody isotypes from a variety of species. Here, both protein 
A and G chromatography were compared as methods to purify the Criy-Fc proteins 
and these methods were also used to purify TLD1C11. For both columns a pre­
column was used to remove any proteins which would non-specifically bind to the 
Sepharose matrix. The pre-column consisting of Sepharose CL4B (GE healthcare) 
was packed under gravity and washed with PBS to remove the ethanol preservative. 
The pre-column was then connected in-line before the protein A or G column. Prior 
to elution of bound protein from the column, the pre-column was taken out of line.
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Table 2.3 reports the binding buffer, wash buffer and elution buffer used in the 
protein A and G chromatography of Crry-Fc and TLD1 Cl 1.
Method Binding buffer Wash buffer Elution
buffer
Crry-Fc purification by 
protein A chromatography
1.5M 
glycine/NaOH, 3M 
NaCl pH 9.
Same as binding 
buffer
0.1M 
glycine/HCl 
pH 2.5
Crry-Fc purification by 
protein G chromatography
None PBS 0.1M 
glycine/HCl 
pH 2.5
TLD1C11 monoclonal 
antibody purification by 
protein A chromatography
1M glycine/NaOH, 
0.15M NaCl pH 8 . 6
Binding buffer 
followed by 
0.1M citrate pH 
6 .
0.1M citrate 
pH 3
TLD1C11 monoclonal 
antibody purification by 
protein G chromatography
None PBS 0.1M 
glycine/HCl 
pH 2.5
Table 2.3 Protein A and G chromatography methods along with the binding 
buffer, wash buffer and elution buffer used.
2.3.3.1 Crry-Fc purification
For protein A purification of 5SCR-Fc, cell culture supernatant was mixed 1: 1 with 
the binding buffer (table 2.3). The supernatant was passed over a 10ml protein A 
column (ProSep A, Millipore). The columns were then washed, the pre-column 
disconnected and bound protein was eluted. The protein was eluted in 3ml fractions 
neutralised with 300j l x 1 1M Tris/HCl pH 9. Fractions were assessed for protein 
content by their absorbance at 280nm in a spectrophotometer.
For protein G purification, 5SCR-Fc containing supernatant was not mixed with a 
binding buffer but was passed over a 10ml protein G column (ProSep G, Millipore).
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The column was washed and bound protein was eluted, neutralised and screened as 
above.
2.3.3.2 TLD1C11 purification
The method used to purify the TLD1C11 monoclonal antibody from hybridoma 
supernatant varied depending upon which culture method was used. Supernatant 
generated using the Tecnomouse or CELLine flask contained ultra low bovine 
immunoglobulin FBS. In this case no bovine antibodies which would co-purify on 
protein G were present in the supernatant so protein G chromatography was used. 
The supernatant was run over the pre-column and protein G column connected in 
series. The columns were washed and bound protein was eluted as above. When 
supernatant generated from conventional T80 flasks was used, the TLD1C11 was 
purified using protein A chromatography to limit bovine antibody contamination. 
The supernatant was mixed 1:1 with binding buffer (table 2.3). The supernatant was 
passed over the pre-column and protein A connected in series. The columns were 
washed with the binding buffer, the pre-column disconnected and the protein A 
column washed with 0.1M citrate pH 6  to reduce bovine immunoglobulin 
contamination. Bound antibody was eluted as described previously.
2.3.4 Generation of affinity columns
Antibody affinity columns of TLD1C11, 512 and anti-rat Ig were generated using 
CNBr-activated Sepharose 4B (GE Healthcare). A TLD1C11 affinity column was 
also generated using the Affi-Gel® Hz matrix (Bio-Rad).
2.3.4.1 CNBr-activated Sepharose
The antibody to be bound to the matrix was dialysed into coupling buffer overnight 
at 4°C. The CNBr-activated Sepharose was swollen in ImM HC1, lg  (dry weight) of 
Sepharose was used per 3mg of protein to be coupled. The Sepharose was washed 
with ImM HC1, 200ml/g of Sepharose. The Sepharose was equilibrated in coupling 
buffer then added to the antibody in a covered vessel. The Sepharose and antibody 
were placed on a roller for two hours at room temperature. The supernatant was then
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removed from the Sepharose and the remaining active sites were blocked by 
incubating the Sepharose in 0.1 M Tris/HCl pH 8  for two hours at room temperature. 
The Sepharose was packed into a column (2.5cm diameter) under gravity and washed 
with 3 cycles of 5 gel volumes of 0.1 M sodium acetate, 0.5M NaCl pH 4 followed by 
0.1M Tris/HCl, 0.5m NaCl pH 8 . The column was then equilibrated in PBS 0.01% 
(w/v) azide and stored at 4°C.
2.3.4.2 Affi-gel Hz matrix
Antibody affinity columns were also made using an Affi-Gel ® Hz immunoaffinity 
kit (Bio-Rad). The antibody to be coupled to the matrix was dialysed into the 
supplied coupling buffer. To oxidise the carbohydrate groups on the antibody, 1ml 
of sodium periodate (2 0 mg) was added per 1 0 ml of antibody ( 1  mg/ml) and incubated 
on a roller at room temperature for 1 hour, the incubation was carried out in the dark. 
Glycerol (200mM) was added and the reaction mixed for 10 minutes. The antibody 
was dialysed into the provided coupling buffer to remove the sodium periodate. 
Affi-gel Hz matrix (5ml) was equilibrated in coupling buffer to remove the alcohol 
preservative and the matrix was incubated with the antibody for 24 hours at room 
temperature. The matrix was then packed into a column under gravity and washed 
with PBS. The column was stored at 4°C in PBS 0.01% (w/v) azide
2.3.5 Use of affinity columns
To purify all Crry proteins from cell culture supernatant, clarified cell culture 
supernatant was passed over a pre-column connected in line with the relevant affinity 
column as described previously. The columns were then washed with PBS and 
bound protein was eluted from the affinity column using 0.1M glycine/HCl pH 2.5. 
Fractions (3ml) were neutralised with 300pl 1M Tris/HCl pH 9 and assessed for 
protein content as described previously.
To automate the affinity purification of the Crry proteins the TLD1C11 (anti-Crry) 
affinity column was packed into a XK-16 column (G E Healthcare) under gravity. 
The column was run using an AKTA Prime system (G E Healthcare). Each run 
consisted of a 2 column volume (40ml) equilibration with TBS, a supernatant load, a
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3 column volume wash with TBS and a 3 column volume elution with 0.1M glycine/ 
HC1 pH 2.5. The elution was collected in 2 ml fractions neutralised with 200pl 1M 
Tris/ HC1 pH 9. All buffers were filtered through a 0.22pm filter prior to use and the 
supernatant was filtered through a 0.45pm filter.
2.3.6 Ammonium sulphate cuts
Ammonium sulphate was used to precipitate 5SCR-Fc from cell culture supernatant. 
Solid ammonium sulphate was added to cell culture supernatant which was stirred at 
4°C. To achieve a cut of 40% saturation, 24g per 100ml supernatant was added. To 
increase the cut to 45% saturation a further 3g was added, another 3g was added to 
increase the cut to 50% saturation. Following each cut, the supernatant was stirred at 
4°C for 2 hours to allow complete protein precipitation. The precipitate was then 
harvested by centrifugation at 12,000g for 15 minutes. Following the protein 
harvest, the supernatant was subjected to the increasing cuts while the pellet was 
dissolved in PBS.
2.3.7 Anion and cation exchange chromatography
Ion exchange methods separate proteins based upon their differences in charge, anion 
exchange columns bind negatively charged proteins while cation exchange columns 
bind positively charged proteins. Proteins were separated using an increasing salt 
gradient. For the purification of 5SCR-Fc pre-packed Mono Q and Mono S columns 
(G E Healthcare) were used as the anion and cation exchange columns respectively. 
For the purification of rat C3 a Source Q column (GE Healthcare) was used as an 
anion exchange column. The columns were connected to an AKTA Purifier Liquid 
Chromatography System (GE Healthcare) with an automated Frac 901 fraction 
collector and UV absorbance meter.
2.3.7.1 Anion exchange of 5SCR-Fc
Following a cut of 50% saturation on 5SCR-Fc cell culture supernatant, the pellet 
was resuspended in 5mM sodium phosphate pH 8  and loaded onto a Mono Q 
column. The proteins were separated 0-150mM NaCl gradient over 25 column
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volumes followed by 150-500mM over a further 20 column volumes.
2.3.7.2 Cation exchange of 5SCR-Fc
An ammonium sulphate cut of 50% saturation was carried out on 5SCR-Fc cell 
culture supernatant and the pellet resuspended in malonate buffer. The resuspended 
pellet was loaded onto a Mono S column and the proteins were separated using an 
increasing salt gradient. The gradient was 0-250mM NaCl over 30 column followed 
by 250mM- 500mM NaCl over a further 10 column volumes.
2.3.7.3 Rat C3
Fresh rat serum (100ml) was mixed with 900ml 4 %  (w/v) PEG 6000, 5mM EDTA in 
PBS and incubated at 4°C for 30 minutes. The pellet was harvested by centrifugation 
at 10,000g for 30 minutes. The supernatant was retained and mixed with 385ml 30% 
(w/v) PEG 6000, 5mM EDTA in PBS. After incubation at 4°C for 30 minutes, the 
pellet was harvested at 10,000g for 30 minutes. The supernatant was discarded and 
the pellet resuspended in 5mM KPO4 , 5mM EDTA, 5mM benzamidine, pH 7.8. The 
pellet was loaded onto a Source Q column and the proteins were separated by a 0- 
0.5M NaCl gradient over 20 column volumes. The C3 containing peak was 
identified by dot blot and dialysed into 50mM NaP0 4  pH 6 . The C3 peak was loaded 
onto a Mono S column. The proteins were separated by a 0-1M NaCl gradient over 
20 column volumes. C3 was identified by dot blot and dialysed into lOmM HEPES, 
150mM NaCl pH 7.4 for storage at -80°C and further studies. In order to generate 
C3b-like C3b (C 3 m a ) ,  the rat C3 was methylamine inactivated. For this the C3 was 
dialysed against Borate Buffered Saline (BBS) while methylamine was diluted to 
0.2M in BBS. The C3 was incubated 1:1 with the 0.2M methylamine (0.1M final) 
for 2 hours at 37°C. The C3ma was dialysed against PBS to remove the methylamine 
and stored at -80°C.
2.3.8 Cibacron Blue
Affi-gel® blue affinity gel (Bio-Rad) was used as a source of Cibacron Blue F3GA 
dye which binds albumin. A 3ml column was poured under gravity and equilibrated
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in 20mM sodium phosphate pH 7.1. The protein sample was applied to the column 
and the column was washed with 20mM sodium phosphate, pH 7.1. The column was 
then washed in the 20mM sodium phosphate, 1.4M NaCl, pH 7.1 to elute bound 
albumin. For all the washes 2ml fractions were collected.
2.3.9 Gel filtration
Gel filtration separates proteins based upon size. Gel filtration columns consist of 
beads which contain pores; small proteins are able to enter these pores and are 
retained by the column. While large proteins are unable to enter the pores so pass 
through the column more quickly. For gel filtration of the proteins described here, a 
Superdex 200 (GE Healthcare) was used on the AKTA Purifier. Generally, protein 
was loaded with a maximum volume of 2.5% of the column volume (CV) i.e. 0.5ml 
loaded onto a 20ml column, and proteins were separated with a 1.5 column volume 
isocratic elution.
2.3.10 Dialysis and concentration of the proteins
Following purification of the protein of interest, fractions containing the protein were 
combined and dialysed into PBS unless otherwise stated. For the dialysis of all 
proteins, the dialysis tubing (Medicell International Ltd) used had a molecular weight 
cut off of 12-14 kDa. Following dialysis the proteins were concentrated to between 
0.5-1 mg/ml using an appropriate size Amicon ultrafiltration cell (Millipore). Table
2.4 shows the membrane cut off used to concentrate each protein.
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Protein Molecular weight cut off (kDa)
5SCR-Fc 1 0 0
4SCR-Fc 1 0 0
3SCR-Fc 1 0 0
4SCR 1 0
3 SCR 1 0
TLD1C11 1 0 0
C3 1 0 0
Table 2.4 Proteins purified and the molecular weight cut off of the membrane 
used for concentration.
84
2.4 Protein analysis
Determination of protein concentration and purity using SDS PAGE and ELISA 
analysis.
2.4.1 Buffers
Buffer Contents
Sodium Dodecyl Sulphate 
(SDS) stacking gel buffer: 0.5M Tris, 0.4% (w/v) SDS, pH 6 .8 .
SDS resolving gel buffer: 1.5M Tris, 0.4% (w/v) SDS, pH 8 .8 .
Non-reducing loading buffer: 0.1M Tris, 10% (v/v) glycerol, 2% (w/v) SDS, 
0.01% bromophenol blue, pH 6 .8 .
Reducing loading buffer: 5% (v/v) P-mercaptoethanol in non-reducing buffer.
Running buffer: 25mM Tris, 191mM glycine, 1% (w/v) SDS
Coomassie stain: 0.2% (w/v) Coomassie blue R250 in 45% (v/v) 
methanol, 1 0 % (v/v) acetic acid in dH2 0 .
Destain: 2 0 % (v/v) methanol, 8 % (v/v) acetic acid in dH2 0 .
Gel drying buffer: 4% (v/v) glycerol, 20% (v/v) methanol in dH2 0 .
Transfer buffer: 25mM Tris, 191mM glycine, 20% (v/v) methanol.
ELISA coating buffer: 0.2M Na2C 03, pH 9.6.
ELISA developing solution: 4 OPD tablets (Dako) dissolved in 12ml dH2 0  plus 
5pi of 30% (v/v) H2O2 .
2.4.2 Protein concentration
The concentration of purified proteins was obtained by measuring their absorbance a 
280nm in a spectrophotometer (Jenway). The concentration was calculated using the 
following equation:
C = A / e where C is concentration (mg/ml), A is absorbance and e is the extinction 
coefficient when the pathlength is 1 cm.
Table 2.5 shows the extinction coefficients used for each protein.
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Protein Extinction coefficient
TLD1C11 1.4
5SCR-Fc 1.3
4SCR-Fc 1.2
3SCR-Fc 1.3
4SCR 1.2
3 SCR 1.3
C3 1.0
Table 2.5 The extinction coefficients of the proteins purified in this thesis.
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2.4.3 Antibodies
The antibodies used within this project for Western blot, dot blot and ELISA analysis
are detailed below in table 2.6.
Name Antigen
recognised
Isotype Species Source
TLD1C11 Rat Crry IgGl Mouse Prof. W. Hickie, 
(Dartmouth, USA)
512 Rat Cny IgGl Mouse Prof. H. Okada, 
(Nagoya, Japan)
Anti-rat Ig Rat Ig Polyclonal Sheep Binding Site
Anti-rat Crry Rat Crry Polyclonal Rabbit In house
Anti-rat Ig 
HRPO
Rat Ig Polyclonal Donkey Jackson
Laboratories
Anti-mouse Ig 
HRPO
Mouse Ig Polyclonal Goat Jackson
Laboratories
Anti-rabbit Ig 
HRPO
Rabbit Ig Polyclonal Donkey Jackson
Laboratories
Anti-human
C3c
Human C3c, 
also cross 
reacts with rat 
C3c
Polyclonal Sheep Binding Site
Anti-sheep Ig 
HRPO
Sheep Ig Polyclonal Donkey Binding Site
Anti-bovine Ig 
HRPO
Bovine Ig Polyclonal Donkey Jackson
Laboratories
Anti-rat IgGl 
HRPO
Rat IgGl IgGl Mouse Southern Biotech
Anti-rat IgG2a 
HRPO
Rat IgG2a IgGl Mouse Southern Biotech
Anti-rat IgG2b 
HRPO
Rat IgG2b IgG2b Mouse Southern Biotech
Anti-rat IgG2c 
HRPO
Rat IgG2c IgG2a Mouse Southern Biotech
Anti-rat IgM 
HRPO
Rat IgM IgGl Mouse Southern Biotech
Table 2.6 A summary of the antibodies used within this project.
2.4.4 SDS PAGE analysis
Electrophoretic separation of proteins was carried out using the Hoefer mighty small 
gel apparatus. Gels were poured with an acrylamide concentration according to the 
size of the proteins to be resolved, low molecular weight proteins were resolved on 
higher percentage gels while high molecular weight proteins were resolved on lower
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percentage gels. Typically gels were poured with a 5% acrylamide stacking gel and 
a 7.5-12.5% acrylamide resolving gel. Table 2.7 gives the gel recipes.
Percentage gel —> 5%
(stacking)
7.5%
(resolving)
10% 11% 12.5%
Stacking gel Buffer (ml) 2.4 - - - -
Resolving gel Buffer (ml) - 7.5 7.5 7.5 7.5
40% Acrylamide (ml) 1.3 5.6 7.5 8.4 9
10% Ammonium 
Persulphate (pi)
100 300 300 300 300
dH20  (ml) 6.1 16.4 14.5 13.6 13.0
TEMED (pi) 10 30 30 30 30
Table 2.7 Gel recipes for stacking and resolving SDS PAGE mini-gels, recipe 
makes 4 mini-gels.
In general, the protein or protein mixture of interest was mixed with either 15 pi of 
non-reducing or reducing loading buffer and boiled for 5 minutes. The samples were 
loaded into the wells of the SDS PAGE gel within a running tank (Hoefer) 
containing running buffer. The gels were subjected to electrophoresis at 200V for 
between 45-60 minutes. Time depended upon the percentage gel being used.
2.4.5 Silver staining
In order to detect between 100ng-2pg of protein, SDS PAGE gels were silver stained 
(Morrissey 1981). Gels were:
■ rinsed in CIH2O
■ soaked for 30 minutes in 50% (v/v) methanol, 10% (v/v) acetic acid
■ soaked in 5% (v/v) methanol, 7% (v/v) acetic acid for 30 minutes
■ rinsed with dH2 0
■ soaked in 5% (v/v) glutaraldehyde for 30 minutes
■ washed in dH2 0  overnight
■ soaked in DTT (5pg/ml in CIH2O) for 30 minutes
■ rinsed with dH2 0
■ stained with 0.1 % (w/v) AgNC>3 in dH20 for 30 minutes
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■ rinsed in dtfeO
■ developed in 0.28M Na2CC>3 containing 0.0185% (v/v) formaldehyde.
■ development was stopped by adding solid citric acid (~lg/50ml developing 
solution).
All steps were carried out with agitation. Following the silver staining procedure, 
gels were soaked in gel drying buffer and dried as described below.
2.4.6 Coomassie staining
To detect 2-5pg of protein SDS PAGE gels were Coomassie stained. Following 
electrophoresis, the gels were soaked in Coomassie stain with agitation for 30 
minutes. Excess stain was removed and the gels soaked in destain solution with 
agitation until the background staining was minimised and the bands were clearly 
visible. Gels were soaked in gel drying buffer for at least 30 minutes. The gels were 
placed between pre-soaked acetate gel drying film (Promega) and stretched within a 
gel drying frame overnight.
2.4.7 Western blotting
To identify specific proteins of interest within a SDS PAGE gel, Western blotting 
was used. Table 2.8 gives details of the Western blots carried out in this thesis. 
Following electrophoresis, the gel was soaked in transfer buffer along with 
nitrocellulose (VWR), blotting paper and sponges. The nitrocellulose was placed on 
top of the gel and these were sandwiched between blotting paper between sponges 
within a cassette. The cassette was placed within a blotting tank (Hoefer system) 
with the nitrocellulose closest to the anode and the gel closest to the cathode. The 
transfer was run at 100V for 1 hour. The nitrocellulose was removed from the tank 
and cassette, and blocked with PBS, 5% (w/v) non-fat dried milk (PBS milk) for 30 
minutes at room temperature. Following blocking, the blot was probed with a 
relevant antibody at lpg/ml in PBS milk overnight at 4°C. The blot was washed and 
probed with a horseradish peroxidase (HRPO) conjugated secondaiy antibody 
(1/1000 -  1/10000) in PBS milk. In some instances, for example when detecting a 
rat Fc domain, the primary antibody was directly conjugated to the enzyme and this 
incubation was carried out for an hour at room temperature. In between the
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incubations with primary and secondary antibodies as well as after the secondary 
antibody incubation the blots were washed 3 times for 10 minutes in PBS, 0.1% (v/v) 
Tween followed by 3 times 10 minute washes in PBS. Blots were developed using 
Super Signal Reagent (Pierce) by mixing the reagents 1:1 and incubating the blot in 
them for 3 minutes. The Super Signal Reagent was removed from the blot and the 
blot was exposed to X-OMAT UV-film (Kodak) and developed in a Compact X2 
developer (X-Ograph Ltd).
Western Primary antibody Secondary antibody
Detection of Crry fusion 
proteins
Anti-rat Ig HRPO
Detection of all Crry 
proteins
TLD1C11 Anti-mouse Ig HRPO
C3 detection Anti-human C3c Anti- sheep Ig HRPO
Detection of TLD1C11 - Anti-mouse Ig HRPO
Bovine antibody detection - Anti-bovine Ig HRPO
Cofactor assay Anti-human C3c Anti-sheep Ig HRPO
Table 2.8 Western blots carried out along with the detection antibodies used.
2.4.8 Dot blots
Proteins (1-2 pi depending upon concentration) were spotted directly onto 
nitrocellulose. The nitrocellulose was left to air dry and then was blocked at room 
temperature for 1 hour in PBS milk. Dot blots were probed and developed as with 
Western blots.
2.4.9 ELISA
ELIS As were used to identify and quantify the Crry proteins and TLD1C11, table 
2.9. ELISA plates (MP Biomedicals) were used for the ELISAs. All steps were 
carried out for 1 hour at 37°C and were separated by washing the wells of the plate 3 
times with 1 50j l x 1 PBS, 0.1% (v/v) Tween. In brief, the plate was coated with lOOpl 
per well of a capture protein or antibody at 1 pg/ml in ELISA coating buffer, blocked 
with 150pl per well of PBS, 5% (w/v) milk and incubated with the sample of interest
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or standard in an appropriate dilution (lOOpl per well). The plate was incubated with 
lOOpl per well of detection antibody at ljxg/ml followed by lOOpl per well of a 
HRPO conjugated secondary antibody at 1/1000 or with the conjugated antibody 
alone. The ELIS As were developed with lOOpl per well of ELISA developing 
solution and stopped with 50pl of 10% H2 SO4  when background began to increase. 
Absorbance was read at 490nm in a microplate reader.
ELISA Capture Sample Detection
antibody
Secondary
antibody
Quantification and 
detection of Crry- 
Fc proteins
TLD1C11 Cell culture 
supernatant or 
pure protein
Anti-rat Ig HRPO
Quantification and 
detection of non- 
Fc Crry proteins
TLD1C11 Cell culture 
supernatant or 
pure protein
anti-Crry
(polyclonal
antiserum)
Anti-rabbit Ig 
HRPO
Quantification and 
detection of 
TLD1C11
5SCR-Fc Cell culture 
supernatant or 
pure protein
Anti-mouse Ig 
HRPO
DAF-Fc immune 
response
Rat DAF- 
human Fc
Serum HRPO 
conjugated anti­
rat IgM, IgGl, 
IgG2a, IgG2b or 
IgG2c
Crry-cys immune 
response
Crry-cys Serum HRPO 
conjugated anti­
rat IgM, IgGl, 
IgG2a, IgG2b or 
IgG2c
Crry-Fc immune 
response
Crry-Fc Serum HRPO 
conjugated anti­
rat IgM, IgGl, 
IgG2a, IgG2b or 
IgG2c
CD59-Fc response CD59-Fc Serum HRPO 
conjugated anti­
rat IgM, IgGl, 
IgG2a, IgG2b or 
IgG2c
Table 2.9 ELIS As used along with capture, sample and detection antibodies.
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2.5 Functional analysis
The functional analysis of the Crry proteins.
2.5.1 Buffers and reagents
Buffer Contents
Complement Fixation Diluent 
(CFD; Oxoid):
2.8mM Barbituric acid, 145.5mM NaCl, 0.8mM 
MgCl2 , 0.8mM CaCl2 , 0.9mM Sodium Barbital, 
pH 7.2
Alternative pathway (AP) buffer: 5mM sodium barbitone, 150mM NaCl, 7mM 
MgCl2, lOmM EGTA
HBS-P (Biacore): lOmM HEPES, 150mM NaCl, 0.005% (v/v) 
Surfactant P20, pH 7.4
HBS-EP (Biacore): lOmM HEPES, 150mM NaCl, 0.005% (v/v) 
Surfactant P20, 3mM EDTA, pH 7.4
PBS; 8.2mM Na2HP04, 1.5mMKH2P 04, 137mM 
NaCl, pH 7.4.
2.5.2 Classical pathway haemolysis assay
2.5.2.1 Preparation of sheep erythrocytes
Sheep erythrocytes (TCS) were washed into PBS and diluted to 4% (v/v). 
Amboceptor (rabbit anti-sheep erythrocytes, Behring Diagnostics) was diluted 1 in 
250 in PBS and incubated 1:1 with the sheep erythrocytes for 30 minutes at 37°C. 
The antibody coated sheep erythrocytes (E) were washed into CFD and diluted to 2% 
(v/v).
2.5.2.2 Titre of rat serum
To establish the amount of rat serum required to cause 60% lysis an assay was 
carried out using a serum titration. Two 10-step 1:2 serial dilutions of rat serum 
were set up, one beginning at 1/10 and the other at 1/15. Fifty micro-litres of each 
concentration was incubated with 50pl antibody coated sheep E and 50pl CFD in a 
round-bottomed 96-well plate. Control wells were included for 100% lysis in which
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the rat serum was substituted for 50pl 0.1% (v/v) NP40 and 0% lysis in which the rat 
serum was substituted for 50pl CFD. Each concentration was carried out in 
duplicate. Following incubation at 37°C for 30 minutes, the remaining sheep E were 
pelleted by centrifugation at 900g for 5 minutes. The supernatant (50pl) was 
removed from each well and added to lOOpl dFfeO in a flat-bottomed 96-well plate. 
The absorbance at 415nm was measured and was used to calculate the degree of lysis 
(proportion of haemoglobin released)
Percentage lysis was calculated using the following equation:
% lysis = 100 X (A4i5TeSt - A415°/o) / (A415100/o - A415°/o)
The concentration of serum giving 60% lysis was used in subsequent assays.
2.5.2.3 Function of Crry proteins
To compare the function of the Crry proteins they were diluted in a 10-step 1:2 serial 
dilution beginning at 140nM of Cny. As a control, a 10-step 1:2 serial dilution of rat 
immunoglobulins (Ig) was used. In the assay 50pl antibody coated sheep E were 
incubated with 50pl of Crry from the dilution series and 50pl rat serum diluted to 
give 60% lysis in the absence of inhibition. Controls for 100% and 0% lysis were 
included. Each incubation was carried out in triplicate. The assay was incubated at 
37°C for 30 minutes. Following the incubation the remaining sheep E were pelleted, 
the absorbance at 415nm measured and the percentage lysis calculated. The 
following equation was used to calculate percentage inhibition of lysis.
Inhibition of lysis (%) = 100 x (%lysis with rat Ig- %  lysis with Crry) / %  lysis rat Ig 
Percentage inhibition of lysis (y-axis) was plotted against the log of concentration (x- 
axis) and was used to calculate the concentration of each Crry protein that caused 
50% inhibition of lysis (IH50).
2.5.3 Alternative pathway haemolysis
2.5.3.1 Titre of rat serum
Guinea pig erythrocytes (GPE) were washed into AP buffer and diluted to 1.5% 
(v/v). To establish the amount of serum needed to cause 60% lysis, rat serum diluted 
in two 10-fold 1:2 serial dilutions beginning at 1 in 2 and 1 in 3. Fifty micro-litres of 
serum from the dilution series was incubated with 50pl GPE and 50pl AP buffer.
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Control wells contained 50pl 0.1% NP40 instead of serum for 100% lysis or 50jal AP 
buffer instead of the serum for 0% lysis. The assay was carried out in duplicate. The 
assay was incubated at 37°C for 30 minutes, the absorbance at 415nm was measured 
and percentage lysis calculated as described for the classical pathway haemolysis 
assay.
2.5.3.2 Function of Crry proteins
To compare the Crry proteins they were diluted in a 10-fold 1:2 serial dilution 
beginning at 560nM Crry. GPE (50pi) were incubated with 50pl Crry proteins from 
the concentration titre and 50pl rat serum (at a concentration that caused 60% lysis in 
the absence of inhibition). Controls included a titre of rat Ig beginning at 560nM, 
100% lysis and 0% lysis as described previously. Following the incubation at 37°C 
for 30 minutes, the absorbance at 415nm was measured. The percentage lysis, 
percentage inhibition of lysis and the concentration of the Crry proteins required to 
cause 50% inhibition of lysis (IH50) was calculated as described above.
2.5.4 Cofactor assay
Rat C 3 m a  (2.5pg) was incubated with 0.5pg rat factor I and 2pg of individual Crry 
proteins, the reaction volume was taken to 50pl with PBS. The following control 
incubations were included:
Control Purpose
C 3 m a  (2.5pg) only Rule out contamination with both 
factor I and cofactors
C 3 m a  (2.5pg) and factor I (0.5pg) only Rule out contamination of either with 
cofactors
C 3 m a  (2.5pg), factor I (0.5pg) and human 
soluble complement receptor 1 (sCRl, 
2ng)
Positive control
C3\iA(2.5pg) and human sCRl (2pg) Rule out contamination of CR1 and 
C 3 m a  with factor I
5SCR-Fc, 4SCR-Fc, 3SCR-Fc, 4SCR or 
3SCR with C3MA(2.5pg)
Rule out contamination of Crry 
proteins and C 3 m a  with factor I
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All incubations were carried out at 37°C for 4 hours. Following incubation 6pl of 
each reaction was loaded onto a 10% SDS PAGE gel. The gel was either silver 
stained or Western blotted and probed for C3.
2.5.5 Decay accelerating function
The ability of the Crry proteins to decay the alternative pathway C3 convertase was 
assessed by surface plasmon resonance using the Biacore® 3000. The Biacore® 
utilises a gold covered chip coated with dextran, molecular interactions occur on this 
dextran. Any molecular interactions causing mass changes alter the read out of the 
machine (Malmqvist 1999).
2.5.5.1 Surface preparation
One hundred RU of human C3b dimer (lOOng/ml in lOmM citrate pH4) was amine 
coupled to the chip surface (CM5 chip, Biacore®). The remaining active sites on the 
chip surface were blocked with 0.1M ethanolamine pH 8.5 (figure 2.4). The 
covalently immobilised human C3b was used to form the AP C3 convertase with 
factors B and D. This convertase was used to cleave rat C3 resulting in the 
deposition of rat C3b on the surface. HBS-P supplemented with ImM MgCl2 was 
used as the running buffer for the system, the flow rate was 5pl/min. Following 
immobilisation of human C3b, human factors B and D (Quidel, 200pg/ml and 
12pg/ml respectively) were mixed 1:1 and 20pl was injected across the chip surface 
immediately followed by 20jxl rat C3 (0.9mg/ml). The factors B and D formed 
C3bBb which cleaved rat C3 resulting in the deposition of rat C3b on the surface 
through nucleophilic attack upon the thioester group within C3b by amine groups on 
the chip surface. The cycle of C3bBb formation followed by rat C3b deposition was 
repeated until 5000RU of rat C3b had been deposited. The surface was stabilised by 
a lOpl injection of 50mM diethylamine pH 11 to remove any loosely bound rat C3b.
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Figure 2.4 Sensogram of the preparation of the chip surface.
The association of human C3b dimer with the chip was first tested by injection of 
human C3b dimer (lOpl). The non-specifically bound human C3b dimer was 
removed from the surface by injection of 5pl 50mM NaOH. The surface was activated 
with 35pl of N-hydroxysuccinimide and 1-ethyl-3 (3-dimethylaminopropyl)- 
carbodiimide hydrochloride (mixed 1:1). The human C3b dimer was injected in 2pl 
injections until 100RU was reached. The surface was blocked with 35pi 0.1M 
ethanolamine pH 8.5.
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2.5.5.2 Crry and human C3b interaction
Due to the presence of human C3b on the chip surface the interactions between rat 
Crry and human C3b were investigated. Therefore a chip was coated with 100RU of 
human C3b dimer followed by injection of factors B and D (described previously, 
section 2.5.5.1). Immediately following formation of the human C3 convertase lOp.1 
of 4SCR (700pg, 25pM) was injected to assess whether rat Crry could decay the all­
human C3 convertase. The injection was followed by an injection of human CD55 
(lOpl, lpM) which has previously been shown to shown to decay the human C3 
convertase on the chip surface (Harris, Abbott et al. 2005). On a separate CM5 chip, 
200RU of 4SCR (25pg/ml in lOmM citrate pH 4) was amine coupled to the surface 
following the previously described method (section 2.5.5.1). Human C3b dimer 
(20pl, 5mM) was injected across the surface to assess binding between human C3b 
and rat Cny.
2.5.5.3 Decay acceleration assay
The deposited rat C3b was used to form the C3bBb convertase using a 30pl injection 
of human factors B and D in the concentrations described previously. The 
convertase was allowed to decay naturally (in the presence of no complement 
regulators) or lOpl of a Crry protein from a 5-fold 1:2 serial dilution beginning at 
1.8pM was injected. A separate convertase was built up on the surface for each 
concentration of each protein. Prior to each convertase formation lOpl 50mM 
diethylamine pH 11 was injected to ensure that no Crry from the previous injection 
remained on the surface. By measuring the amount of convertase remaining on the 
chip surface following decay and comparing with the amount of convertase in the 
absence of any regulation, percentage decay was calculated as:
Percentage decay = 100 x (y axis natural - y axis after Crry) / y axis natural.
The percentage of decay (y-axis) was plotted against concentration (x -axis) and the 
concentration of inhibitor to decay 50% of the convertase was calculated.
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2.5.6 Affinity analysis
2.5.6.1 Affinity analysis 500RU coat
The affinity of the 4SCR and 3 SCR Crry proteins for rat C3b was assessed using 
surface plasmon resonance and the Biacore® 3000. HBS-P (Biacore®) was used as 
the buffer. Fifty RU of human C3b dimer was immobilised on a CM5 chip as 
described previously (section 2.5.5.1). Human factors B and D (lOOpg/ml and 
6pg/ml respectively) were used in 15pi injections to form the C3 convertase and with 
injections of rat C3 deposited 500RU of rat C3b on the surface. The surface was 
stabilised by a lOpl injection of 50mM diethylamine pH 11 to remove loosely bound 
rat C3b. Both 3 SCR and 4SCR were diluted in a 6-fold 1:2 serial dilution and each 
concentration was injected across the surface with a 90 second contact time followed 
by a 60 second dissociation in buffer, flow rate lOpl/min. The 4SCR concentration 
began at 350pg/ml (12.5pM) while 3SCR began at 700pg/ml (33.3pM). Each 
concentration was injected in duplicate. The dissociation equilibrium constant (KD) 
was calculated by plotting the response (y-axis) against concentration (x-axis). The 
point at which response no longer increases with concentration is the Rmax. The 
concentration corresponding to 50% Rmax is the KD (figure 2.5). In Biacore the 
chi shows how well the data fits to the computer-modelled interaction, the smaller
9 9the chi the more reliable the data. Chi is calculated using the following equation:
X2 = Z ( 0 - E ) 2/E
where O is the observed value and E is the expected value
2.5.6.2 Affinity analysis 1000RU coat
The affinity analysis was repeated on the same chip with the coat of rat C3b 
increased to 1000RU by forming the C3bBb convertase by injecting human factors B 
and D followed by rat C3 as described above. The surface was stabilised as before 
and the injections of 4SCR and 3SCR repeated. With this experiment the 4SCR 
serial dilution began at 700pg/ml (25pM) and the 3SCR serial dilution began at 
700pg/ml (33.3pM). The dissociation equilibrium constant (KD) was calculated as 
described above
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Figure 2.5 Calculation of Rmax and KD
The point at which response no longer increases with concentration is the Rmax. Half 
of Rmax (50% Rmax) corresponds to the dissociation equilibrium constant (KD).
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2.5.7 TLD1C11 ligand interaction
To investigate the interaction of TLD1C11 (anti-Crry monoclonal antibody) with 
Crry surface plasmon resonance was used. TLD1C11 (60pM in lOmM citrate pH 
4.5) was deposited on the surface of a CM5 chip within the Biacore® 3000 using 
amine coupling (section 2.5.5.1), 750RU was deposited. An excess of 5SCR-Fc 
(20jj,1 at 0.6mM) was injected across the surface and the interaction monitored.
2.6 In vivo analysis
The assessment of the half-life, immunogenicity, in vivo complement inhibition and 
therapeutic efficacy of 4SCR-Fc and 4SCR.
2.6.1 Buffers and reagents
Buffer Contents
PBS (phosphate buffered 8.2mM Na2HP04, 1.5mMKH2P04, 137mMNaCl,
saline) pH 7.4.
FACS buffer PBS, 1% (w/v)BSA, lOmM EDTA, 0.01% (w/v) 
sodium azide, pH 7.4
CFD 2.8mM Barbituric acid, 145.5mM NaCl, 0.8mM 
MgCl2, 0.8mM CaCl2, 0.9mM Sodium Barbital, pH 
7.2
All animals were obtained from Charles River Laboratories and maintained 
according to Home Office guidelines within the Biomedical Services Unit (BSU) at 
the School of Medicine, Cardiff University.
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2.6.2 In vivo half-life
2.6.2.1 Iodination
4SCR-Fc and 4SCR (lmg of each) were labelled with 125I using Iodobeads (Pierce) 
according to the method of Fraker and Speck (Fraker and Speck 1978). Following 
iodination, the proteins were isolated from the reaction mix by gel filtration into PBS 
using PD10 columns (G E Healthcare), 600pl fractions were collected. The fractions 
corresponding to the highest protein concentration were combined and used in the 
subsequent experiment. The iodination was carried out by Prof. B. P. Morgan, 
Department of Medical Biochemistry and Immunology.
2.6.2.2 In vivo experiment
Two groups of 5 female Lewis rats were used. Group A were injected i.v. with 
150pl 4SCR-Fc whilst group B were injected i.v. with 150pl 4SCR, approximately 
12 x 106 cpm of each protein. The animals were tail bled at the following time points 
1, 3, 5, 15 and 30 minutes, 1, 2, 4, 6, 8, 24, 36, 48, 72 and 96 hours post injection. 
For the bleeds until 2 hours post injection, 20pl of blood was collected into 0.5ml 
200mM EDTA to prevent clotting. To enable accurate detection of decreasing 
amounts of radioactivity the blood volume collected was increased to 30pi for the 4- 
10 hours post injection bleeds, 50pl for the 24 and 48 hours post injection bleeds and 
lOOpl for the 72 hour post injection bleed, all bleeds were taken into 0.5ml 200mM 
EDTA. At 96 hours post injection, 1ml of blood was collected into lOOpl 200mM 
EDTA. The in vivo experiment was carried out in collaboration with Dr Anwen 
Williams, Department of Rheumatology, who carried out the i.v injections and 
collected the tail bleeds.
2.6.2.3 Determination of half-life
The amount of radioactivity in the injection was counted by adding lOpl of the 
injection to 1ml foetal bovine serum (FBS) and 9ml PBS. One millilitre was counted 
to a Wallac Multigamma Gamma counter to give the total counts/ml. To calculate 
protein bound counts, 1ml 20% (v/v) trichloroacetic acid (TCA) was added to 
precipitate the protein and the supernatant isolated by centrifugation at 900g for 10
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minutes. One millilitre of the supernatant was counted to give the free iodine 
measurement. Protein bound counts was calculated as follows:
Protein bound counts = total counts -  (2 x free iodine counts)
To ascertain the total counts from the bleeds, 0.5ml FBS was added to each bleed and 
the total counts were obtained above. The free iodine was measured by adding 1ml 
20% TCA, centrifuging to pellet the precipitated protein and measuring the counts of 
lml of the supernatant. The protein bound counts were calculated as described 
previously.
For each time point the protein bound counts per ml of blood was calculated and 
expressed relative to the protein bound counts at 5 minutes post administration to 
account for the initial distribution through the body as follows:
% of 5 minute level = 100 x protein bound counts at time, T / protein bound counts at
5 minutes
The percentage counts (y-axis) were plotted against the log of time in hours (x-axis). 
The half-life was calculated from the slope of the linear region of the line.
(3-half-life = 0.693 / -slope
2.6.3 Immunogenicity study
2.6.3.1 In vivo experiment and measurement of immune response
Three groups of 5 female Wistar rats were injected i.v. with 1 mg/kg of sCrry-cys 
(group A), rat DAF-human Fc (group B) or Crry-Fc (group C) on day 0, 3, 7, 14, 21 
and 28. The animals were tail bled (200pl) on day 0 (pre-bleed), 7, 14, 21, 28 and 
35. The blood was allowed to clot at room temperature for 30 minutes, stored on ice 
for 30 minutes and the serum was harvested by centrifugation at 12000g for 10 
minutes. The immune response was measured by detecting antibody generation 
using ELISAs. Section 2.4.9 describes the ELISA set up. This experiment was 
carried out in collaboration with Dr Anwen Williams, Department of Rheumatology, 
who carried out the injections and collected the blood samples.
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2.63.2 Characterisation of the immune response
To determine if the Crry-Fc immune response recognised the whole molecule or just 
part of the molecule an ELISA was carried out as described in section 2.4.9 coating 
with Crry-Fc, sCrry-cys or CD59-Fc (same Fc domain; rat IgG2a). An ELISA was 
also used to calculate the concentration of Crry-Fc remaining in the serum taken at 
each time point. The concentration of Crry-Fc at each time point was calculated 
from the standard curve, a 10-fold 1:2 dilution beginning at 1 pg/ml.
The affect of the immune response on the function of Crry was judged using CHO 
cells expressing rat Crry on their surface. These cells had been generated in house 
previously by transfecting CHO cells with the pDR2AEFla vector containing DNA 
encoding the full length of rat Crry including the transmembrane region. Deposition 
of antibodies from the immune sera was detected by incubating 50pl of cells at 2 x 
106/ml in FACs buffer with either 50pl of immune serum at 10% (v/v) in FACs 
buffer, TLD1C11 (anti-Crry monoclonal antibody at 1 pg/ml) or normal rat serum at 
10% (v/v) in FACs buffer for 30 minutes at 4°C. The cells were washed three times 
by centrifugation at 300g for 3 minutes and resuspension in FACs buffer. Deposition 
of anti-Crry antibodies was detected by incubating the cells with 5% donkey anti­
mouse Ig RPE (Dako; cross reacts with rat Ig) for 1 hour at 4°C. The cells were 
washed as previously described and fixed in 1.5% (v/v) formaldehyde prior to 
processing on a FACSCalibur (Becton Dickinson).
Changes in C3 deposition on the Crry expressing CHO cells were used to assess 
whether the deposited antibodies inhibited the function of Crry. The CHO cells (50pl 
at 2 x 106/ml in FACs buffer) were incubated with 50pl rabbit polyclonal anti-CHO 
antiserum (heat-inactivated) at 10% (v/v) in FACs buffer at 4°C for 30 minutes. 
Cells that were not antibody coated were incubated in FACS buffer for the same 
period. The cells were washed as described previously and were incubated with 
either 100pl immune response serum from the day 35 bleeds, normal rat serum, 
normal rabbit serum or rabbit polyclonal anti-Crry antiserum. All were heat 
inactivated and at 20% (v/v) in FACs buffer, the incubation was carried out for 30 
minutes at 4°C. The cells were washed in CFD three times by centrifuging the cells 
at 300g for 3 minutes and resuspending in CFD. The cells were incubated in lOOpl 
of 2% (v/v) rat serum for 30 minutes at 37°C. The deposition of C3 was detected
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with lOOpl of mouse ascites anti-human C3b monoclonal antibody (C3/30; cross 
reacts with rat C3) at 0.2% (v/v) in CFD, the incubation was carried out at 4°C for 30 
minutes. The anti-C3b antibody was detected with lOOpl of donkey anti-mouse Ig 
RPE at 1% (v/v) by incubation at 4°c for 1 hour. The cells were fixed in 1.5% 
formaldehyde and processed as above.
2.6.4 In vivo complement inhibitory activity
The in vivo complement inhibitory activity (CH50) of 4SCR-Fc and 4SCR was 
investigated in rats with EAMG (experimental autoimmune myasthenia gravis; see 
section 2.6.5). The rats were tail bled (lOOpl) pre-disease induction and then at the 
following time points: 2, 4, 6, 24, 48, 72 and 96 hours post induction. The blood was 
allowed to clot at room temperature for 30 minutes, stood on ice for 30 minutes and 
then centrifuged at 12,000g for 10 minutes. The serum was isolated from the clot.
2.6.4.1 CH50 assay
For each animal the serum was first diluted to 2% (v/v) in CFD and then this diluted 
serum was further diluted: 95%, 90%, 87.5%, 83%, 75%, 50%, 25%, 17.5%, 12.5%, 
10%, 5%, 2.5% and 1.3% (v/v). Serum (50pl) from each concentration was 
incubated with 50pl antibody coated sheep erythrocytes (described section 2.5.2) in a 
round-bottomed 96-well plate for 30 minutes at 37°C. To establish 0% lysis, 50pl 
sheep erythrocytes were incubated with 50pl CFD and to establish 100% lysis, 50pi 
cells were incubated with 50pl dF^O. The assay was carried out in triplicate. 
Following the incubation 150pl CFD was added and the cells pelleted by 
centrifugation at 900g for 5 minutes. Supernatant (150pl) from each well was 
transferred to a flat-bottomed 96-well plate and the absorbance at 415nm was 
measured.
For each time point percentage lysis was calculated as described in section 2.5.2 and 
was plotted against log of serum volume used (pi). The volume of serum to bring 
about 50% lysis was calculated. The volume of serum to bring about 50% lysis at 
each time point was expressed relative to the volume of serum from the pre-bleed 
calculated to cause 50% lysis as follows:
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%  haemolytic activity = 100 x (volume of serum to cause 50% lysis for the pre­
bleed/ volume of serum to cause 50% lysis at time
(D)
Percentage haemolytic activity (y-axis) was plotted against time in hours (x -axis).
2.6.5 Therapeutic activity
2.6.5.1 EAMG disease induction
On day 0, 3 groups of 6 female Lewis rats (160-200g) were injected i.p with 1 mg/kg 
of mAb35, a rat monoclonal anti-acetylcholine receptor antibody (Piddlesden, Jiang 
et al. 1996). The animals were also administered an appropriate therapeutic agent 
i.v. Animals in group A were given PBS (lml/animal), those in group B 4SCR at 
lOmg/kg and those in group C 4SCR-Fc at 20mg/kg. Prior to injection a pre-bleed 
was taken by tail tipping, further bleeds were taken at 2, 4, 6, 24, 48, 72 and 96 hours 
post induction and processed at described in section 2.6.4.
Animals were assessed daily for evidence of EAMG. The weights of the animals 
were measured as well as the clinical score. The clinical score was measured by the 
ability of the animals to grasp and lift the lid of a mouse cage.
0. no disease
1. reduced grip strength in front paws, could grip but not lift
2. loss of grip in front paws
3. loss of grip and hind limb weakness and wasting
4. loss of grip and hind limb paralysis
After the onset of clinical symptoms rats were given pre-wetted food. The animals 
were sacrificed by a schedule 1 method when weight loss was equal to or greater 
than 20% of the original body weight, or when the clinical score reached 4. This 
experiment was carried out in collaboration with Dr Anwen Williams, Department of 
Rheumatology, who administered the i.v injections and Dr Jayne Chamberlain- 
Banoub who administered the i.p injections, collected the blood samples, clinically 
scored the animals and carried out the histology (method 2.6.5.2).
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2.6.5.2 Histological analysis
The soleus muscle was isolated from the sacrificed rats and subjected to flash 
freezing in isopentane cooled on dry ice, the muscles were stored at -80°C. The 
muscles were embedded in OCT medium (Agar Scientific) and 10pm sections were 
cut on a cryostat and transferred to slides (Surgipath). Slides were acetone fixed for 
5 minutes and stained with Bungarotoxin (BuTx)-rhodamine conjugate (Molecular 
probes) at 0.5% (v/v) in PBS 1% (w/v) BSA for 40 minutes at room temperature in a 
humid chamber. The sections were also stained for C3 deposition, C9 deposition and 
macrophage infiltration with an appropriate antibody, see below.
Purpose Antibody Supplier Concentration Working
dilution
C3 deposition Goat anti-rat C3c Nordic
laboratories
8mg/ml 1:400
C9 deposition Sheep anti-human 
C9
In house n/a, polyclonal 
antiserum
1:400
Macrophage
infiltration
Mouse anti-rat 
CD68
Serotec 0.5mg/ml 1:400
In between antibody incubations, the slides were washed 3 times in PBS for 5 
minutes each. Secondary antibodies at 0.5% (v/v) (donkey anti-mouse Ig FITC or 
donkey anti-goat/sheep Ig FITC both Jackson) were incubated with the slides in PBS 
1% (w/v) BSA for 40 minutes at room temperature in a humid chamber. Following 
washings in PBS the sections were mounted in Vectashield (Vector Laboratories) to 
prevent fading of the fluorescent signal and analysed on a fluorescent microscope.
To assess inflammatory infiltration by Haematoxylin and Eosin (H and E) staining, 
the isolated soleus muscle was fixed in 10% (v/v) formaldehyde overnight at 4°C and 
paraffin-wax embedded by the Department of Histology. The embedded muscle was 
cut into 8pm sections and transferred to glass slides. Sections were dried at room 
temperature for at least an hour followed by 60°C overnight. The sections were 
placed in 100% xylene for 10 minutes followed by fresh xylene for 5 minutes to 
remove the paraffin. Sequential 5 minute incubations in 100% ethanol, 95% (v/v)
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ethanol, 70% (v/v) ethanol and tap water were carried out. Sections were stained 
with Harris’ Haematoxylin for 5 minutes, ‘blued’ in Scott’s tap water and then 
washed in ordinary tap water. The staining was differentiated in 1% acid alcohol 
(70% (v/v) ethanol, 0.04% (v/v) hydrochloric acid) for 1-2 seconds and washed in 
tap water. The sections were stained in Eosin for 2 minutes, washed in tap water, 
dehydrated by sequential 5 minute incubations in 70% (v/v) ethanol and 95 %  (v/v) 
ethanol, cleared in 100% xylene for 10 minutes and mounted with XAM neutral 
mounting medium (BDH).
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Chapter 3: Generation of recombinant forms of rat Crry.
3.1 Introduction
Since its emergence in the 1970’s recombinant DNA technology has enabled 
enormous advances to occur in the understanding of gene structure and protein 
function, and it has revolutionised protein production. To produce recombinant 
proteins the relevant piece of DNA can be amplified using the polymerase chain 
reaction (PCR). This DNA can be cut (restricted) and ligated into an expression 
vector using enzymes. The vector can then be used to transfect a host system, which 
is used to produce large quantities of the protein of interest. The protein of interest 
can then be purified and used in protein interaction studies or in the case of this 
project as a therapeutic reagent.
Recombinant DNA technology has revolutionised the possibilities for drugs as large 
amounts of pure protein can be created and purified. Such technology has been used 
in many situations such as the generation of tissue plasminogen activator for 
administration after a myocardial infarction, the production of insulin for 
administration in type I diabetes and the generation of factor VIII to treat 
haemophiliacs (Lubiniecki and Lupker 1994). A number of different host systems 
are available including bacteria, yeast and eukaryotic cells. Each system has its own 
advantages and disadvantages and the choice of system depends upon the protein to 
be produced and final use of the protein. For this project, eukaryotic cells have been 
employed to generate all the proteins. In particular Chinese Hamster Ovary (CHO) 
cells were used. This host was chosen despite the lower production rates compared 
to bacteria, as eukaryotic cells carry out appropriate post-translational modifications, 
glycosylate and correctly fold proteins, where as bacteria do not. These post- 
translational modifications may be important when generating a therapeutic as 
different modifications may cause proteins to have neoepitopes which are 
immunogenic and result in the reagent’s enhanced clearance and/or a reduction in 
function. Glycosylation is also crucial to producing Fc fusion proteins as without 
correct glycosylation Fc fail to fold correctly and function (Leatherbarrow, 
Rademacher et al. 1985; Tao and Morrison 1989; Walker, Lund et al. 1989). The
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ability of eukaryotic cells to carry out post-translational modifications including 
folding also makes the downstream processes of purification easier.
For this project the aim was to generate two kinds of Crry-Fc: one that functioned 
effectively in its original form to inhibit complement, and a second that could be 
further engineered into a ‘prodrug’ (see section 1.5.6.4). This latter form would need 
the active site to be close to the Fc so that the function of the Crry would be sterically 
hindered. The functional site of rat Crry has not yet been identified however, it is 
known that the first 4 N-terminal SCRs are active when expressed as a soluble 
protein (Fraser, Harris et al. 2002). To identify the SCRs of rat Crry in which 
function resides and to identify suitable constructs for the above reagents, SCR 
deletion mutants were generated consisting of the N-terminal SCRs. The reagents 
generated were 5SCR-Fc, 4SCR-Fc, 3SCR-Fc, 4SCR and 3SCR. The Fc fusion 
proteins and non-Fc proteins were generated so that any reduction in function could 
either be attributed to the deletion of an active site or steric restriction from the Fc.
The Fc used to generate these proteins was the Fc of rat IgG2a. Use of a rat Fc 
should result in the generation of a less or non-immunogenic molecule compared to 
those containing a human Fc used for preliminary studies (Harris, Williams et al. 
2002). IgG2a has a very short upper hinge, the polypeptide stretch between the end 
of CHI and the first cysteine of the inter-heavy chain disulphide bond (Schneider, 
Wensel et al. 1988; Tan, Shopes et al. 1990; Brekke, Michaelsen et al. 1995). The 
length of the upper hinge in part dictates antibody flexibility, a shorter hinge being 
less flexible. A lack of flexibility in a Crry-Fc protein will maximise steric hindrance 
and be advantageous in the generation of a ‘prodrug’.
The reagents generated in this chapter contain the N-terminal SCRs of Crry with the 
numbering beginning with the SCR at the N-terminus. Therefore 5SCR-Fc contains 
the 5 N-terminal SCRs of rat Crry fused to the Fc of rat IgG2a, 4SCR-Fc contains 
only the 4 N-terminal SCRs fused to the Fc while 3SCR-Fc contains the 3 N-terminal 
SCRs and the Fc. Similarly 4SCRs and 3 SCRs contain the 4 and 3 N-terminal SCRs 
of Crry without the Fc (figures 3.1 and 3.2).
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Figure 3.1 Crry reagents generated.
A. Schematic of the Crry reagents generated. Fc fusion proteins containing 5, 4 and 
3 SCRs of rat Crry were generated and non-Fc proteins containing the 4 and 3
SCRs of rat Crry. The Fc fusion proteins consisted of the rat Fc, linked to SCRs
of Crry through the antibody hinge.
B. Representation of DNA encoding Crry showing the position o f the primers
(arrows) used to amplify the Crry proteins. For all reagents primer Crryl was 
used. This primer was used along with primers Crry2, 4SCRFc, 3SCRFc, SCR4 
or SCR3 to generate 5SCR-Fc, 4SCR-Fc, 3SCR-Fc, 4SCR or 3SCR respectively. 
Primers used to generate 4SCR and 3 SCR included a stop codon, more details are 
given in table 2.1. SP signal peptide, SCR short consensus repeat.
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Figure 3.2 Nucleotide and amino acid sequence of the first five N-terminal 
SCRs of rat Crry.
The DNA sequence of the first 5 N-terminal SCRs of rat Crry and the amino acid 
sequence of the polypeptide is shown opposite. The nucleotide number is given in 
blue on the right hand side with the first nucleotide of the mature protein assigned 
to position 1, the amino acid number is given in grey on the left hand side, the first 
amino acid of the mature protein is assigned to position 1 (boxed), sequence 
encoding the signal peptide is highlighted in red, the introduced mutation is shown 
in bold in blue and the SCR divisions are shown by the first amino acid of each 
SCR in bold in grey. The positions of the primers are shown in green in the 
nucleotide sequence, and are labelled above. Primers SCR3 and 3SCRFc 
contained the same sequence except for the presence of a stop codon within the 
SCR3 primer. Primers SCR4 and 4SCRFc also contained the same sequence 
except for additional nucleotides in the 4SCRFc primer, shown in bold, and primer 
SCR4 contained a stop codon. Primers CrryA and CrryB used to clone the 5SCRs 
of Crry in the two step PCR were complementary, CrryA was the sense primer 
whilst CrryB was the antisense primer.
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The aims of the work described in this chapter are:
1. To clone cDNA encoding the Fc of rat IgG2a into the pDR2AEFla 
expression vector to generate the pDR2-Fc vector.
2. To clone cDNAs encoding the 3 SCRs, 4SCRs and 5SCRs of rat Crry into 
either the pDR2-Fc vector or the parent pDR2AEFla vector (figure 3.3).
3. To transfect CHO cells with these constructs in order to obtain expression of 
the proteins.
4. To identify and adopt a purification strategy for these proteins.
5. To biochemically characterise the proteins by SDS-PAGE and Western blot 
analysis.
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Figure 3.3 Schematic of the plasmids used to generate the Crry constructs.
A. To generate the Crry-Fc reagents, the Crry cDNA was ligated into a 
plasmid in frame with the cDNA sequence encoding the Fc portion of an 
antibody. The Crry cDNA and Fc were joined together by the common 
BamHl digestion site.
B. To generate the non-Fc reagents the cDNA was ligated into a vector 
without cDNA encoding the Fc, the cDNA terminated by a stop codon.
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3.2 Specific methods and results
3.2.1 Cloning strategy
The Fc was cloned from a plasmid that had been previously generated in house and 
was ligated into the pDR2AEFla expression vector to generate the pDR2-Fc vector 
(Charreau, Cassard et al. 1994). DNA encoding the 5 N-terminal SCRs of rat Crry 
were amplified by RT-PCR from rat oligodendroglioma cell (33B) RNA. A two 
stage cloning step eliminated an internal BamHl site. This DNA was ligated into the 
pDR2-Fc vector which subsequently formed a template for PCR of the 3 and 4 SCR 
forms. These fragments were ligated into either the pDR2-Fc vector or the parent 
vector (pDR2AEFla) to generate an expression system for either the Fc or non-Fc 
proteins respectively. The cloning strategy is pictorially demonstrated in figure 3.4.
3.2.2 Generation of the Fc.
DNA encoding the Fc of IgG2a was amplified from a vector that had previously been 
engineered in house to contain the Fc; this enabled the correct restriction sites to be 
introduced into the construct. The DNA within this vector had been amplified from a 
hybridoma line secreting monoclonal rat IgG2a. The Fc was amplified using primers 
IgG.l and IgG.2, IgG.l contained a BamHl restriction digest site at the 5’ end and 
overlapped the DNA encoding the hinge region while IgG.2 contained an EcoRV 
restriction site at the 3’ end and was downstream of the DNA encoding the CH3 
region after the stop codon (figure 3.5A and 3.6) (method 2.1.4). Once the PCR 
product had been viewed by agarose gel electrophoresis (figure 3.5B), it was 
purified, digested with the relevant restriction enzymes and ligated into pDR2AEFla 
(method 2.1.5- 2.1.8). Chemically competent DH5a were then transformed using 
this vector by heat shock and bacterial colonies were screened by PCR for expression 
of the insert (method 2.1.10). A positive bacterial colony was selected, grown up 
and the plasmid purified by a QIAquick® spin miniprep purification kit (Qiagen) 
(method 2.1.11). The fidelity of the PCR reaction was checked by sequencing the 
product (method 2.1.12).
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Figure 3.4 The cloning strategy used to generate recombinant Crry.
1. The DNA encoding the Fc was ligated into the pDR2AEFla vector to create 
the pDR2-Fc vector.
2. DNA encoding the 5 SCRs of rat Crry was ligated into the pDR2-Fc vector.
3. The 5SCR-Fc vector was used as a template to generate the DNA encoding 
the 3 and 4 SCRs of rat Crry.
4. The DNA encoding the 3 and 4 SCRs was ligated into either the pDR2AEFla 
vector or the pDR2-Fc vector resulting in the generation of 4 different 
vectors.
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Figure 3.5 Amplification of the Fc of rat IgG2a for ligation into pDR2AEFla.
A. Representation of the DNA encoding the Fc showing the positions o f the 
primers used to clone the Fc. Primers IgG.l and IgG.2, shown as arrows, 
were used to amplify the cDNA encoding the Fc. The product included a 
stop codon at the 3’end.
B. A band of 771 bp encoding the cDNA of the Fc of rat IgG2a was amplified 
by PCR and visualised by agarose gel electrophoresis.
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Figure 3.6 Nucleotide and amino acid sequence of the Fc of rat IgG2a.
The sequence o f the Fc DNA construct cloned into pDR2AEFla and the amino acid 
sequence of the polypeptide is shown above. The nucleotide number is given in blue 
with the first nucleotide o f the mature protein assigned position 1, the amino acid 
number is given in grey, the first amino acid of the CHI domain is assigned position
1. The positions o f the primers are shown in green in the nucleotide sequence; IgG. 1 
is labelled above the nucleotide sequence while IgG.2 is labelled below the amino 
acid sequence. The stop codon in highlighted in red.
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3.2.3 Cloning of DNA encoding Crry
3.2.3.1 Cloning and ligation of DNA encoding Crry into the pDR2-Fc vector.
In order to generate the 5 SCRs of rat Crry, total RNA was isolated from rat 
oligodendroglioma cells (33B) and RT-PCR was undertaken. The cDNA generated 
by the RT reaction was used as the template to amplify the 5 N-terminal SCRs of rat 
Crry. PCR was carried out in two steps to remove a BamHl restriction digest site 
within the Crry that could later interfere with generation of the expression vector. 
Briefly, step 1 was used to amplify the DNA in two sections; the 3’ end of one 
section was complementary to the 5’ end of the other section and contained a base 
mutation to remove the restriction site. In step 1 primers Crryl and CrryA were used 
to amplify segment 1 while primers CrryB and Crry2 were used to amplify segment
2. In step 2, these complementary regions were allowed to anneal and the annealed 
product was used to amplify the entire 5 SCRs of Crry containing the mutation using 
primers Crryl and Crry2. Further details of this PCR reaction are given in method 
2.1.4.3 and the PCR is pictorially demonstrated in figure 3.7A.
Following purification of the PCR product (figure 3.7B), it was digested with 
BamHl and Xbal and ligated into the pDR2-Fc vector in frame with the Fc of 
IgG2a. The common BamHl restriction site in both the Fc and Crry cDNA formed 
the link between the DNA fragments. Following digestion and ligation all cloning 
reactions described here and subsequently were treated in the same way: DH5a 
chemically competent bacteria were transformed with the vector by heat shock and 
bacterial colonies were screened by PCR. A positive bacterial colony was selected, 
grown up and the DNA was purified using a QLAprep® miniprep spin purification kit 
(Qiagen) (method 2.1.6- 2.1.12). The sequences were checked for fidelity.
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Figure 3.7 Amplification of 5SCRs Crry.
A. In step 1 of the PCR to generate 5SCRs Crry cDNA, two primers were used 
to amplify fragment 1 (Crryl and CrryA) whilst two other primers were used 
to amplify fragment 2 (CrryB and Crry2). In step 2 o f the PCR, DNA 
fragments 1 and 2 were allowed to anneal to each other through the 
complementary region. Full length cDNA encoding the 5SCRs o f Crry was 
generated in a PCR reaction using primers Crryl and Cny2
B. In step 1 bands o f 383bp and 708bp encoding fragments 1 and 2, respectively, 
were amplified by PCR and visualised by gel electrophoresis (lanes 1 and 2). 
In step 2 a band o f 1.09kbp encoding the full length 5 SCRs cDNA was 
amplified by PCR and also visualised by gel electrophoresis (lane 3).
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In order to clone the DNA encoding the 4 and 3 SCRs of rat Crry for ligation into the 
pDR2-Fc vector the 5SCR-Fc plasmid was used as the template. Primers Crryl and 
4SCRFc were used to clone the 4SCR construct while primers Crryl and 3SCRFc 
were used to clone the 3 SCR construct. Following agarose gel electrophoresis 
(figure 3.8), the products were purified from the reaction mix and the plasmid 
template using a gel purification kit (Geneclean III, QBiogene). The products were 
digested with BamHl and Xbal as for the 5SCR construct. Products were then 
ligated into the pDR2-Fc vector and processed as described for the 5SCR-Fc vector.
3.2.3.2 Cloning and ligation of DNA encoding soluble Crry (non-Fc) into 
pDR2AEFla.
The 4 and 3 SCR Crry constructs were generated using the 5SCR-Fc vector as a 
template. Primers Crryl and SCR4 were used to amplify DNA encoding the 4SCRs 
while primer Crryl was used with primer 3SCR to amplify DNA encoding the 
3 SCRs. Both 3’ primers, 3 SCR and 4SCR, contained a stop codon prior to the 
restriction enzyme site. The PCR products were extracted from the agarose gel 
(Geneclean III, QBiogene) (figure 3.8), digested with the Xbal and BamHl 
restriction enzymes and ligated into the pDR2AEFla vector. The constructs were 
processed as described previously.
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Figure 3.8 Amplification of DNA encoding the 4 and 3SCR forms of Crry for 
ligation into the pDR2-Fc vector or the pDR2AEFla vector.
cDNA encoding the 4SCRs and 3SCRs o f rat Crry to create the Fc and non-Fc 
constructs were amplified by PCR and visualised by agarose gel electrophoresis. 
For ligation into the pDR2-Fc vector, amplification o f the 4SCR gave a product 
of 768bp, lane 1, while amplification o f 3SCR gave a product o f 582bp (lane 2). 
In order to generate the non-Fc proteins the antisense primers for both 3 SCR and 
4SCR contained an additional stop codon, this gave a product o f 771 bp for 
4SCR, lane 3, and for 3 SCR a product o f 585bp, lane 4.
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3.2.4 Transfection
CHO cells were transfected with the expression vectors containing DNA encoding 
the different Crry proteins using LipofectAMINE™ as described in method 2.2.2. 
Following selection with 400pg/ml of Hygromycin B stable transfectants were 
established. Western blot analysis of cell supernatant confirmed expression of the 
relevant protein (figure 3.9). The transfected CHO cells were cloned out by limiting 
dilution to 1 cell per well and high expressing cells were detected using an ELISA 
(method 2.4.9). The clones with the greatest secretion levels were selected and 
expanded. Cell culture supernatant was collected from tissue culture flasks or the 
adopted tissue culture growing system (see chapter 5) and a method of purifying the 
proteins was established.
3.2.5 Optimisation of Purification
There were a number of different possible methods for purifying the proteins so these 
were compared to find the most efficient method, which gave a high purity product 
in high yields with the least number of steps. The methods were all investigated 
using 5SCR-Fc cell culture supernatant. The first approach was to purify the Fc 
proteins via the Fc group, using either protein A or protein G chromatography. 
Methods using classical column chromatography were also investigated as a method 
of purifying both the Fc and non-Fc proteins. Antibody affinity methods were also 
tested and finally optimised.
3.2.5.1 Protein A
Many antibody Fc domains have a high affinity for protein A. However, the 
literature documents that rat IgG2a Fc has a very low affinity for protein A 
(Akerstrom, Brodin et al. 1985). Nevertheless, affinity of certain Fc domains for 
protein A can be increased by using high salt and/or high pH binding buffers (Palmer 
2002). To investigate whether such an approach could be used to purify 5SCR-Fc, 
cell culture supernatant was mixed 1: 1 with the appropriate binding buffer (1.5M 
glycine/NaOH, 3M NaCl pH 9) and passed over a protein A column (ProSep A,
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Millipore). The column was washed and bound protein was eluted using the elution 
buffer (table 2.3). Fractions containing protein were identified by their absorbance at 
280nm, combined, dialysed against PBS and concentrated using an Amicon 
ultrafiltration cell. Although protein was eluted from the protein A column, SDS- 
PAGE analysis revealed that the protein consisted of multiple bands, Western 
blotting revealed that none of these bands were 5SCR-Fc (figure 3.10).
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Figure 3.9 Western blot analysis of cells expressing Crry proteins.
A. Supernatants harvested from CHO cells expressing 5SCR-Fc, 4SCR-Fc and 
3SCR-Fc, proteins were separated on a 7.5 %  gel and Western blotted onto 
nitrocellulose. The Western was probed with anti-rat IgG HRPO. 3SCR- 
Fc (1) gave a band of 120kDa with a smaller form visible at 40kDa. 4SCR- 
Fc (2) gave a band of 140kDa and 5SCR-Fc (1) gave a band of 160kDa.
B. The expression of the non-Fc proteins was analysed by loading an 11% gel 
with supernatant taken from transfected CHO cells expressing 4SCR and 
3 SCR Crry. Following electrophoresis the gels were Western blotted and 
probed with TLD1C11, a monoclonal anti-Crry antibody, followed by anti­
mouse IgG HRPO. 4SCR (1) gave a band at 28kDa whilst 3 SCR (2) gave a 
band at 21 kDa.
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Figure 3.10 SDS PAGE analysis of the protein A product.
A. The product from the elution of the protein A column was resolved on a 7.5 
%  gel and Coomassie stained. The product was a mix of proteins (arrows) 
consisting of a protein that only just entered the gel, a protein with a mass 
of 120kDa and a number of smaller proteins.
B. To test whether the product contained 5SCR-Fc, protein was resolved on a
7.5 %  gel (lane 2) along side 5SCR-Fc supernatant (lane 1) as a positive 
control. Following Western blotting, onto nitrocellulose it was probed with 
anti-rat IgG HRPO. 5SCR-Fc was detected in the supernatant showing that 
the probing and development of the Western was successful but no 5SCR- 
Fc was detected in the product revealing that 5SCR-Fc was not purified 
using protein A chromatography.
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3.2.5.2 Protein G
As with protein A, many antibodies and Fc fusion proteins can be purified due to the 
affinity of Fc for protein G. This method is especially applicable to rat IgG2a as the 
Fc of this isotype has a good affinity for protein G (Akerstrom, Brodin et al. 1985). 
However, the use of this technique is limited by the fact that bovine antibodies 
present in the foetal bovine serum (FBS) used to supplement cell culture media also 
have a high affinity for protein G. Bovine antibodies therefore co-purify and become 
a major contaminant or even compete out binding of rat Fc. FBS depleted of bovine 
antibodies was used to culture CHO cells prior to purification of 5SCR-Fc from the 
supernatant using this method. The supernatant was passed over the protein G 
column (ProSep G, Millipore), the column was washed and bound protein was eluted 
using the elution buffer. The absorbance at 280nm was used to identify the fractions 
that contained protein; these fractions were combined, dialysed against PBS and 
concentrated. Purification of the 5SCR-Fc protein using this method gave a product 
consisting of multiple proteins shown by SDS-PAGE. Western blotting showed that 
these proteins were not 5SCR-Fc (figure 3.11).
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Figure 3.11 SDS PAGE of the protein G product.
A. The product eluted from the protein G column was resolved on a 7.5% gel 
and stained with Coomassie. The product consisted of a number o f proteins 
(arrows), the most prevalent o f which was at 120kDa.
B. To ascertain if the elution contained 5SCR-Fc, the product (lane 2) and 
5SCR-Fc cell culture supernatant (lane 1) to act as a positive control were 
resolved on a 7.5 %  gel. Following Western blotting, it was probed with 
anti-rat IgG HRPO. The positive control developed but the product from 
the protein G column did not indicating that 5SCR-Fc was not purified by 
protein G.
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3.2.5.3 Anti-rat immunoglobulin affinity chromatography
An affinity column was generated using sheep polyclonal anti-rat immunoglobulins 
(Binding site) (method 2.3.4.1). Ten milligrams of the antibody was bound to 
Sepharose. Supernatant containing 5SCR-Fc was passed over the column, the 
column was washed with PBS and bound protein was eluted using the appropriate 
elution buffer (method 2.3.5). No protein was obtained from the elution; this was 
probably due to a weak interaction between the polyclonal antibody and ligand 
resulting in low efficiency binding. This result was confirmed by ELISA, which 
showed very little depletion of the supernatant run through (figure 3.11). Any 
protein that did bind was most probably lost in the wash of the column.
3.2.5.4 Anti-Crry affinity chromatography
Monoclonal anti-Crry (TLD1C11) was purified by protein G affinity 
chromatography. Ten milligrams was coupled to Sepharose and supernatant 
containing 5SCR-Fc was passed over the column. The column was washed with 
PBS and the bound protein was eluted using low pH. Fractions containing protein 
were identified and processed as with the previous methods. This method resulted in 
the purification of 5SCR-Fc (figure 3.12A). However, the yield was low with each 
run producing 0.5mg of protein. An ELISA (method 2.4.9) using serial dilutions of 
supernatant from before the column and run through revealed that the low yield was 
not due to low expression levels of the protein but a low capacity of the column as 
the purification did not deplete the supernatant of 5SCR-Fc (figure 3.12C). Another 
antibody affinity column was generated using a different monoclonal anti-Crry 
antibody, 512, which had previously been purified in house. An 8mg column was 
generated and used to purify 5SCR-Fc from cell culture supernatant following the 
above protocol. This column also resulted in the purification of 5SCR-Fc, SDS- 
PAGE analysis revealed that the eluted protein was pure (figure 3.12B). However, 
the yield (600jag) was also low using this column. As the yield was low, antibody 
affinity methods appeared unlikely to generate the large amount of Crry proteins 
required for this project. This project requires at least 40mg of protein to enable 
therapeutic testing and functional characterisation. Whilst these methods gave pure 
protein, to achieve the amount needed multiple purification runs would be necessary.
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Therefore classical methods were investigated as a way of producing pure protein in 
high yields.
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Figure 3.11 ELISA analysis of the purification of 5SCR-Fc by the anti-rat 
immunoglobulin (Ig) column.
To assess the degree o f supernatant depletion bought about by the anti-rat Ig column 
and hence the expected yield, an ELISA was carried out as follows. The plate was 
coated with TLD1C11, blocked and incubated with a sample o f supernatant from 
before and after the column (1:2 serial dilutions). The plate was probed with anti-rat 
IgG HRPO. 5SCR-Fc was detected in both the pre column supernatant and the run 
through. Very little difference was seen between the two supernatants revealing that 
the lack o f yield from this method was due to a lack of binding to the column and 
not low expression levels o f the protein.
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Figure 3.12 SDS PAGE and ELISA analysis of purification by anti-Crry 
chromatography.
A. The product from the TLD1C11 anti-Crry affinity column was resolved on 
a 7.5% gel and Coomassie stained (lane 1). The product had a mass of 
160kDa, the correct mass for 5SCR-Fc. To confirm that the product was 
5SCR-Fc a Western blot was carried out probing with anti-rat IgG HRPO 
(lane 2). The band at 160kDa developed confirming that the product was 
5SCR-Fc.
B. The product of the 512 column was separated on a 7.5% gel. Lane 1 was 
Coomassie stained and revealed a product of 160kDa, the correct mass for 
5SCR-Fc. Lane 2 was Western blotted and probed with anti-rat IgG 
HRPO. A band developed confirming that the product was 5SCR-Fc.
C. To assess the degree of supernatant depletion by the TLD1C11 anti-Crry 
column an ELISA plate was coated with TLD1C11. Following blocking, 
the plate was incubated with a sample of supernatant from before the 
column and a sample of run through, both in a serial dilution. The plate 
was probed with anti-rat IgG HRPO and developed. 5SCR-Fc was detected 
in both the pre and post column supernatant revealing that the low yield 
was due to the low capacity of the column as opposed to low expression 
levels of 5SCR-Fc.
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3.2.5.5 Classical chromatography
Both anion and cation exchange were investigated as methods for purifying 5SCR-Fc 
from cell culture supernatant. First the percentage of ammonium sulphate required to 
precipitate the 5SCR-Fc was optimised, this removed the bulk of contaminating 
protein and allowed resuspension of the protein in a small volume. A 40% saturated 
ammonium sulphate cut was carried out on 5SCR-Fc cell culture supernatant by 
gradual addition of crystalline ammonium sulphate to supernatant at 4°C. The cut 
was then increased to 45% and then to 50%. On each occasion the pellet was 
isolated by centrifugation and dissolved in PBS. Analysis of the cuts by SDS PAGE 
revealed that a 50% saturated cut was necessary to precipitate the 5SCR-Fc (figure 
3.13A). A 50% saturated cut was therefore carried out on 500ml 5SCR-Fc 
supernatant and the pellet resuspended in 5mM sodium phosphate pH 8. The pellet 
(1.5mg) was loaded onto a Mono Q column (GE Healthcare) and the proteins 
separated by a segmented gradient (figure 3.13B). The proteins were separated using 
a gradient of 0-150mM NaCl over 25 column volumes followed by a gradient of 
150-500mM NaCl over a further 20 column volumes. Analysis of the fractions by 
SDS PAGE revealed that whilst 5SCR-Fc was present in peaks from the column, the 
yield was low and it was not pure (figure 3.14A and B), the major contaminant 
appeared to be albumin. Adjusting the gradient to resolve the different proteins did 
not decrease the level of contamination.
Cibacron Blue, a dye which has an affinity for albumin, was employed as a method 
for removing the albumin contamination (Travis, Bowen et al. 1976; Leatherbarrow 
and Dean 1980). The fractions containing 5SCR-Fc from the Mono Q column were 
pooled and dialysed against 20mM sodium phosphate pH 7.1. This was then passed 
over the Cibacron Blue column (Bio Rad) and the protein run through collected in 
fractions. The column was then washed with 1.4M NaCl in 20mM sodium 
phosphate at pH 7.1 to remove the albumin. SDS PAGE analysis of the eluted 
fractions revealed that the 5SCR-Fc protein also bound to the column and was eluted 
with the albumin (figure 3.14C). This method was therefore not suitable for 
removing albumin contamination.
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Figure 3.13 Purification of 5SCR-Fc by anion exchange chromatography.
A. Equal amounts o f protein from the 40, 45 and 50% saturated ammonium 
sulphate cuts o f the cell culture supernatant were separated on a 7.5% SDS 
PAGE gel in lanes 1, 2 and 3 respectively. Following electrophoresis and 
transfer to nitrocellulose, the blot was probed with anti-rat IgG HRPO. 5SCR- 
Fc was detected in both the 45 and 50% cuts.
B. Chromatogram o f the anion exchange o f the resuspended pellet containing 
5SCR-Fc. The Mono Q column was loaded with protein from the 50% 
ammonium sulphate cut and separated using an increasing salt gradient. The 
UV trace is shown in blue with the gradient illustrated by conductivity in pink, 
the fractions are indicated in grey.
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Figure 3.14 SDS PAGE analysis of anion exchange purification of 5SCR-
Fc
A. and B. Fractions 25, 26, 41, 50, 54, 57, 64 and 68 from the anion 
exchange of the 5SCR-Fc pellet were resolved on 7.5% gels. The gel was 
either Coomassie stained (A) or Western blotted onto nitrocellulose and 
probed with anti-rat IgG HRPO (B). The Western blot showed that 
5SCR-Fc was present in fraction 50, however, the Coomassie stained gel 
showed that the product was not pure, the major contaminant being at 
47.5kDa.
C. Fractions collected of the run through (lanes 1-6) and the elution (lanes 7- 
9) of the Cibacron Blue column were run on a 7.5% gel. The gel was 
Western blotted onto nitrocellulose and probed with anti-rat IgG HRPO. 
5SCR-Fc was detected in the elution fractions along with albumin.
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Cation exchange was also investigated as a method of purifying 5SCR-Fc from cell 
culture supernatant. A 50% saturated ammonium sulphate cut was carried out on the 
cell culture supernatant, the pellet was harvested by centrifugation and resuspended 
in malonate buffer (50mM malonic acid, 37.5mM NaOH, 4mM betaine 
monohydrate, pH 5.4). The pellet (4mg) was loaded onto a Mono S column (GE 
Healthcare) and the proteins were separated using an increasing salt gradient: 0- 
250mM NaCl over 30 column volumes followed by 250-500mM NaCl over a further 
10 column volumes. Dot blot analysis revealed which fractions contained 5SCR-Fc, 
these fractions were combined. However, the product was impure with the major 
contaminant being at 55kDa (figure 3.15).
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Figure 3.15 SDS PAGE analysis of the cation exchange purification of 5SCR- 
Fc.
A. The product from the Mono S column was resolved on a 7.5% gel and 
Coomassie stained. This revealed that the product was not pure, the 
product contained numerous bands the most prevalent of which was at 
55kDa.
B. To ascertain if the product from the cation exchange column contained 
5SCR-Fc, the product (lane 1) was Western blotted (7.5% gel) along 
with 5SCR-Fc cell culture supernatant as a positive control (lane 2). 
Probing with anti-rat IgG HRPO revealed a band corresponding to 
5SCR-Fc in the Mono S product.
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3.2.5.6 Optimisation of anti-Crry affinity chromatography
As the only method to give pure 5SCR-Fc was monoclonal anti-Crry affinity 
chromatography this method was optimised in order to maximise yield. TLD1C11 is 
a mouse IgGl antibody and the cell line was available in house. The TLD1C11 used 
previously to make the anti-Crry column gave low yields and Western blot analysis 
of the TLD1C11 showed that it was contaminated with bovine antibodies (figure 
3.16A). A method to generate large amounts of TLD1C11 with minimised 
contamination was therefore sought. The use of high expression cell culture systems 
is dealt with in chapter 5 and was adopted for this purpose. The optimisation of the 
purification is discussed here. The batch of TLD1C11 used for the previous affinity 
column had been purified using protein G affinity chromatography (method 2.3.3.2) 
for which mouse IgGl has a good affinity. However, bovine antibodies also have a 
good affinity for protein G and this resulted in co-purification and contamination of 
the mouse IgGl.
Where supernatant had been collected from cells grown in media supplemented with 
conventional FBS, protein A affinity chromatography was used. The supernatant 
was mixed with a binding buffer (1M glycine/NaOH, 0.15M NaCl pH 8.6) and was 
run over the protein A column. The column elution was optimised by eluting with 
0.1M citrate at pH steps 6, 5, 4 and 3 in order to establish which pH to use to elute 
the antibody. Elutions at pH 6 and 3 resulted in protein being washed off the 
column, SDS PAGE analysis of these elutions revealed that the pH 6 elution 
contained bovine antibodies whilst the pH 3 elution contained TLD1C11 as well as 
bovine antibody contamination (figure 3.16B). A method was therefore established 
which involved an additional wash of the column with 0.1M citrate pH 6 followed by 
an elution with 0.1M citrate pH 3. Adoption of this method reduced bovine 
immunoglobulin contamination but did not completely remove it.
In the high expression systems (Integra Biosciences CL1000 flasks) very little serum 
containing media is used so it is financially viable to use ultra low bovine 
immunoglobulin FBS. The problems of bovine immunoglobulin contamination are 
therefore eliminated and the antibody can be purified using protein G as previously 
described. This approach gave good yields of pure TLD1C11 (figure 3.16C). 20mg
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of TLD1C11, purified by both methods discussed above, was used to make an anti- 
Crry column. The column was used to purify 5SCR-Fc however the yield was still 
low and the supernatant remained undepleted revealing that the column had a lmg 
capacity.
As the yield from the TLD1C11 column was low it was investigated whether the 
binding of the antibody to Sepharose via lysine residues resulted in a reduction of the 
antibody’s activity. This was investigated by making a column where covalent 
binding of the antibody to the matrix occurs via the carbohydrate groups present on 
the Fc of the antibody. This results in more of the antibody molecules binding to the 
matrix in the correct conformation for ligand binding and therefore column yields are 
increased. TLD1C11 (lOmg) was coupled to Affi-Gel Hz matrix (Bio Rad) 
according to method 2.3.4.2. The resulting column was used to purify 5SCR-Fc 
from cell culture supernatant. SDS PAGE analysis revealed that 5SCR-Fc was a 
minor constituent of the elution; the major component was a protein with a mass of 
55kDa (figure 3.16D). Analysis of antibody that had not coupled to the matrix 
during the coupling process revealed that this band was a by-product of the coupling 
process as it was present in the antibody after the coupling but was absent before 
(figure 3.16D). Use of this column did not result in increased yields and it could not 
be concluded whether binding via the lysine residues reduced the ligand binding 
ability of TLD1C11. A possible reduction in function due to binding via the lysine 
residues was demonstrated using the Biacore® 3000. TLD1C11 was amine coupled 
to a CM5 chip and 5SCR-Fc was flowed over the chip (method 2.5.7). As the 
masses of TLD1C11 and 5SCR-Fc are equivalent, a response shift for 5SCR-Fc 
binding should be equivalent to the amount of TLD1C11 bound. However, the 
resulting response was much lower than expected indicating that the amine coupling 
of TLD1C11 through lysine residues had resulted in a reduction of its ligand binding 
ability (data not shown). Despite this result the decision was taken to make a large 
capacity column using amine coupling as the alternative column had given an 
unwanted by-product.
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Figure 3.16 SDS PAGE of the optimisation of the anti-Crry method.
All proteins were analysed on 7.5% gels.
A. A gel loaded with TLD1C11 used to make the previous anti-Crry column 
(described section 3.2.4.4) was either Coomassie stained (lane 3) or 
transferred to nitrocellulose where it was probed with anti-bovine IgG 
HRPO (lane 1) or anti-mouse IgG HRPO (lane 2). The Coomassie stain 
revealed that the protein consisted of a doublet at 175kDa while the 
Western blots revealed that the TLD1C11 also contained bovine 
antibodies.
B. The products of the pH 3 and pH 6 elutions of the protein A column were 
analysed by Coomassie staining (lanes 1 and 2) or by Western blotting 
(lanes 3-6). Lanes 3 and 4 were probed with anti-mouse IgG HRPO 
while lanes 5 and 6 were probed with anti-bovine IgG HRPO. Both the 
pH 6 and pH 3 elutions consisted of proteins that just entered the gel, the 
Western blots revealed that the pH 6 elution consisted of bovine IgG and 
not mouse IgG (lanes 5 and 3 respectively) while the pH 3 elution 
consisted of both mouse IgG (lane 4) and bovine IgG (lane 6).
C. The product from the protein G column (lanes 1 and 2) was Coomassie 
stained (lane 1) or Western blotted and probed with anti-mouse IgG 
HRPO (lane 2), lane 3 contains TLD1C11 culture supernatant. The 
Coomassie stain revealed that the product contained a protein with a mass 
of 175kDa, the Western blot confirmed that this band was TLD1C11.
D. The product (lane 1) from the Affi-Gel Hz anti-Crry column along with 
the TLD1C11 antibody that had not coupled with the matrix during the 
coupling procedure (lane 2) was Coomassie stained. The product (lane 3) 
was transferred to nitrocellulose and probed with anti-rat IgG HRPO. 
The major band of the product (lane 1) was 55kDa, this band was also in 
the TLD1C11 that had not coupled to the column (lane 2) along with 
uncoupled TLD1C11 at 175kDa, suggesting it was a by-product of the 
coupling procedure. The Western blot of the product revealed that it did 
contain 5SCR-Fc although this was a minor constituent.
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3.2.6 Purification of the Crry proteins
TLD1C11 was purified from hybridoma culture supernatant using both protein A and 
G affinity chromatography. A lOOmg column was made and used to purify all the 
Crry proteins, to prevent cross contamination of the proteins the column was 
thoroughly washed with elution buffer, pH 2.5, between purifications. In order to 
purify the proteins cell culture supernatant was first passed over a Sepharose pre­
column before the anti-Crry column. The anti-Crry column was washed and bound 
protein eluted using the relevant elution buffer. Fractions were collected and those 
containing protein were identified by their absorbance at 280nm, dialysed against 
PBS and concentrated. The column had a lOmg capacity. The Crry proteins had 
differing yields due to different expression levels. All the Fc fusion proteins gave a 
yield of 4-5mg/l of supernatant, the non-Fc proteins gave a yield of lmg/1 of 
supernatant.
In order to further optimise the purification and automate the process, the TLD1C11 
column was packed into an XK16 column (GE Healthcare) and run using an AKTA 
Prime system (GE Healthcare). Each run consisted of a column equilibration step, a 
supernatant load, a wash and elution using 0.1M glycine/HCl pH 2.5 (figure 3.17). 
This provided a fast and efficient way of purifying the proteins.
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Figure 3.17 Chromatogram of the automated purification of the Crry proteins.
TLD1C11 column was loaded with cell culture supernatant containing 4SCR-Fc after 
an equilibration step. The column was then washed and bound protein was eluted 
using an appropriate elution buffer. The UV trace is shown in blue while the 
conductivity is in pink.
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3.2.7 SDS-PAGE characterisation of soluble recombinant Crry.
The purified constructs were analysed by SDS PAGE under reducing and non­
reducing conditions (figures 3.18A and 3.18B). Under non-reducing conditions the 
5SCR-Fc protein had a molecular weight of 160kDa, the 4SCR-Fc protein 140kDa 
and the 3SCR-Fc protein 120kDa. This was confirmed by Western blot analysis 
probing with anti-Crry and anti-rat IgG. The anti-Crry Western also revealed smaller 
forms of the proteins as the double antibody detection is very sensitive. 5SCR-Fc 
had smaller forms at 80 and 60kDa, the 4SCR-Fc protein has smaller forms of 75 and 
55kDa and the 3SCR-Fc protein had smaller forms at 70 and 50kDa. The molecular 
weight of the proteins was confirmed by mass spectrometry analysis (figures 3.19- 
3.21). The masses differed slightly from the masses given by SDS PAGE, 5SCR-Fc 
was 139kDa, 4SCR-Fc 117kDa and 3SCR-Fc 99kDa. Mass spectrometry also 
revealed smaller forms of the proteins corresponding to doubly charged species or 
partial forms of the proteins. Under reducing SDS PAGE conditions the 5SCR-Fc, 
4SCR-Fc and 3SCR-Fc fusion proteins had molecular weights of 80, 75 and 70kDa 
respectively. This reduction in molecular weight is due to the disulphide bonds 
between the constituent arms of the fusion protein being broken. This result was 
confirmed by Western blot analysis probing with anti-Crry and anti-rat IgG. High 
molecular weight aggregates of the proteins were visible on the anti-Crry Western.
Under non-reducing conditions, the 4SCR protein gave a diffuse band at 28kDa 
while the 3SCR protein gave a band of 21 kDa (figure 3.18C). This was confirmed 
by Western blot analysis probing with anti-Crry. Under reducing conditions two 
bands were visible for the 4SCR protein, the Western blots probed with anti-Crry 
confirmed both to be 4SCR. The broad band reducing to two single bands is most 
likely due to different glycosylation of the protein as there is a glycosylation site in 
SCR4 of rat Crry (ASN 212). The 3 SCR protein under reducing conditions had a 
mass of 25kDa. This slight increase of molecular weight is most likely an affect of 
its cysteine rich nature of the protein coupled with its low molecular weight as it 
loses it’s conformation through reduction. This increase in molecular weight upon 
reduction is characteristic of SCR containing proteins. The low molecular weight of 
these two proteins makes any change in glycosylation or conformation more apparent 
in this percentage gel. Mass spectrometry was also used to confirm the molecular
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weights of 4SCR and 3SCR, as 28kDa and 21 kDa respectively (figures 3.22 and 
3.23).
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Figure 3.18 SDS PAGE of Crry proteins.
A. 5SCR-Fc, 4SCR-Fc and 3SCR-Fc were resolved on a 7.5% gel using non­
reducing conditions. Lanes 1-3 were Coomassie stained whilst lanes 4-9 
were transferred to nitrocellulose and probed with TLD1C11 followed by 
HRPO conjugated anti-mouse IgG (lanes 4-6) or with anti-rat IgG HRPO 
(lanes 7-9). Coomassie staining revealed bands at 160kDa, 140kDa and 
120kDa in lanes 1-3 corresponding to 5SCR-Fc, 4SCR-Fc and 3SCR-Fc 
respectively. The identity was confirmed by the Western blots, additional 
bands visible on the anti-Crry Western correspond to partial-forms of the 
fusion protein.
B. 5SCR-Fc, 4SCR-Fc and 3SCR-Fc were resolved on a 10% gel under 
reducing conditions. Lanes 1-3 were Coomassie stained whilst lanes 4-9 
were Western blotted and probed with TLD1C11 and followed with anti­
mouse IgG HRPO (lanes 4-6) or anti-rat IgG HRPO (lanes 7-9). Bands on 
the Coomassie at 80kDa, 70kDa and 60kDa in lanes 1-3 respectively 
corresponded to 5SCR-Fc, 4SCR-Fc and 3SCR-Fc. The identity of these 
bands was confirmed by the Western blots, high molecular weight 
aggregates were also seen on the anti-Crry blot (lanes 4-6).
C. 4SCR and 3SCR were separated on an 11% gel under non-reducing 
conditions (lanes 1-4) and reducing conditions (lanes 5-8). Lanes 1, 2, 5 
and 6 were Coomassie stained and lanes 3, 4, 7 and 8 were Western blotted 
and probed with TLD1C11 followed by anti-mouse IgG HRPO. Under 
non-reducing conditions broad bands at 28kDa and 21kDa, lanes 1 and 2 
respectively, were visible corresponding to 4SCR and 3 SCR. Under 
reducing conditions tighter bands at 28kDa and 25kDa were apparent 
corresponding to 4SCR and 3 SCR. The identity of all the bands was 
confirmed by the Western blots.
Key: 5Fc is 5SCR-Fc, 4Fc is 4SCR-Fc, 3Fc is 3SCR-Fc, 4 is 4SCR and 3 is 3SCR
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Figure 3.19 Mass spectrometry analysis of 5SCR-Fc.
Mass spectrometry revealed that 5SCR-Fc had a molecular weight o f 139kDa; 
there were also other peaks present at 96kDa, 69kDa and 41 kDa. Mass 
spectrometry trace is shown with the protein corresponding to each peak shown 
schematically.
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Figure 3.20 Mass spectrometry trace of 4SCR-Fc.
Mass spectrometry revealed that 4SCR-Fc had a mass o f 117kDa, a peak at 
58kDa was also present corresponding to the half-form or doubly charged 
whole molecule. The trace is shown with the protein corresponding to each 
peak represented schematically.
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Figure 3.21 Mass spectrometry trace of 3SCR-Fc.
The mass of 3SCR-Fc was 99kDa by mass spectrometry analysis. Additional 
peaks were also visible at 76kDa, 49kDa and 25kDa corresponding to the 
proteins schematically represented on the mass spectrometry trace.
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Figure 3.22 Mass spectrometry trace of 4SCR.
Mass spectrometry analysis gave the mass of 4SCR as 28kDa. A peak was also 
present at 57kDa due to aggregated (dimerised) 4SCR.
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Figure 3.23 Mass spectrometry analysis of 3SCR.
The mass of 3 SCR was 21 kDa given by mass spectrometry analysis. A peak was 
also present at 43kDa due to dimerised 3SCR.
3.3 Discussion
Since its cloning in 1994, the exact active site of rat Crry has remained unknown 
(Sakurada, Seno et al. 1994). The first 4 N-terminal SCRs of rat Crry are 
homologous to SCRs in the same position in mouse Crry and these SCRs are highly 
homologous to SCRs 1-4, 8-11 and 15-18 of human CR1. It is therefore reasonable 
to extrapolate what is known about the function of these SCRs of CR1 to Crry. In 
CR1 both C3b and C4b bind within these SCRs so it is assumed that the binding sites 
of C3b and C4b lie within the first 4 N-terminal SCRs of rat Crry (Klickstein, 
Bartow et al. 1988; Krych, Hourcade et al. 1991). This assumption is confirmed by 
data already available in the literature where various recombinant forms of rat and 
mouse Crry containing either the 5 or 4 N-terminal SCRs have been expressed. 
Mouse Crry has been expressed as an Fc fusion protein containing 5 SCRs, this 
protein demonstrated in vitro function as well as therapeutic efficacy in antibody- 
induced glomerulonephritis (Quigg, Kozono et al. 1998). A soluble recombinant 
form of rat Crry containing 5 SCRs was found to be therapeutically effective in a 
model of tubulointerstital injury when targeted to the glomerular and proximal 
tubular epithelial (He, Imai et al. 2005). A 4SCR form of rat Crry has also been 
expressed and has demonstrated in vitro function (Fraser, Harris et al. 2002). The 
generation of the recombinant forms of Crry described in this project, as well as 
identification of a potential ‘prodrug’ and active fusion protein, will advance current 
work in the field by enabling further functional analysis of rat Crry to be carried out. 
The SCR deletion mutants described in this thesis have been compared for their 
ability to inhibit complement in lysis assays, cause decay acceleration of the 
convertases and act as cofactors for factor I (chapter 4).
Here, various soluble recombinant forms of rat Crry have been expressed and 
purified. These forms contained the 5, 4 or 3 N-terminal SCRs as an Fc fusion 
protein with the Fc of rat IgG2a, or they contained the 4 or 3 N-terminal SCRs as a 
non-fusion protein. The cDNA for the 5SCRs of Crry was cloned from a rat 
oligodendroglioma cDNA. An internal BamHl site was removed and this vector was 
used as a template from which to clone the other forms of Crry. The Fc was cloned 
from a plasmid already expressing the cDNA. Following ligation of the appropriate
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cDNA into the plasmid, CHO cells were transfected and expression of the Crry 
proteins was detected by Western blot analysis.
A number of different methods were investigated to purify 5SCR-Fc and these are 
summarised in table 3.1. The use of both protein A and G columns resulted in 
proteins being isolated from the supernatant but these were shown by SDS PAGE 
analysis not to contain 5SCR-Fc. Antibody affinity methods were also tested, an 
anti-rat immunoglobulin column failed to purify 5SCR-Fc due to a low antibody- 
antigen affinity. Two different monoclonal anti-Crry columns resulted in the 
purification of 5SCR-Fc, although the protein was pure, the yield was low so 
alternative purification methods were tested. Both cation and anion exchange 
chromatography resulted in the purification of 5SCR-Fc from supernatant but in both 
instances 5SCR-Fc was impure and was the minor constituent of the protein yield. In 
light of this the use of one of the anti-Crry columns (TLD1C11) was optimised and 
used to purify all the Crry proteins. The method was optimised by altering the 
hybridoma culture conditions, the purification methodology of the monoclonal 
antibody as well as by investigating different column matrices and making larger 
capacity columns.
Method Outcome
Protein A Protein was obtained from the column but it did not contain 
5SCR-Fc.
Protein G 5SCR-Fc was not present in the column elution.
Anti-rat Ig No protein was obtained from the column.
Anti-Crry Gave pure but low yields, method was later optimised.
Anion exchange 5SCR-Fc was a minor product, the major product was albumin.
Cation exchange Product from the column was impure.
Table 3.1 Summary of the purification methods investigated and their outcomes.
The purified proteins were characterised by SDS PAGE analysis under reducing and 
non-reducing conditions. 5SCR-Fc gave a major band at 160kDa under non­
reducing conditions, which reduced to 80kDa, 4SCR-Fc was 140kDa non-reduced 
but 70kDa reduced and 3SCR-Fc was 120kDa non-reduced and 60kDa reduced.
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These weight reductions under reducing conditions represent the breaking of the 
disulphide bonds within the protein and its subsequent breakage in half. 4SCR was 
28kDa under both reducing and non-reducing conditions while 3SCR was 21 kDa 
non-reduced and 25kDa reduced. The molecular weights are summarised in table 
3.2.
Protein Molecular weight 
non-reduced (kDa)
Molecular weight 
reduced (kDa)
Molecular weight from 
mass spectrometry (kDa)
5SCR-Fc 160 80 139
4SCR-Fc 140 70 117
3SCR-Fc 120 60 99
4SCR 28 28 28
3 SCR 21 25 21
Table 3.2 The Crry proteins generated and their molecular weights under non­
reducing and reducing conditions.
In summary, this chapter describes the generation and purification of 5SCR-Fc, 
4SCR-Fc, 3SCR-Fc, 4SCR and 3 SCR as recombinant forms of rat Crry. These 
reagents have been cloned, expressed in CHO cells and purified from cell culture 
supernatant.
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Chapter 4: Functional characterisation of the Crry proteins.
4.1 Introduction
In the previous chapter, I described the generation, purification and biochemical 
characterisation of various recombinant forms of rat Crry. The proteins generated 
contained the 5, 4 or 3 N-terminal SCRs of rat Crry. The proteins generated were 
termed 5SCR-Fc, 4SCR-Fc, 3SCR-Fc, 4SCR and 3 SCR. The aim of generating 
these SCR deletion mutants of Crry was to enable the identification of an active 
Crry-Fc reagent for testing in therapy and the identification of a Crry-Fc protein that 
could be further engineered to create a ‘prodrug’. In this chapter, I describe the 
functional characterisation of the recombinant Crry proteins.
As discussed in the introduction, Crry regulates C by accelerating decay of the 
convertases as well as acting as a cofactor for the fl mediated cleavage of C3b and 
C4b. Therefore a variety of functional assays were carried out. Functional analysis 
of the proteins was carried out using both CP and AP haemolysis assays, fl cofactor 
assays and by using surface plasmon resonance to investigate the ability of the Crry 
proteins to decay the alternative pathway C3 convertase. Surface plasmon resonance 
was also used to investigate the influence SCR deletion had upon the affinity of the 
proteins for C3b. In both types of haemolysis assay equimolar amounts of Crry were 
used to compare the ability of the Crry proteins to inhibit the lysis of erythrocytes. 
This lysis can proceed via the CP or the AP of C depending upon which target cells 
are used along with the appropriate buffer. In the cofactor assay, the Crry proteins 
were compared for their ability to assist fl in its cleavage of C3. Surface plasmon 
resonance was investigated using a Biacore® 3000. This is a system which measures 
molecular interactions in real time, the readout is directly proportional to the mass of 
protein bound to the chip surface. The chip consists of a gold covered glass surface 
coated with dextran and it is on this dextran that the molecular interactions occur. 
Any mass changes brought about by molecular interactions at the chip surface alter 
the surface plasmon resonance changing the readout (Malmqvist 1999) (Figure 4.1). 
This technology was used to assess the ability of the Crry proteins to cause enzyme 
decay of the AP C3 convertase using a method developed in house (Harris, Abbott et 
al. 2005). In this experiment the enzyme was built up on the chip surface and
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equimolar molar amounts of the Cny proteins compared for their ability to enhance 
its decay. Surface plasmon resonance was also used to investigate the affinity of the 
SCR deletion mutants of Cny for rat C3b. This rounded investigation of the function 
of the Crry proteins will enable identification of a reduction in function due to 
deletion of a SCR or steric hindrance and also an appreciation of which aspect of the 
function of Crry has been affected.
The aims of this chapter are:
1. To analyse the function of the recombinant Crry proteins by both CP and 
AP haemolysis assays.
2. To compare the cofactor activities of the Crry proteins.
3. To compare the proteins in their ability to decay the C3 convertase.
4. To investigate the impact of the SCR deletions on the affinity of Crry for 
rat C3b.
5. To bring together all these methods used for functional analysis to 
identify a suitable protein to be used in therapy or to be further engineered 
to form the ‘prodrug
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(fi)Figure 4.1 Surface plasmon resonance measurements using the Biacore 3000.
A. A diagram of the flow cell used for surface plasmon resonance. The 
molecular interactions occur on a gold covered chip. The change in 
absorption of polarised light from the chip provides a measurement of 
molecular interactions. Antibody on the surface illustrated here.
B. A sensogram read out from the Biacore®. A shift upwards in the y-axis 
represents an association taking place between an immobilised protein i.e. 
C3b and an analyte i.e. Crry while a shift down towards the x-axis shows 
dissociation occurring. Regenerating the surface to elute the analyte can 
increase the dissociation. The sensogram can be used to calculate 
concentration and kinetic rate constants.
Figures adapted from An introduction to Biacore’s surface plasmon reasonance technology 
available from Biacore.
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4.2 Specific methods and results
4.2.1 Classical pathway haemolysis assay
The ability of 5SCR-Fc, 4SCR-Fc, 3SCR-Fc, 4SCR and 3SCR to inhibit the CP of C 
was assessed using antibody-sensitised sheep erythrocytes (sheep EA) as target cells 
and rat serum as the source of C. The assay is described in detail in method 2.5.1. In 
brief, sheep EA were incubated with a concentration of rat serum that caused 60% 
lysis along with a dilution of the Crry proteins. The Crry proteins were in a 10-fold 
1:2 serial dilution. The assay was carried out in Complement Fixation Diluent 
(CFD). A dilution series of rat immunoglobulins (Ig, Sigma) was also used as a 
negative control that had no CReg ability, this ruled out any non-specific effects the 
proteins may have had on cell lysis especially the Fc fusion proteins. C-mediated 
lysis of EA was determined by measuring the haemoglobin release of the cells at 
415nm. The amount of inhibition of lysis for each concentration of inhibitor was 
calculated using the following equation:
Percentage (%) inhibition = 100 x (% lysis rat Ig - % lysis test) / %  lysis rat Ig 
Percentage inhibition was plotted against inhibitor concentration (figure 4.2) and the 
amount of inhibitor to cause 50% inhibition of lysis was calculated (IH50) (Table 
4.1).
All the proteins were effective at inhibiting the CP-mediated lysis of sheep EA. 
5SCR-Fc, 4SCR-Fc, 4SCR and 3SCR had good C inhibitory activities with IH50s in 
the range of 16.7- 39.8nM. Interestingly the 4SCR-Fc reagent had a slightly 
enhanced function compared to 5SCR-Fc and 4SCR. This could be attributed to the 
SCR deletion giving rise to a slightly more rigid molecule where two Crry moieties 
are in close proximity, acting synergistically to bring about more efficient decay than 
the single Crry in 4SCR or the less rigid Crry moieties in 5SCR-Fc. The 3SCR-Fc 
reagent had a much reduced function compared to the other proteins; the IH50 was 
significantly different from the other proteins at 112.8nM, compared to 4SCR-Fc and 
3SCR (p<0.001). This reduction in function was not seen in the 3 SCR reagent so 
cannot be attributed to deletion of an active site SCR, instead it can be attributed to 
steric hindrance caused by the deletion of SCR bringing the active site close to the 
Fc.
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Figure 4.2 Classical pathway haemolysis assay: Graph of % inhibition of lysis 
against concentration of Crry.
The Crry reagents were compared for their ability to inhibit CP-mediated lysis of 
antibody coated sheep erythrocytes. All the Crry proteins inhibited lysis. 5SCR-Fc 
(dark blue), 4SCR-Fc (pink), 4SCR (turquoise) and 3SCR (purple) showed 
comparable functions. 3SCR-Fc (yellow) showed a reduced function. Each data 
point represents the mean value +/- 1 SD o f a single experiment performed in 
triplicate. Representative graph from three separate experiments.
5SCR-Fc 4SCR-Fc 3SCR-Fc 4SCR 3SCR
IH50 39.8 16.7 112.8 31.0 20.3
SD 2.7 0.6 17.7 0.7 1.3
Table 4.1 Classical pathway haemolysis assay: IH50 for each Crry protein.
IH50 is the concentration (nM) o f the respective Crry protein that causes 50% 
inhibition o f lysis. SD, standard deviation of three measurements.
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4.2.2 Alternative pathway haemolysis assay
The assay used to compare the ability of the Crry proteins to regulate the AP of C is 
described in detail in method 2.5.2. Guinea pig erythrocytes (GPE) were used as the 
target cell with rat serum as the source of C. The assay was carried out using AP 
buffer which contains EGTA preventing CP activity by chelating out calcium 
necessary for Cl formation. GPE were incubated with a dilution of the Crry proteins 
and rat serum at a concentration sufficient to cause 60% lysis. The Crry proteins 
were diluted in a 10-fold 1:2 serial dilution. Rat Ig were used as negative control and 
the concentration of the Crry proteins to cause 50% inhibition of lysis was calculated 
as previously described (Table 4.2). Figure 4.3 shows the plot of inhibitor 
concentration against percentage inhibition of lysis.
In contrast to the CP assay, a significant difference was seen between the activities of 
4SCR and 4SCR-Fc (p<0.05) as well as between the rest of the proteins and the 
3SCR reagents, p<0.001 between 3 SCR and either 5SCR-Fc, 4SCR-Fc or 4SCR. 
The 4SCR protein was the most active protein needing the lowest concentration to 
cause 50% inhibition of lysis, 74.1nM, the 4SCR-Fc protein was less active, the IH50 
was 167.8nM. This showed that the AP regulatory activity was sterically hindered 
even in the 4SCR-Fc, presumably because an active site required for this regulation 
lies closer to the Fc. The 5SCR-Fc was active but as with the CP assay showed a 
slightly reduced function compared to 4SCR-Fc. The 3 SCR form of Crry showed 
some activity, IH50 635.3nM, although 50% inhibition of lysis was not achieved 
with the concentrations used in this assay. This reduction in activity can be 
attributed to a deletion of an active site revealing that a crucial AP regulatory site lies 
within the fourth N-terminal SCR of rat Crry. The 3SCR-Fc showed no activity with 
the concentrations used in this assay as any remaining activity in the 3 SCR reagent is 
sterically hindered by the Fc.
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Figure 4.3 Alternative pathway haemolysis assay: Graph of % inhibition of lysis
against concentration of Crry protein.
The ability o f the Crry reagents to inhibit AP mediated lysis of guinea pig 
erythrocytes was assessed. 4SCR (turquoise) was most efficient at regulating the 
AP, followed by 4SCR-Fc (pink) and 5SCR-Fc (dark blue). 3SCR (purple) showed 
some activity in this assay whilst no activity was detected for 3SCR-Fc (yellow). 
Each value represents the mean value +/- 1 SD o f a single experiment performed in 
triplicate.
5SCR-Fc 4SCR-Fc 3SCR-Fc 4SCR 3SCR
IH50 312.9 167.8 Undetected 74.1 545
SD 23.1 17.8 N/A 1.8 51
Table 4.2 Alternative pathway haemolysis assay: IH50 for each Crry protein.
IH50 is the concentration (nM) o f the respective Crry protein needed to cause 50% 
inhibition o f lysis. SD, standard deviation o f 3 measurements.
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4.2.3 Cofactor assay
4.2.3.1 Purification of rat C3 and generation of C3b-like C3
To assess the ability of the Crry proteins to act as cofactor for the fl-mediated 
cleavage of C3b both rat fl and C3b were needed. Factor I had been previously 
purified in house (Fraser, Harris et al. 2002). Rat C3 was purified from rat plasma; 
details of the purification are given in method 2.3.7.3. Briefly, following 
polyethylene glycol (PEG) cuts on rat plasma, the C3-containing pellet was dissolved 
in 5mM KPO4 , 5mM EDTA, 5mM benzamidine, pH 7.8. The proteins were initially 
separated by anion exchange on a Source Q column (GE Healthcare). The gradient 
was from 0M to 0.5M NaCl over 20 column volumes and protein was detected at 
290nm as benzamidine also absorbed at 280nm interfering with protein detection at 
this wavelength (figure 4.4A). The C3 containing peak (fractions 44-47) was 
identified by dot blot analysis (figure 4.4B) and dialysed into 50mM NaPC>4 pH 6. 
The peak was then subjected to cation exchange on a Mono S column (GE 
Healthcare) with a gradient of 0-1M NaCl over 20 column volumes (figure 4.5A). 
The peak containing C3 was identified by dot blot analysis and the fractions 12-16 
combined. The C3 was analysed by SDS PAGE on a 10% gel under non-reducing 
and reducing conditions (figure 4.5B and C). To obtain C3b-like C3, the C3 was 
methylamine inactivated by incubation with 0.1M methylamine in borate buffered 
saline, pH 8.3 for 2  hours at 37°C. The inactivated C3 ( C 3 m a )  was then dialysed into 
PBS to remove the methylamine.
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Figure 4.4 Anion exchange purification of rat C3 from plasma.
A. Chromatogram of the anion exchange of rat C3. The product from the 
30% PEG cut of rat plasma was loaded onto the Source Q column. The 
proteins were separated using an increasing salt gradient, demonstrated 
by a change in conductivity (pink). This separation resulted in 3 major 
peaks, the corresponding fraction numbers are shown in grey beneath 
the peaks.
B. Dot blot of the Source Q fractions. The fractions corresponding to the 
peaks as well as the initial run through fractions (fractions 1-10) and a 
sample that had not been loaded onto the column (pre) were dotted onto 
nitrocellulose (lpl). Following blocking, the dot blot was probed with 
sheep anti-human C3c (known to cross react with rat C3) followed by 
HRPO conjugated anti-sheep IgG. The fraction numbers corresponding 
to each dot are below the dots. Fractions 44-47 had a strong 
development for rat C3 whilst fractions 66-74 showed low amounts of 
rat C3. Fractions 44-47 corresponding to the second peak to elute from 
the Source Q column were processed further.
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Figure 4.5 Cation exchange purification of rat C3.
A. Chromatogram of the cation exchange of rat C3. Fractions 44-47 from the 
Source Q column were dialysed into 50mM NaPC>4 , pH 6 and loaded onto a 
Mono S column. The proteins were separated using an increasing salt 
gradient, change in conductivity in pink. The gradient resulted in the 
elution of two peaks, the fraction numbers corresponding to these peaks are 
shown in grey beneath the respective peak.
B. Dot blot of the Mono S peaks, lpl of each fraction corresponding to the 
peaks and pre column sample were dotted onto nitrocellulose and probed 
with sheep anti-human C3c followed by anti-sheep IgG HRPO. The 
fraction number for each dot is shown at the bottom right hand comer of 
each dot. The first peak (fractions 12-16) contained rat C3, these fractions 
were therefore combined.
C. SDS PAGE analysis of the purified C3. A 10% SDS PAGE gel was loaded 
with the product from the Mono S column (lanes 1 and 3) along side a 
sample of protein that had not been loaded onto the column (lanes 2 and 4). 
The samples were either reduced (lanes 1 and 2) or non-reduced (lanes 3 
and 4). The pre column sample contained a mixture of proteins, the major 
one was C3 identified by its a-chain (112kDa) and p-chain (75kDa) under 
reducing conditions. The mono S product was rat C3, again identified by 
its characteristic breakdown under reducing conditions.
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4.23.2 Cofactor assay
In the cofactor assay C3ma was incubated with fl and individual Crry proteins. The 
following controls were included:
Control Purpose
C 3 m a Rule out contamination with both factor 
I and cofactors
C 3 m a  and factor I Rule out contamination of either with 
cofactors
C 3 m a , factor I and human soluble 
CR1 (sCRl)
Positive control
C 3 m a  and human sCRl Rule out contamination of CR1 and 
C 3 m a  with factor I
Either 5SCR-Fc, 4SCR-Fc, 3SCR- 
Fc, 4SCR or 3SCR with C 3 m a
Rule out contamination of Crry proteins 
and C 3 m a  with factor I
The incubations were carried out for 4 hours at 37°C. Following incubation the 
samples were resolved on 10% SDS PAGE gels under reducing conditions and either 
Western blotted and probed for rat C3 or silver stained (figure 4.6A and B). All Crry 
proteins had cofactor activity shown by the presence of a 43kDa band (figure 4.6C). 
The cleavage product was also seen in the control incubations of the cofactor with 
C 3 m a  without fl, due to the contamination of the cofactors (Crry and CR1) or C 3 m a  
with fl. As the Crry and sCRl are recombinantly produced it is highly unlikely that 
these proteins are contaminated, it is more likely that the C3ma has a slight factor I 
contamination.
This background cleavage provided an interesting and revealing observation as it was 
most prevalent in the 4SCR incubation, slightly less in the 5SCR-Fc and 4SCR-Fc 
incubations and barely visible in the 3SCR reagent incubations. This indicated that 
in the presence of added fl the reactions were driven further so Western blot and 
silver stain analysis was no longer sensitive to slight changes in the efficiency of 
cleavage and production of the 43kDa fragment. With less fl, at the level provided
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with the contamination, the reactions did not proceed as far and the analysis revealed 
differences in activity of the proteins. Hence 4SCR appeared to be the most active 
cofactor followed by 5SCR-Fc and 4SCR-Fc, with the 3SCR reagents having a much 
reduced function.
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Figure 4.6 SDS PAGE analysis of the cofactor assay.
A. Following incubation, 6jil of each test sample was resolved on a 10% SDS 
PAGE gel and Western blotted. It was probed with sheep anti-human C3c 
(known to cross react with rat C3) followed by anti-sheep IgG HRPO. No 
cleavage product was seen in incubations 1 and 2 showing that any cleavage 
can be attributed to the cofactor. In the presence of f l ,  all the Crry proteins 
acted as a cofactor for the cleavage of C3 (lanes 10-14). In the absence of f l  
(lanes 5-9) cleavage was also seen for 5SCR-Fc, 4SCR-Fc and 4SCR due to a 
low level f l  contamination of the C 3 m a . Cleavage was seen for human CR1 
with and without factor I (lanes 3 and 4).
B. Similarly, 6pl samples of the cofactor incubations were resolved on a 10% 
SDS PAGE gel and silver stained. This result confirms the Western blot but 
also highlights additional bands resulting from the cleavage at 76kDa just 
above the p-chain of C3. The Crry-Fc proteins are also apparent at 70kDa, 
62kDa and 55kDa for the 5SCR-Fc, 4SCR-Fc and 3SCR-Fc proteins 
respectively, CR1 is visible at 200kDa. The non-Fc Crry proteins are of 
lower molecular weights that are not apparent on the gel.
C. Diagram of the C3 chain structure showing the cleavage by fl. The C3 
convertase cleaves C3 in the a-chain resulting in the release of C3a (8kDa) 
and the formation of C3b (189kDa). Factor I in the presence of a cofactor 
cleaves the a-chain resulting in 68kDa and 43kDa fragments of the a-chain 
(blue arrows), when C 3 m a  is used as the substrate the resulting fragments are 
76 and 43kDa. CR1 can cause an additional cleavage of the a-chain (red 
arrow). The disulphide bonds are indicated by thin black lines and the C- and 
N-terminus ends of the peptide chains are marked.
Figure adapted from Complement Methods and Protocols. B. P. Morgan. 2000. New Jersey, 
USA. Humana Press.
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14
C3ma + + + + + + + + + + + + + +
Factor I - + + - - - - - - + + + + +
Cofactor - - CR1 CR1 5Fc 4Fc 3Fc 4 3 5Fc 4Fc 3Fc 4 3
Key: 5Fc is 5SCR-Fc, 4Fc is 4SCR-Fc, 3Fc is 3SCR-Fc, 4 is 4SCR, 3 is 3SCR and CR1 is human CR1
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4.2.4 Decay accelerating function
The decay accelerating abilities of 4SCR-Fc, 3SCR-Fc, 4SCR and 3 SCR were 
investigated using surface plasmon resonance, 5SCR-Fc was not included in this 
experiment as previous functional analysis showed that it did not differ in function 
compared to 4SCR-Fc. The method is described in detail in method 2.5.5. Briefly, a 
CM5 chip (Biacore®) was coated with 100RU of human C3b dimer. This human 
C3b was used to form the C3 convertase by injecting factors B and D. The 
convertase was used to cleave rat C3 resulting in deposition of rat C3b on the chip 
surface in a native orientation through the generation of a reactive thioester group. 
Cycles of C3 convertase formation followed by rat C3b deposition were repeated 
until an excess of rat C3b compared to human C3b had been deposited. The 
procedure for depositing rat C3b is demonstrated in figure 4.7.
We first showed that rat Crry is species specific for C3b in that Crry neither directly 
bound with human C3b nor caused decay of the human C3 convertase meaning that 
the human C3b on the chip surface would not interfere with subsequent assays 
(figure 4.8). Human fB can form a convertase with rat C3b. To compare the abilities 
of the Crry proteins to decay the C3 convertase, the convertase was formed on the 
chip and decayed using the Crry proteins in a 1:2 serial dilutions. A separate 
convertase was built up on the surface for each concentration of each protein. Decay 
in the presence of Crry was compared to the decay of the convertase in the absence 
of any decay acceleration, natural decay, figure 4.9.
All proteins had the ability to decay the C3 convertase at the highest concentrations 
used although not to the same degree. The ability to decay the convertase titred out 
much quicker with the 3SCR reagents (figure 4.9D) than the 4SCR reagents (figure 
4.9C), at the lowest concentration used of the 3 SCR reagents no increased decay 
compared to natural decay was seen whilst the 4SCR reagents still accelerated decay. 
The amount of convertase remaining after each injection was expressed relative to 
natural decay and plotted against concentration (figure 4.10) to quantify the activity 
of the proteins (table 4.3). The results show the concentration of Crry protein needed 
to decay 50% of the convertase. The 4SCR reagent had a slightly better activity than
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4SCR-Fc, 0.3 pM compared to 0.75pM, due to steric restriction of the 4SCRs of Crry 
in the Fc fusion protein. The 3SCR reagents had a much reduced activity with 2pM 
of the 3SCR protein and 2.8pM of the 3SCR-Fc needed to cause 50% decay. This 
reveals that SCR4 of Crry contains an active site necessary for efficient decay 
acceleration of the AP. This correlates with the AP haemolysis assay where the 
3 SCR reagents had a much reduced function.
4SCR-Fc 3SCR-Fc 4SCR 3SCR
Concentration required for 50% 
removal of convertase (|iM)
0.75 2.80 0.30 2.00
Table 4.3 The concentration of the Crry proteins necessary to cause 50% decay 
of the convertase.
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Figure 4.7 The immobilisation of rat C3b on the chip surface.
The chip was coated with 100RU o f human C3b dimer and this was used to drive the 
deposition o f rat C3b. Rat C3 was flowed across the chip following formation of 
C3bBb with factors B and D. Cleavage o f rat C3 resulted in the deposition of rat 
C3b. This cycle o f C3bBb formation followed by rat C3b deposition was repeated 
until the total amount o f rat C3b deposited reached 5000RU, far in excess o f the 
human C3b deposited. The nature o f the C3b deposited was checked by flowing 
factors B and D across the surface, the formation o f the convertase was observed 
along with its natural decay. Any loosely bound C3b was removed from the surface 
using a short injection o f 50mM diethylamine/PBS pH 11.
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Figure 4.8 The interaction of rat Crry with human C3b.
A. 4SCR was deposited on the surface of the chip and human C3b dimer (5mM) 
was flowed across the surface, no increase in response was seen revealing 
that rat Crry does not interact with human C3b.
B. Human C3b was deposited on the chip surface and the human C3 convertase, 
C3bBb, was formed by injection of human factors B and D. Injection of 
4SCR caused no accelerated decay of the convertase while human CD55 was 
able to cause enhanced decay demonstrating that Crry does not interact with 
the human C3 convertase.
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Figure 4.9 Graphs showing the decay of the C3 convertase on the surface of a 
Biacore® chip.
Each graph represents a different protein and the different lines on each graph 
illustrate the different concentrations used. Each graph shows the formation of the 
convertase shown by an increase in the y axis and then decay of the convertase either 
accelerated by a Crry protein or natural decay in the absence of any decay 
accelerating factor, decay is shown by a decrease in the level of the y axis. The 
formation and decay of the convertase is marked on figure A. For each graph the 
pink line represents 1.8pM of the respective Crry protein, light green represents 
900nM, light blue 450nM, dark green 225nM, dark red llOnM, dark blue 55nM 
(absent in the 4SCR-Fc titration). Natural decay is shown in purple.
A. Decay caused by 4SCR-Fc. Following injection of 4SCR-Fc an initial 
binding event was seen as evidenced by an increase in the level of the y-axis. 
This was followed by rapid decay of the convertase. Each protein 
concentration used caused enhanced decay compared to natural decay. The 
amount of convertase remaining after the accelerated decay caused by the 
Crry proteins was compared to the amount remaining at the same time point 
with natural decay to quantify the decay accelerating abilities of the proteins.
B. Decay caused by 3SCR-Fc. Enhanced decay was observed for the 1.8pM, 
900nM and 450nM injections. The other concentrations did not significantly 
enhance decay.
C. Decay caused by 4SCR. All concentrations exhibited an initial binding to the 
convertase followed by the decay of the convertase.
D. Decay caused by 3 SCR. Concentrations between 1.8pM and 225nM caused 
enhanced decay of the convertase, for the other concentrations used there was 
little observable difference with natural decay.
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Figure 4.10 Graph comparing decay accelerating abilities of the Crry 
proteins.
A plot of the percentage o f convertase left after injection of Crry against 
concentration of Crry reagent injected. The decay accelerating abilities of 4SCR- 
Fc (dark blue) and 4SCR (pink) were greater than 3SCR-Fc (yellow) and 3SCR 
(light blue). The graph was used to determine the concentration needed to cause 
50% decay o f the convertase.
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4.2.5 Affinity analysis
Surface plasmon resonance was also used to establish the affinity of the 4SCR and 
3 SCR proteins for rat C3b and to investigate whether the reduction in function 
corresponded to a reduced affinity for C3b. Only the 4SCR and 3 SCR proteins were 
investigated as this will reveal if the removal of the fourth N-terminal SCR has 
resulted in a reduction in affinity. Any difference with the Fc fusion proteins can 
reasonably be attributed to steric restriction caused by the Fc domain. Prior to 
affinity analysis, the 4SCR and 3 SCR proteins were gel filtered using a Superdex 
200 (GE Healthcare) column to remove any aggregated protein and to ensure the 
proteins were in the correct buffer (lOmM HEPES, 150mM NaCl pH 7.4) (method
2.3.9). A chip (CM5; Biacore®) was coated with 100RU of human C3b dimer. As 
previously described, this human C3b was used to form the C3 convertase which in 
turn cleaved rat C3 causing deposition of C3b on the surface in a native 
conformation, figure 4.7. For affinity analysis only 500RU of rat C3b was bound to 
the chip. The chip surface was stabilised by injecting lOpl 50mM diethylamine/PBS 
pH 11 to elute any loosely bound rat C3b. The 4SCR reagent (12.5pM) was diluted 
in a 1:2 serial dilution in HPS-P buffer (Biacore®; lOmM HEPES, 150mM NaCl,
0.005% (w/v) surfactant P20, pH 7.4). Each concentration was flowed over the chip 
in duplicate (figure 4.11 A). A 1:2 serial dilution of 3SCR was also created 
beginning at 33pM and these dilutions were also flowed over the rat C3b coated chip 
(figure 4.1 IB; method 2.5.6).
The amount of rat C3b on the chip surface was then increased to 1000RU by 
injecting factors B and D along with rat C3. The chip surface was stabilised and the 
affinity analysis was repeated. The higher density of rat C3b enabled more reliable 
affinity data for the 3 SCR reagent to be collected. In the second affinity analysis, the 
4SCR concentration series began at 25pM and the 3 SCR concentration series began 
at 33pM. For each protein, the response was plotted against concentration and 
steady state affinity analysis was used to calculate the affinity of the Crry proteins for 
rat C3b (figure 4.13). The affinity (KD) of the 4SCR protein with the two different 
densities of rat C3b was comparable, 5.1xlO'6M and 5.61xlO'6M, and was greater 
than the affinity of 3 SCR (table 4.4). The 3 SCR affinity dramatically altered with 
the different C3b coats, 1.36x10"4 and 6.65x10'5 because the interaction has a much
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lower affinity. Coating with the lower density resulted in very little response with 
the 3 SCR reagent, the response was close to the noise limit of the machine so the 
data is not reliable. Coating with 1000RU of rat C3b increased the response seen 
with the 3 SCR interaction. However, for both analyses the concentration of 3 SCR 
used did not reach the KD. Whilst an accurate determination of the 3SCR/C3b 
affinity cannot be determined, these data illustrate that deletion of the fourth N- 
terminal SCR of rat Crry reduces the affinity for rat C3b.
500RU rat C3b coat 1000RU rat C3b coat
KD (M) RMax (RU) Chi2 KD (M) RMax (RU) Chi2
4SCR 5.1 x 10-6 79.9 0.104 5.6 x 10-6 135 0.4
3SCR 1.4 x 10-4 70.7 0.114 6.7 x 10'5 90.8 0.122
Table 4.4 Affinity results for 4SCR and 3SCR.
KD is the dissociation equilibrium constant, the greater the number the lower the affinity. 
RMax is the anticipated maximum response for each protein, the point at which response no 
longer increases with concentration.
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Figure 4.11 Sensograms from the affinity analysis of 3SCR and 4SCR binding to 
500RU of rat C3b.
Sensograms from the affinity experiment carried out when the chip surface was 
coated with 500RU of rat C3b. Each protein was injected across the surface at a 
variety of concentrations as indicated by the concentrations on each sensogram.
A. 4SCR affinity analysis. All concentrations of 4SCR injected had a clear 
binding.
B. 3SCR affinity analysis. The maximum response difference achieved with the 
3SCR proteins was much lower than for the 4SCR protein. Injection of the 
lower concentrations resulted in very little binding. Both these observations 
indicate that 3SCR has a reduced affinity compared to 4SCR.
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Figure 4.12 Sensograms from the affinity analysis of 4SCR and 3SCR with 
1000RU rat C3b.
Sensograms from the affinity experiment carried out when the chip surface was 
coated with 1000RU of rat C3b. Each protein was injected across the surface in a 1:2 
serial dilution, concentrations indicated on each sensogram.
A. 4SCR affinity analysis, binding was seen for every concentration of 4SCR 
used.
B. 3 SCR affinity analysis, the response with the 1000RU coat was greater than 
the response with the 500RU coat.
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Figure 4.13 Calculation of the steady state affinity constants.
In order to calculate the affinity constants, response was plotted against 
concentration, shown here for the data achieved with the 1000RU coat of rat C3b.
A. Example curve showing calculation of Rmax, the point at which response no 
longer increases with concentration. The KD (dissociation equilibrium 
constant) corresponds to 50% Rmax.
B. 4SCR plot of response against concentration used to calculate the KD, 
5 .6 x 1 0 ^ .
C. 3 SCR plot of response against concentration used to calculate the KD, 
6.7x 10'5M.
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4.3 Discussion
In this chapter I have described the functional characterisation of the recombinant 
forms of rat Crry generated in chapter 3. These forms are 5SCR-Fc, 4SCR-Fc, 
3SCR-Fc, 4SCR and 3 SCR. This characterisation was carried out to locate 
functional domains so that a Crry-Fc reagent with no reduction in function could be 
identified and developed as an active therapeutic reagent. The functional 
characterisation was also carried to identify a Crry-Fc reagent that had no function or 
a reduced function as an Fc fusion protein but was fully active as a non-fusion 
protein. This reagent would be further engineered to create the ‘prodrug
Most of the knowledge of rat Crry function comes from observations of its mouse 
homologue, mouse Crry, which was first identified and has been well characterised. 
The generation and functional characterisation of recombinant forms of rat Crry 
described in this thesis has also contributed to knowledge of its function. Functional 
analysis of mouse Crry has revealed that the protein contains both decay accelerating 
activity and cofactor activity (Kim, Kinoshita et al. 1995). A recombinant form of 
rat Crry consisting of five N-terminal SCRs has been expressed in P i c h i a  p a s t o r i s ,  
this protein was shown to contain both CP and AP regulation as assessed by 
haemolysis assay (He, Alexander et al. 1997). Moreover, a recombinant form of rat 
Crry containing four N-terminal SCRs has been expressed in a bacterial system and 
was shown to be functional in a classical pathway haemolysis assay as well as a fl 
cofactor assay (Fraser, Harris et al. 2002). These studies have revealed that the first 
four N-terminal SCRs can regulate C, however, further questions about the function 
of Crry remain. For instance, haemolytic assays look at the overall inhibition of C 
and do not differentiate decay acceleration from cofactor activity. Also, no study has 
looked at the affinity of the various recombinant forms of Crry for rat C3b and 
dissected out the contribution from individual SCR domains. The functions of the 
human homologue, human complement receptor 1 (CR1) have been located to SCRs 
1-3, 8-10 and 15-17 with the SCRs being numbered from the N-terminus (Klickstein, 
Bartow et al. 1988). In particular decay accelerating activity has been located to 
SCRs 1-3 whilst cofactor activity has been located to SCRs 8-10 and 15-17 (Krych, 
Clemenza et al. 1994; Krych-Goldberg, Hauhart et al. 1999). The functional data 
compiled here contributes to the literature by providing a comparison of different 
SCR containing proteins enabling the function of rat Crry to be understood in more
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depth.
The ability of the Crry proteins to inhibit the lysis of erythrocytes via both the CP 
and AP was investigated. All the proteins were effective at inhibiting the CP while 
the 3SCR reagents showed a marked reduction in the ability to inhibit the AP. This 
suggests that the removal of the fourth SCR of rat Crry removes a site involved in 
inhibiting the alternative pathway. This is supported by the observation of steric 
hindrance in the 4SCR-Fc reagent compared to the 4SCR protein showing that an 
active site lies close to the Fc and hinge. This has an interesting similarity to DAF in 
which SCRs 1-4 are necessary for AP regulation while SCRs 1-3 are sufficient to 
regulate the CP (Coyne, Hall et al. 1992). In the classical pathway, differences in 
function are seen between 3SCR-Fc and 3 SCR showing that the Fc sterically 
hindered the ability to regulate the CP. This implies that sites for the regulation of 
the CP lie within the third N-terminal SCR close to the Fc as well as in the fourth N- 
terminal SCR demonstrated by the reduced ability of 3 SCR compared to 4SCR to 
regulate the CP. Differences were also seen between 4SCR-Fc and 5SCR-Fc with 
the 4SCR-Fc protein being more active. This may be due to the more rigid nature of 
the 4SCR-Fc protein resulting in the Crry arms can act together causing more 
efficient regulation. This synergy between two complement regulatory domains has 
been noted in human CR1. Correct spacing between two active sites within CR1 is 
needed to bring about efficient decay of the C5 convertase suggesting they act 
synergistically. Also the decay of the C3 convertase bought about by CR1 is 
increased if two copies of one active site are present in a recombinant protein 
(Krych-Goldberg, Hauhart et al. 1999; Krych-Goldberg, Hauhart et al. 2005). All the 
proteins had cofactor activity although fl titration revealed that the 4SCR was the 
most active followed by 5SCR-Fc and 4SCR-Fc with the 3 SCR reagents being least 
active.
Surface plasmon resonance assessment of the ability of the Crry proteins to decay the 
AP C3 convertase confirmed the reduced ability of the 3 SCR proteins to regulate the 
AP, although activity was seen for these proteins at the higher concentrations used 
within this assay. The 4SCR protein showed a slightly better function than 4SCR-Fc. 
Activity was seen for the 3 SCR proteins at higher concentrations. This suggested 
that AP function was not entirely removed with the fourth N-terminal SCR but that
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the affinity of 3SCR for C3b was less than 4SCR. This was confirmed by steady 
state affinity analysis. The functional analysis is summarised in table 4.5.
Classical
pathway
Alternative
pathway
Decay
acceleration
Cofactor
activity
C3b
affinity
5SCR-Fc ++ + N/A ++ N/A
4SCR-Fc ++ +(steric)
+
(steric) ++ N/A
3SCR-Fc +(steric) - +/- + N/A
4SCR ++ ++ ++ ++ ++
3SCR ++ +/- +/- + +/-
Table 4.5 Summary of the functional analysis of the recombinant forms of Crry.
The functional data for the Crry proteins is summarised by a ranking system. 
Proteins which were the most functional in the respective assay or had a high affinity 
are marked ++, proteins showing reduced function or affinity are marked +, proteins 
showing very little activity are marked +/- whilst proteins showing no function are 
marked -. N/A means that the protein was not tested in the particular assay.
These data are supported by the literature which report functional homology between 
CR1 and Crry. As already stated, the function of CR1 lies within SCRs 1-3, 8-10 
and 15-17. A study using domain-by-domain phylogenetic analysis classified SCRs 
into 11 sub-families: a-k (McLure, Dawkins et al. 2004). This study classified the 
functional SCRs of CR1 a, j, e. The first three N-terminal SCRs of rat and mouse 
Crry were also classified a, j, e. As there is close homology between these SCRs 
demonstrated by their classification, it indicates that function may lie in these SCRS 
in Crry. Interestingly the fourth N-terminal SCR of Crry was classified as f  and so 
was SCR 4, 11 and 18 of CR1. Again, this homology and conservation suggests that 
this SCR has some functional role.
In conclusion, functional analysis has revealed interesting insights into the function 
of Crry. The fourth N-terminal SCR contained a C3b binding site and removal of 
this SCR altered the ability of the proteins to decay the convertase and had a 
particularly striking effect on the ability to inhibit the AP. Cofactor activity and CP 
inhibition were also affected. The functional analysis revealed that functional sites
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within Crry were deleted before steric hindrance needed to create a ‘ prodrug ’ was 
achieved. This thesis will therefore now focus upon 4SCR-Fc as a promising active 
therapeutic.
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Chapter 5: The bulk generation of 4SCR-Fc and 4SCR
5.1 Introduction
In the previous chapter, I discussed the functional characterisation of the Crry 
proteins described in chapter 3, the aim was to identify two Crry-Fc reagents with 
different properties. One Crry-Fc would effectively inhibit C and could be used 
therapeutically in rat models of disease. The other form would be non-functional as 
Crry-Fc due to steric hindrance imparted on the Crry by the proximity of the Fc, but 
fully active as a non fusion protein. This form would be further engineered into a 
‘prodrug’ as been discussed previously (section 1.5.6.4). However, the functional 
characterisation only identified one type of Crry-Fc, the fully active form that could 
be used in vivo without further engineering. Development of a ‘prodrug’ of Crry-Fc 
was not possible as removal of SCRs reduced the affinity of Crry for C3b and 
reduced the function of Crry before sufficient steric hindrance was achieved. This 
thesis will therefore now focus upon 4SCR-Fc as an effective anti-complement 
reagent and this will be compared with 4SCR to show the effect that the Fc has on 
the activity, half-life and therapeutic efficacy of the protein.
Sufficient quantities of the proteins for in vivo testing of the reagents need to be 
generated. As already discussed in chapter 3, mammalian cells including CHO have 
lower protein expression levels than other expression systems such as bacteria and 
yeast. We chose to use CHO cells as the expression system, despite their lower 
expression levels, as they carry out appropriate post-translational modifications of 
proteins including folding and glycosylation which are necessary for correct 
function. Correct post-translational modifications of proteins may also reduce 
immunogenicity as proteins need to resemble their native form so that an immune 
response is not mounted causing clearance and inhibition of function. A point of 
consideration in generating proteins for therapeutic use is the contamination of 
proteins with bacterial toxins. This may be a particular issue when using a bacterial 
expression system. One way protein yields from mammalian cell cultures can be 
increased is by using a high density culture system; these have become increasingly 
common in protein production in recent years with a surge of protein therapeutics 
entering the market place. These high density culture systems aim to increase the
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amount of protein produced per unit of medium by driving the culture until the 
medium is completely exhausted such as in a fermenter system or by maximising the 
number of cells cultured in the medium such as the Tecnomouse (Integra 
Biosciences).
Fermenter systems, that is the culturing of cells within stirred tank reactors, have 
historically been limited by oxygen supply, waste product accumulation, the need for 
sophisticated process control, shear sensitivity of animal cells and the challenges of 
growing adherent cell lines (Glacken, Fleischaker et al. 1983). However, the 
development of the technology allowing such issues to be resolved has enabled many 
different therapeutics and diagnostic products to be produced by mammalian cells 
within these systems. Among the proteins produced in such systems is follicle- 
stimulating hormone which is produced by CHO cells using fermenter cultures and 
has been used to treat infertile women (Loumaye, Dreano et al. 1998).
Hollow fibre systems, the culturing of cells on the outside of hollow fibres used to 
provide nutrients to the cells, were originally described in 1972 but the use of this 
technology was limited by irregular oxygenation of the cells (Knazek, Gullino et al. 
1972). In the early nineties, the Tecnomouse (Integra Biosciences) was launched 
which enabled optimal combination of nutrient supply via hollow fibres and oxygen 
supply via silicon membranes. This marked the beginning of the growth of hollow 
fibre systems and now many membrane based cell culture systems are on the market 
including the CELLine flasks (Integra Biosciences).
The advent of high density culture systems has been crucial for monoclonal antibody 
production. Since the introduction of hybridoma technology in 1975 the in vivo 
production of ascites in mice has been preferred for its cost effectiveness and high 
yields of antibody (Kohler and Milstein 1975). However, due to growing ethical 
concern leading to a ban of ascites production in many European countries including 
the UK, and the risk of product contamination with non-specific immunoglobulins 
and viruses, an in vitro alternative became necessary. High density culture systems 
have provided such an alternative. In order to generate large quantities of 4SCR-Fc, 
4SCR and TLD1C11 (anti-Crry antibody) high density culture systems were used. 
The optimisation and comparison of these systems is described here. The following
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high density culture systems were used: a B Braun Biotech eukaryotic fermenter 
system (Bioreactor), Integra Biosciences CELLine flasks (CL1000 flasks) for both 
adherent and non-adherent cells and an Integra Biosciences Tecnomouse.
The aims of this chapter were:
1. To compare hybridoma high density culture systems and to use these to 
generate large quantities of TLD1C11 for the purification of 4SCR and 
4SCR-Fc.
2. To compare high density culture systems for anchorage dependent cells and 
use these to generate large quantities of 4SCR and 4SCR-Fc to enable in vivo 
characterisation of the proteins and to generate sufficient quantities of the 
reagents for in vivo therapy.
5.2 Specific methods and results 
5.2.1 Generation of TLD1C11
The TLD1C11 hybridoma was cultured using the Tecnomouse (Integra Biosciences), 
a CL1000 flask (Integra Biosciences) or a conventional tissue culture flask (T80, 
Nunc). These systems were compared for protein production by an ELISA (method
2.4.9). The cell numbers within the Tecnomouse and CL1000 flask were recorded 
using a haemocytometer and cell viability was assessed using trypan blue staining. 
SDS PAGE analysis of the product from the Tecnomouse and CL1000 flask was 
carried out to investigate whether the use of high density culture systems caused 
aggregation of the protein or breakdown of the product.
5.2.1.1 Tecnomouse
The Tecnomouse (Integra Biosciences) uses hollow fibre technology. In this 
technology fine hollow fibres are bundled together and cells are cultivated on the 
outside of these fibres. Oxygenated culture medium is circulated within the fibres. 
The porous fibre membrane allows nutrients and metabolic waste products to pass 
across the membrane, while large cellular protein products are retained within the 
cellular compartment. This technology allows the culture of a large number of cells
197
in a small volume resulting in a concentrated product. The Tecnomouse is shown 
diagrammatically in figure 5.1 along with a photograph of the equipment.
The Tecnomouse was prepared and inoculated following method 2.2.5.3. In brief, 
following preparation of the Tecnomouse system and cassette, 6 x 108 cells (total) 
were harvested from T80 tissue culture flasks in the log phase of growth. The cells 
were resuspended in 10ml high density hybridoma medium (described 2.2.1) and 
were placed in the Tecnomouse cassette. Every seven to ten days the bulk culture 
medium was replaced and the cells were harvested, split 1 in 4 and reseeded. The 
cell number of the remaining harvest was counted, as well as the number of viable 
cells using trypan blue staining. The total cell number remained around 108 
throughout the culture period; it peaked at 2xl09 around day 20 and day 60. The cell 
viability remained on average at about 50%, towards the end of the culture period the 
viability dropped to 20% for five consecutive harvests. This may have been due 
deterioration of conditions within the cassette over the culture period, gradual 
blockage of the hollow fibres may have resulted in impaired gas and nutrient 
exchange. This decrease in viability also corresponded with a decrease in cell 
number. It was at this point that the culture was stopped (figure 5.2A).
To assess the yield of TLD1C11, the supernatant harvested was used in an ELISA 
(method 2.4.9). The rate of production was 0.8mg/ml of harvest which was 
significantly higher than a T80 flask which was 5pg/ml (table 5.1). SDS PAGE 
analysis of the medium harvest revealed that the antibody was visible on an SDS 
PAGE gel at the Coomassie detection level showing how much greater the protein 
expression was than in a T80 flask where product was not visible at the Coomassie 
level. The protein was at the correct mass, 175kDa (figure 5.2B). The identification 
of the protein was confirmed by Western blot analysis. The Western blot showed 
other TLD1C11 bands that were not visible on the Coomassie stained gel. This 
shows that some smaller forms of TLD1C11 were produced under the high 
expression conditions, perhaps half forms or degraded antibody, but the majority had 
the correct mass.
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T80 flask Tecnomouse CELLine flask
Yield 5jj,g/ml 0.8mg/ml 1 mg/ml
Table 5.1 Methods used to generate TLD1C11 and their yields.
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Figure 5.1 Tecnomouse diagram and photograph
A. A diagram of the Tecnomouse cassette. The cell compartments are shown in 
grey, nutrients move into this compartment whilst metabolic waste products 
move out. Gases diffuse in and out. Medium is pumped around in the 
extracellular space (Lukacik, Roversi et al. 2004).
B. A photograph of the Tecnomouse. The cassette sits within the control unit 
which maintains temperature at 37°C and the cells in 5% CO2, medium is 
pumped into the cassette. The large bottle to the left is the medium which is 
pumped around the extracellular space.
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Figure 5.2 Assessment of cell viability, number and product formed in the 
Tecnomouse culture.
A. Graph showing the change in cell number and viability for the duration o f the
o
TLD1C11 Tecnomouse culture. The cell number (pink) remained around 10 
but did peak at 109 around days 20 and 60. The viability (blue) remained 
around 50% until the end of the culture when it decreased to 20-30% indicating 
deterioration in culture conditions in the cassette, cell number also decreased 
during this period.
B. SDS PAGE analysis o f the product from the Tecnomouse. A 7.5% gel was 
loaded with a sample of Tecnomouse supernatant and Coomassie stained after 
electrophoresis (lane 1) or transferred to nitrocellulose and probed with anti­
mouse IgG HRPO (lane 2). On the Coomassie gel the major product was 
around 50kDa, characteristic o f albumin from the bovine serum used to 
supplement the culture medium. A at 175kDa was also present. Western blot 
revealed that this 175kDa was TLD1C11, however, a number o f smaller 
products were also identified.
5.2.1.2 CL1000 flasks
A CELLine CL1000 flask (Integra Biosciences) consists of two compartments 
separated by a semi-permeable membrane with a lOkDa cut off. Within the small 
compartment cells are cultured in high density hybridoma medium while bulk culture 
medium (described in method 2.2.1) is within the larger compartment. The semi- 
permeable membrane between these two compartments allows nutrients to diffuse 
into the cellular compartment to feed the cells and allows metabolic waste products 
to diffuse away from the cells. The cut off of the membrane retains, within the 
cellular compartment, the protein products of the cells as well as proteins in the 
bovine serum, used to supplement the medium, necessary for cell growth. This flask 
enables the culture of a large number of cells in a small volume resulting in the 
production of a concentrated product (figure 5.3).
The flask was prepared and maintained following method 2.2.4.2. The flask was
n
inoculated with 2.5 x 10 cells in 15ml high density hybridoma medium. The cells 
had previously been harvested from T80 flasks in a log phase of growth. The cells 
were cultured for ten days before the first harvest and then seven days between 
harvests. For the harvest, the bulk culture medium was replaced and the cells split 1 
in 4 in high density hybridoma medium before reseeding. The cell number was 
established as described previously. The total cell numbers reached a maximum at 5
o o
x 10 and remained around 2.5 x 10 for the culture period. The viability of the cells 
decreased to 40% where it stayed for the culture period (figure 5.4A). The yield as 
calculated by ELISA was 1 mg/ml of harvest supernatant, again significantly higher 
than the T80 flask yield (table 5.1). SDS PAGE analysis revealed that the product 
was visible with Coomassie staining. As with the Tecnomouse, the product was of 
the correct mass, 175kDa, showing that it was neither aggregated nor broken down 
by the culture conditions used (figure 5.4B). The identification of the protein was 
confirmed by Western blot analysis. The Western blot did show additional bands 
indicating that some degradation of the antibody may have occurred but the majority 
of the antibody was the correct mass.
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Figure 5.3 CL1000 flask diagram and photograph.
C. Diagram of the CL 1000 flask. Cells are placed in the flask through the cell 
port. Nutrients pass into the cell compartment and waste products out into 
the bulk medium compartment through the semi-permeable membrane. Gas 
enters the cell compartment through the gas permeable membrane while the 
medium is gassed via the lid.
D. A photograph of a CL 1000 flask.
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Figure 5.4 CELLine flask cell number, viability and SDS PAGE
A. Graph showing the number (pink) and viability (blue) o f the TLD1C11
o
hybridomas cultured in the CL 1000 flask. The cell number peaked at 5 x 10 
and then dropped to 2.5 x 108. The viability began at 100% and dropped to 
around 40% for the duration of the culture.
B. SDS PAGE analysis o f the supernatant from the CL1000 flask. A 7.5% gel 
was loaded with supernatant and was Coomassie stained (lane 1) or 
transferred to nitrocellulose and probed with anti-mouse IgG HRPO (lane 2). 
The major protein in the supernatant was albumin at around 50kDa from the 
bovine serum used to supplement the media. At 175kDa was also visible and 
this was identified as TLD1C11 by Western blot analysis. Half forms or 
degraded forms o f the antibody were also visible on the Western.
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5.2.2 Generation of Crry proteins
The Crry proteins (4SCR-Fc and 4SCR) were generated using a fermenter system, a 
high density culture flask (CL AD1000, Integra Biosciences) and a conventional T80 
tissue culture flask (Nunc). As with the TLD1C11 generation these systems were 
compared for their protein yield using an ELISA (method 2.4.9). SDS PAGE 
analysis of the product was also carried out to investigate if the high culture systems 
caused the proteins to become aggregated or broken down.
5.2.2.1 Fermenter
The fermenter system used here was the BioStat B Plus (B Braun Biotech) with a
0.5-2 litre culture vessel. A fermenter system consists of a control unit and a glass 
vessel. The culture is carried out within the glass vessel which is stirred and has 
temperature, pH and pC>2 controlled using the control unit. The culture of CHO cells 
in the fermenter system is described in method 2.2.4.3. In brief, prior to the culture 
the pH and pC>2 electrodes were calibrated and the vessel siliconised to prevent cells 
adhering to the vessel. Then the glass vessel was removed from the control unit and 
autoclaved to achieve sterility. After autoclaving, the vessel was filled with culture 
medium, connected to the control unit and incubated under culture conditions to 
enable the medium and vessel conditions to stabilise. Following inoculation of the 
cells, the stirring speed was controlled, the pH controlled using CO2 and 0.1M 
Sodium carbonate and the pC>2 controlled using O2 and N2 . Additional system pumps 
enabled medium to be removed and added to the culture and a sample port enabled 
cell numbers and viability to be monitored throughout the fermentation. The 
fermenter is shown schematically is figure 5.5 along with a photograph of the 
system.
As CHO cells are adherent, they were attached to microcarrier beads (Cytodex 1, GE 
Healthcare) for the fermentation. The beads were prepared following the 
manufacturer’s instructions, method 2.2.4.3. For the first fermentation, the beads 
were autoclaved within the vessel in PBS (phosphate buffered saline), the PBS was 
decanted off, the beads washed into medium and the cells were inoculated through 
the injection port once the litre of medium within the vessel had stabilised at the
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desired culture conditions. The vessel was stirred for five minutes every hour within 
the first three hours to enable the cells to attach to the beads. A sample taken from 
the fermenter at three hours post inoculation revealed that cells were attached to the 
beads, hence full stirring was commenced. However, at day three post inoculation 
no cells were visible on the beads so the fermentation was stopped. The addition of 
the cells into the large volume of medium within the vessel had meant that many 
cells did not attach to beads. Also commencing full stirring at 3 hours post 
inoculation may have resulted in weakly attached cells falling off the beads. It was 
therefore decided to attach the cells to the beads outside the vessel prior to 
inoculation and to delay the time before full stirring was commenced for future 
cultures. The beads were therefore prepared in a separate 500ml siliconised glass 
bottle and autoclaved. The beads were washed into medium and the cells added to 
the beads within the 500ml glass bottle. The cells were incubated with the beads 
overnight at 37°C with 5 %  C O 2 with occasional mixing. The beads with the cells 
attached were then added to the culture vessel of the fermenter and the fermentation 
begun. This approach was used to inoculate the 4SCR-Fc fermentation with 1.5 x
Q
10 cells. Following inoculation, the cell numbers went through a long lag phase 
where the cell number was below that of inoculation. Once the culture was
Q ^
established the cell number remained around 10 , decreasing to 2.8 x 10 before a
o
medium change increasing to 8 x 10 after a medium change. The viability also 
altered when the medium was changed, decreasing to 50% before a feed and 
increasing to 100% after a feed (figure 5.6A).
o
For the 4SCR fermentation 2 x 10 cells were attached to beads in a 500ml glass 
bottle and then added to the culture vessel as described above. The cell numbers 
within this culture also went through a long lag phase when the cells were adapting 
to the new culture conditions; it took 8 days for the cell numbers to recover to their
o
inoculation density. The cell numbers remained around 10 , but decreased prior to a
n q
medium change to 6 x 10 and increased after a change to 1 x 10 . The viability of 
the cells remained around 80% at the beginning of the culture, but did dip after the 
medium change to 45%. Both the cell numbers and viability dipped at this point but 
then recovered without any additional medium being added. This effect may have 
been caused by unexpected variations in gas pressure during this time period (figure 
5.6B).
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Figure 5.5 Fermenter diagram and photograph.
A. A diagram of the fermenter culture vessel. The vessel is surrounded by a water 
jacket and contains a stirrer, a temperature probe, a pH probe and a pC>2 probe. 
Gas enters the culture in fine bubbles through the sparger. The lid of the vessel 
contains inlets and outlets which can be attached to the system pumps to 
change media and add acids or bases to maintain pH.
B. A photograph of the fermenter. The culture vessel sits next to the control unit. 
Each variable such as stirrer, temperature, pH, pC>2 is connected to the control 
unit, each one in monitored throughout the culture and controlled.
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Figure 5.6 Fermenter cell numbers and viability.
A. Cell numbers (pink) and viability (blue) in the 4SCR-Fc fermenter culture.
oThe cell number fell over the initial period and then increased to 7 x 10 .
o
Prior to a medium change the cell numbers decreased to 4 x 10 , the cell 
numbers increased following a medium change. The viability also 
increased after an initial lag period, but fell prior to a medium change and 
increased after.
B. Cell numbers (pink) and viability (blue) in the 4SCR fermenter culture. 
The cell numbers went through an initial lag period and then began to 
increase. The numbers fell prior to a medium change and then increased. 
The viability remained steady, dropping slightly through the culture period 
until a rapid drop at day 24 after which it increased again. This drop and 
increase did not correspond to a medium change but may have 
corresponded to an unexpected drop in gas pressure.
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The generation of both the proteins was quantified by ELISA (method 2.4.9). The 
generation of 4SCR-Fc was at a rate of 1.5mg/l of culture while the yield of 4SCR 
was 0.4mg/l of culture (table 5.2). Both these yields were lower than from a T80 
flask which was disappointing. The proteins within the cell culture medium 
generated using the fermenter were not analysed by SDS PAGE because of their low 
concentration within the medium. However, SDS PAGE analysis of the proteins 
purified from the cell culture supernatant generated by this method revealed that the 
proteins were the correct mass showing that the culture method had not affected the 
protein being produced, it had not caused any aggregation or degradation of the 
products additional to that what was seen under conventional culture conditions 
(figure 5.7).
4SCR-Fc 4SCR
T80 Fermenter CELLine T80 Fermenter CELLine
Yield 5pg/ml 1.5pg/ml 150pg/ml lpg/ml 0.4pg/ml 20pg/ml
Table 5.2 Methods used to generate the Crry proteins and their yields.
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Figure 5.7 SDS PAGE analysis of the fermenter products.
A. SDS PAGE o f the 4SCR-Fc fermenter product. The 4SCR-Fc purified from 
the fermenter supernatant was loaded onto a 7.5% gel and subjected to 
electrophoresis. After electrophoresis, the gel was either Coomassie stained 
(lane 2) or transferred to nitrocellulose and probed with anti-rat IgG HRPO 
(lane 1). The product from the fermenter supernatant contained a band o f the 
correct mass and this was confirmed by Western blot analysis to be 4SCR-Fc. 
The culture conditions had not altered protein formation or caused its 
degradation.
B. SDS PAGE o f the 4SCR fermenter product. The 4SCR purified from the 
fermenter culture was resolved on an 11% gel and either Coomassie stained 
(lane 1) or Western blotted onto nitrocellulose and probed with anti-Crry 
(TLD1C11) followed by anti-mouse IgG HRPO (lane 2). The product from 
the fermenter supernatant was the correct mass and it was confirmed as 4SCR 
by the Western blot. The culture conditions had not caused additional 
aggregation or degradation o f the product.
4SCR
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S.2.2.2 CL AD1000 flasks
CELLine CL AD 1000 flasks (Integra Biosciences) were used as high density culture 
flasks to generate 4SCR-Fc and 4SCR. The flasks are identical to CL1000 flasks 
used to culture TLD1C11, described above, except they contain a polyethylene 
terephtalate (PET) matrix within the cell compartment for the cells to attach to. To 
inoculate both the 4SCR-Fc and 4SCR cultures, cells were harvested from T80 flasks 
in a log phase of growth and inoculated into the CL ADI000 flasks at 2.5 x 107 cells 
in 15ml transfected cell medium (defined method 2.2.1). The flasks were allowed to 
establish for ten days and then medium from the cell compartment was harvested 
every seven days. During the harvest the bulk medium was replaced and the medium 
within the cell compartment changed. The harvest from the cell compartment was 
retained as this contained the protein product. The cell numbers within each culture 
were not taken as this would involve trypsinising the cells to remove them from the 
PET matrix and then reseeding the flask, this would reduce protein production. 
Quantification of protein yields revealed that the 4SCR-Fc flask produced 150pg/ml 
of harvest while the 4SCR 20pg/ml of harvest, both yields were higher than T80 
flasks being 5jxg/ml and lpg/ml respectively (table 5.2). SDS PAGE analysis 
showed that the major protein within the supernatants harvested from the cell 
compartments was characteristic of albumin. However, bands corresponding to 
4SCR-Fc and 4SCR were both visible on the Coomassie stains, although the band 
corresponding to 4SCR was weak. The identity of these bands was confirmed by 
Western blot analysis which revealed that the proteins were of the correct mass with 
no additional bands, showing that the culture conditions had not caused additional 
aggregation or degradation of the proteins (figure 5.8).
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Figure 5.8 SDS PAGE analysis of the products from the CL AD1000 flasks.
A. SDS PAGE analysis o f the 4SCR-Fc culture. The supernatant from the cell 
compartment o f the CL AD 1000 flask was resolved on a 7.5% gel and either 
Coomassie stained (lane 1) or transferred to nitrocellulose and probed with anti­
rat IgG HRPO (lane 2). The major protein in the supernatant was albumin shown 
by its characteristic band at 50kDa. A band was visible at 140kDa corresponding 
to the expected mass o f 4SCR-Fc. The identity o f this band was confirmed by 
the Western blot. No additional bands for 4SCR-Fc were seen showing that the 
culture conditions had not caused aggregation o f degradation o f the protein.
B. SDS PAGE analysis o f the 4SCR culture. The supernatant from the cell 
compartment was resolved on a 11% gel and either Coomassie stained (lane 1) or 
Western blotted onto nitrocellulose and probed with anti-Crry (TLD1C11) 
followed by anti-mouse IgG HRPO (lane 2). On the Coomassie stain the major 
protein was at 50kDa corresponding to albumin, a faint band was visible at 
28kDa corresponding with the mass o f 4SCR. The Western blot confirmed the 
identity o f  this band as 4SCR, no additional 4SCR bands were seen showing that 
the culture conditions had not caused aggregation or degradation o f the protein.
5.3 Discussion
Following the identification of 4SCR-Fc and 4SCR as potential therapeutic reagents 
it was necessary to optimise a method for the bulk generation of these reagents. In 
this chapter, I describe the use of various high density culture systems to generate the 
amount of protein necessary. High density culture systems were also used to 
generate large quantities of TLD1C11 (anti-Crry antibody) to enable the purification 
of the Crry proteins.
Since the advent of hybridoma technology in 1975 ascites production has been the 
favoured method to produce high levels of antibody (Kohler and Milstein 1975; 
Hendriksen and de Leeuw 1998). However, increasing ethical concern about this 
technique resulting in its ban in many European countries, coupled with improved 
cell culture equipment and techniques has led to the replacement of ascites 
production with in vitro methods. These methods include the use of hollow fibre 
systems such as the Tecnomouse, roller bottles and static CELLine culture flasks 
(CL 1000 flasks). Conventional low density culture methods have been shown to 
produce between 1 and 100jig/ml antibody depending upon the hybridoma being 
cultured (Falkenberg 1998). High density culture methods have been shown to 
produce far greater amounts with CELLine flasks able to produce 0.7 -  2.5mg/ml 
(Trebak, Chong et al. 1999). The Tecnomouse can produce greater than 1 mg/ml 
(Nagel, Koch et al. 1999).
I have used high density culture methods and demonstrated increased production 
compared to conventional static cultures, in agreement with what is reported in the 
literature. Supernatant from the Tecnomouse contained 0.8mg/ml of TLD1C11, the 
CELLine flask 1 mg/ml and the T80 flask 5pg/ml. The high density culture methods 
had a harvest greater than a T80 flask by at least 160 times. There is a different 
volume yield for each system with the Tecnomouse and CELLine flask generating 
15ml/week while the amount generated from the T80 flask depends upon how many 
are grown. A direct comparison between systems can be achieved by calculating 
how many T80 flasks would need to be grown to generate the same yield as the 
Tecnomouse and CELLine flask. The Tecnomouse yields 12mg/week which would 
be equivalent to 2000ml T80 supernatant per week, harvested from 30 T80 flasks. 
The CELLine flask yields 15mg/week, equivalent to 3000ml T80 flask supernatant
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or 50 flasks. Not only does the culture of this number of flasks represent a 
significant investment of time, but also a high cost in cell culture media especially 
foetal bovine serum (FBS). Both high expression systems use very little FBS, 2.5ml 
of FBS per week as opposed to 300-450ml if T80 flasks were used to generate the 
equivalent amount of antibody. Purification of the TLD1C11 from a larger volume 
of supernatant generated using conventional flasks also increases the time taken. The 
production of monoclonal antibodies in high density systems has significant 
advantages over the traditional ascites generation in terms of reduced animal use and 
suffering and also in terms of a reduction in non-specific antibodies, limited viral 
contamination and the ability to generate antibodies from a wider variety of species 
with such a system.
Out of the two high density culture systems, the CELLine flasks have the greater 
yield. This system is also the least cumbersome as the Tecnomouse has a special 
control unit and can become complicated when many different culture cassettes are 
being used each with their own feed bottle and tubing. The ease of culturing in the 
CELLine flask compared to the Tecnomouse is illustrated by the removal from sale 
of the Tecnomouse by the manufacturers in early 2005 due to decreasing sales as 
customers prefer the CELLine flask which needs no specialist equipment. The high 
expression culture conditions caused no aggregation or degradation of the product 
when investigated by Coomassie staining a polyacrylamide gel but Western blot 
analysis did show some smaller forms of the antibody presumably degradation but 
these forms were minor, the majority of antibody generated was of the correct mass.
Since tissue plasminogen activator (tPA) became the first recombinant therapeutic 
protein produced by mammalian cells to obtain market approval in 1986, the number 
of recombinant proteins being produced for therapeutic use in mammalian cells has 
increased. As previously discussed, mammalian cells have certain advantages in 
recombinant protein production but they are limited by low yields. These low yields 
can be overcome by using high density culture systems such as a fermenter and 
adherent CELLine flasks. Protein generation on a fermenter system can reach the 
gram per litre range (Robinson and Memmert 1991). The expression of proteins 
within this project using a fermenter system was lower than conventional static 
cultures for both 4SCR-Fc and 4SCR. This disappointing lower expression reflects
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the complexity of fermenter cultures and highlights the need for further optimisation. 
Both the cell numbers within the 4SCR-Fc and 4SCR fermenter cultures went 
through a long lag phase as the cells adapted to the culture conditions. Alterations of 
the conditions such as stirring speed and gassing speed may have shortened this lag 
phase by reducing shear stress on the cells. Cell numbers, growth and protein 
production within a fermenter system can be limited by oxygenation, waste 
accumulation, shear stress and nutrient availability. In order to optimise the 
fermenter each one would need to be dealt with. Oxygenation would need to be 
maximised whilst keeping the stress on the cells caused by the gassing process to a 
minimum. Waste accumulation and shear stress need to be minimised, for shear 
stress this would be done by decreasing stirrer speeds and gassing speeds. Nutrient 
availability would need to be maximised by increasing both glucose and glutamine 
content of the medium. As good results were obtained from CELLine flasks (below), 
the fermenter was not fully optimised for these proteins.
The adherent CELLine flasks (CL AD1000 flasks) have been shown to increase 
protein production by BHK (Baby Hamster Kidney) cells by 25 times compared to 
T80 flasks (Mittermaier and Zang-Gandor). In this project the 4SCR-Fc yield was 
150jxg/ml, 30 times greater than the T80 flask and the 4SCR yield was 20pg/ml, 20 
times greater than a T80 flask. This increase in production using CELLine flasks 
represents a saving in time and space needed for the culture and subsequent 
purification of proteins if compared to using conventional cultures. The expression 
may be boosted further by increasing the glucose and glutamine content of the 
medium. SDS PAGE analysis revealed that neither the fermenter nor CELLine 
flasks caused additional aggregation or degradation of the proteins.
Production of proteins using these high density culture systems also resulted in 
minimal contamination of the products after purification. The contamination of the 
proteins with bovine antibodies in particular can be minimised as the ratio of desired 
protein to bovine antibodies is greater using these systems than normal methods 
making the contaminant a minor rather than a major constituent. For instance 15mg 
of TLD1C11 was produced per 2.5ml of bovine serum in the CELLine flasks as 
opposed to 450ml of bovine serum using conventional cultures.
216
In conclusion, various high density culture systems were compared for the generation 
of antibodies and recombinant proteins. For generating antibodies from hybridomas 
and recombinant proteins from anchorage dependent cells, CELLine flasks were 
favoured as they resulted in the generation of high levels of the desired proteins and 
required no specialist equipment or optimisation to use. The CELLine flasks are 
economical and minimally time consuming. Sufficient quantities of the Crry 
proteins for in vivo characterisation have been generated. Following generation all 
proteins were purified from cell culture supernatant as described previously (method 
3.2.5).
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Chapter 6: The in vivo characterisation of 4SCR-Fc and 4SCR
6.1 Introduction
Due to the implication of C in various pathologies (discussed in chapter 1, table 1.2) 
C has itself become a therapeutic target. The concept of developing C inhibitors 
began when hereditary angiodema (HAE) was found to be associated with a Cl-inh 
deficiency (Donaldson and Evans 1963). This disorder was first treated with s- 
aminocaproic acid, an anti-fibrinolytic agent that also inhibits C (Frank, Sergent et al. 
1972). It was later treated with Cl-inh purified from plasma. With the advent of 
molecular biology techniques it was possible to design C inhibitors, furthermore 
hybridoma technology meant that monoclonal antibodies specific for C components 
and with inhibitory function could be used as therapeutics. This has resulted in a 
large number of inhibitors being tested each with their own effects, advantages and 
disadvantages. First generation anti-C therapeutics are discussed in chapter 1 
(section 1.5). Many of these reagents were limited by their short half-life in vivo 
resulting in rapid clearance from the circulation, their immunogenicity in animal 
models preventing testing in models of chronic disease, their immunogenicity in 
humans resulting in limited treatment times or their tendency to systemically inhibit 
C which could render individuals susceptible to bacterial infections. For example, 
treatment of mice with a Crry-Ig fusion protein resulted in mice having an increased 
susceptibility to acute septic peritonitis compared with mice treated with a targeted 
anti-C reagent, CR2-Crry (Atkinson, Song et al. 2005).
The aim of this project was to overcome some of the limitations of the first 
generation therapeutics. The aim was to generate a long lived reagent by generating 
an Fc fusion protein of the CReg Crry. This approach has previously been 
demonstrated to increase the half-life of the CReg DAF (Harris, Williams et al.
2002). In order to confirm that this approach lengthened the half-life of Crry and to 
establish by how much, the half-life of 4SCR-Fc was compared to 4SCR. By 
generating an Fc fusion protein containing both a rat regulator and a rat Fc domain 
the aim was to produce a non-immunogenic reagent that would enable the testing of 
the reagent in rat models of chronic disease. Previous CReg-Fc proteins have 
contained a human Fc or a mouse Fc (Quigg, Kozono et al. 1998; Harris, Williams et 
al. 2002). The human Fc reagent was limited to acute therapeutic studies in the rat
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whilst the mouse Fc reagent was used in murine models. Also, the human 
therapeutic sCRl based on complement receptor 1 has been limited to acute 
therapeutic studies because neutralising antibodies are generated when the reagent is 
injected into non-human species (Piddlesden, Storch et al. 1994). Therefore in this 
study the immunogenicity of Criy-Fc was investigated, in particular the generation of 
neutralising antibodies. A further aim of this project was to generate a ‘prodrug’ of 
Crry that could be activated at the disease site thereby eliminating the problem of 
systemic C inhibition. However, as discussed in chapter 4, this approach proved to 
be non-viable for Crry.
The therapeutic efficacy of the active Crry-Fc (4SCR-Fc) was compared with 4SCR 
in the rat model experimental autoimmune myasthenia gravis (EAMG). EAMG can 
be induced by immunisation of purified AChR (AChR) or by passive transfer of a 
monoclonal anti-AChR antibody (mAb35). In this project mAb35 was used to 
induce the disease which has a pathogenesis very similar to myasthenia gravis (MG). 
MG is a well defined antibody-mediated autoimmune disease of the neuromuscular 
junction characterised by muscle weakness and fatigue. Anti-AChR antibodies bind 
to the motor end plate, reducing the number of functional AChR either by direct 
blockade or by causing accelerated internalisation and degradation of the receptor 
(Drachman, de Silva et al. 1987; Lindstrom, Shelton et al. 1988; Loutrari, Kokla et 
al. 1992). This results in neuromuscular transmission failure (Kaminski, Li et al.
2003). C has been implicated in EAMG as C activation products have been found at 
the motor end plate and C depletion or deficiency abrogates disease (Lennon, 
Seybold et al. 1978; Engel, Sakakibara et al. 1979; Lennon and Lambert 1980; 
Sahashi, Engel et al. 1980; Fazekas, Komoly et al. 1986; Christadoss 1988; Nakano 
and Engel 1993). Anti-C therapy has proved effective in EAMG as sCRl suppresses 
disease in the model by reducing muscle weakness and associated weight loss 
(Piddlesden, Jiang et al. 1996). C may mediate damage in EAMG by causing lysis of 
the membrane at the motor end plate or through the proinflammatory effects of the 
early C components C3a and C5a (Engel and Arahata 1987).
The aims of the work presented in this chapter were:
1. To establish the circulating half-life of 4SCR-Fc in rats and compare this with 
the half-life of 4SCR.
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2. To establish if the Crry-Fc was immunogenic, in particular if antibodies were 
generated to the reagent.
3. To establish the therapeutic efficacy of 4SCR-Fc in EAMG compared to 
4SCR and look at the ability of these reagents to inhibit C within this model.
6.2 Specific methods and results
6.2.1 In vivo half-life
To determine the in vivo half-life of the 4SCR-Fc and 4SCR proteins, these proteins 
were iodinated with I125 and injected intravenously into rats following method 2.6.2. 
This work was carried out in collaboration with Dr Anwen Williams, Dept of 
Rheumatology who performed the i.v. injections and harvested blood samples. The 
amount of the proteins remaining in the circulation of the rats was calculated from 
the counts of blood samples taken at various time points. The half-life that is 
calculated here is the P-phase half-life; this refers to the rate of elimination of the 
proteins from the body as opposed to their distribution throughout the body. 
Calculations used here are based upon the assumption that the clearance of the 
protein is biphasic as the body is viewed as two compartments; a central 
compartment containing the blood and well-perfused organs such as the heart, lungs, 
kidney and liver, and a peripheral compartment consisting of less well-perfused 
tissues such as muscle, fat and skin. Following administration of the proteins into 
the circulation they immediately equilibrate amongst the central and peripheral 
compartments, i.e. the protein will be distributed throughout the body and this is 
referred to as the a-phase half-life. The elimination of the protein occurs 
immediately after administration alongside this distribution and is termed the p-phase 
half-life. The two half-lives can be distinguished if the p-phase half-life is longer 
than the distribution phase. The rate of elimination is assumed to be proportional to 
protein concentration in the system and so can be described by first order kinetics. 
This two-compartment model is explained diagrammatically in figure 6.1.
220
Administration
I
Central
Compartment
1
Equilibration 
a-phase half- 
life
Peripheral
Compartment
Elimination 
P-phase half-life
B.
Distribution 
phase (a)
a>
c3ow
W)o
Elimination phase (p)
Time, t
Figure 6.1 The two-compartment model.
A. A schematic of the two compartment model. The proteins enter the central 
compartment where they reach instantaneous equilibrium before 
equilibrating with the peripheral compartment (1). Elimination begins 
immediately after administration (2).
B. Graph showing the phases of the two-compartment model. Plasma 
concentration plotted against time, the protein shows an initial rapid 
decrease in concentration corresponding to the distribution phase or a- 
phase. There is then a more lengthy elimination phase, the p-phase.
Both figures are adapted from Clinical Pharmacology. 3rd Edition. J.M. Ritter, L.D. Lewis and 
T.G.K. Mant. 1995. London, UK. Emold Arnold. pp26.
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The half-life of the proteins was calculated using the following equations. In the two 
compartment model the exponential decline of the elimination phase is represented 
by:
Ct = Co e_lct or In Ct = In Co -k t
Where Ct is the plasma concentration of the protein at time, t. Co is the theoretical 
initial concentration when time = 0 if the a-phase is discounted and k is the rate 
constant. A plot of In C against t is linear once equilibrium is reached, the y intercept 
corresponds to Co and the slope -k. The half-life is independent of concentration 
and can therefore be related to rate constant, k, by substituting Co as 2 and C as 1 
(Waller 1994). From this,
P-phase half-life = 0.693 / k
To take into account the initial distribution of the proteins through the body, protein- 
bound counts were expressed as a percentage of the counts at 5 minutes. The 
percentage counts were plotted against time in hours (figure 6.2). The slope of the 
graph during the elimination phase was calculated from the linear region. From the 
slope of the graph the p-phase half-life of both the proteins was calculated using the 
above equation. The 4SCR protein was eliminated rapidly from the circulation, the 
distribution throughout the body and the elimination from the body were 
indistinguishable. After the clearance of most of the protein from the body, the line 
began to flatten off corresponding to low levels of radioactivity remaining within the 
rats. The P phase half-life of 4SCR was 7.2 minutes (standard deviation +/- 2.1 
minutes). The 4SCR-Fc had a significant increase in half-life compared to the 4SCR 
reagent, the P-phase half-life of 4SCR-Fc was 52.9 hours (p<0.001 determined by an 
unpaired t-test, standard deviation +/- 16 hours).
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Figure 6.2 0-phase in vivo half-life of 4SCR-Fc and 4SCR.
Time in hours was plotted against the natural log (In) o f protein bound counts as a 
percentage o f the counts at 5 minutes to eliminate the initial distribution phase of 
the proteins. The elimination o f 4SCR-Fc is shown in blue while the elimination of 
4SCR is shown in pink. Data points represent the mean counts +/- 1 SD from 5 
rats. Analysis o f the linear slopes indicated that 4SCR-Fc had a p-phase half-life of 
52.9 hours while 4SCR had a p-phase half-life o f 7.2 minutes.
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6.2.2 Immunogenicity of Crry-Fc
6.2.2.1 Antibody generation
To assess whether a Crry-Fc protein was immunogenic, particularly the join between 
the Crry and Fc that formed a neoepitope, an immune response study was carried out 
in rats. This study was carried out in collaboration with Dr Anwen Williams, Dept of 
Rheumatology who carried out the injections and tail bleeds. In this study there were 
3 groups of 5 normal female Wistar rats. Group A was the negative control injected 
with sCrry-cys, this reagent consisted of 4SCRs of rat Crry with a cysteine tail. This 
reagent had previously been generated in the lab and was used as a negative control 
as it resembles native Crry without the Fc domain (Fraser, Harris et al. 2002). Group 
B was injected with rat DAF-human Fc as a positive control, this reagent consisted of 
4SCRs of rat DAF fused to the Fc of human IgGl. This reagent had also been 
generated in the lab previously and was used as a positive control to prove that this 
dosing regime could be used to mount an immune response to an immunogenic 
protein, namely the human Fc present in the molecule (Harris, Williams et al. 2002). 
Group C was injected with a Crry-Fc reagent, 5SCR-Fc was used here to determine if 
fusing the Crry to the Fc caused the protein to be immunogenic. The experiment was 
carried out following method 2.6.3.1 which involved administering the proteins 
intravenously and collecting tail bleeds at different time points. The serum was 
harvested from the bleeds and screened for antibodies to the injected proteins by 
ELISA.
The DAF-Fc group (group B) mounted an immune response to the protein, proving 
that this injection regime could be used to generate an immune response to an 
immunogenic protein (figure 6.3A). Screening the antibodies produced by ELISA 
revealed that all the animals mounted an IgM response which began class switching 
to IgGl from about day 28 (figure 6.3B), this class switching was seen strongly in 
animals B l, B2 and B3 and more weakly in animal BO. Animal B2 showed the 
weakest IgM response but also showed a switch to IgG2b.
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Figure 6.3 Immune response generated in group B (DAF-Fc).
A. ELISA result showing the antibodies generated to DAF-Fc as detected in 
the day 35 serum samples. All animals (B0-B4) mounted an IgM response, 
class switching was predominantly seen to the IgGl isotype but also to 
IgG2a and IgG2b.
B. Representative ELISA result (animal B2) showing the class switching of 
the antibody response in DAF-Fc animals. The IgM response peaked at day 
7 while class switching was seen from day 28.
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Group A (sCrry-cys) also mounted an immune response, figure 6.4A. All the 
animals mounted a strong IgM response, AO showed IgG2a and IgG2c class 
switching, figure 6.4B. This response in the negative control group was unexpected. 
To explore whether the immune response had been mounted to the cysteine tag at the 
end of the protein an ELISA was carried out coating the plate with an unrelated 
protein (CD59) also containing this tag. No antibodies were detected which 
responded to this protein proving that the response was not caused by the cysteine 
residue (data not shown).
Group C mounted an immune response to the 5SCR-Fc protein, figure 6.5A. In this 
group the IgG2a response was not monitored as the coat for the ELISA, 5SCR-Fc, 
contains IgG2a so the detection antibody would cross react with the coat rather than 
detect any antibodies generated to the protein. All animals within the group mounted 
an IgM response. All animals showed some degree of IgGl and IgG2b class 
switching from around day 28 while C1-C4 also showed IgG2c class switching 
(figure 6.5B). Generation of an immune response raised further questions, we 
wished to address whether the response was specific for the join in the molecule 
between the 5SCRs and the Fc, to one particular part of the molecule such as the 
Crry or the Fc or to the whole molecule. To address these questions an ELISA was 
carried out coating with 5SCR-Fc, sCrry-cys or CD59-Fc (same Fc; rat IgG2a) and 
incubated with the immune serum from one of the animals (method 2.6.3.2). 
Development was seen in the ELISA in response to all three coats revealing that the 
response was to the whole molecule (figure 6.5C). If the response had been to a 
neoepitope formed at the join of the two proteins only the 5SCR-Fc coat would have 
developed. Similarly if the response had been to one part of the molecule either the 
Crry or the Fc, either the sCrry-cys coat or CD59-Fc coat would have also 
developed. Instead the antibodies generated during the immune response recognised 
all three proteins equally.
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Figure 6.4 Immune response in group A (Crry-cys).
A. ELISA results for the Crry-cys group (group A) showing response at day 
35 for all animals (A0-A4). All animals mounted an IgM response 
which mainly class switched to IgG2a and IgG2c, some IgGl and IgG2b 
class switching was seen.
B. Representative ELISA result (animal A0) showing class switching o f the 
antibodies generated by group A animals. The IgM response was the 
strongest, peaking at day 7 and remaining constant. Class switching was 
evident at day 28 when IgG2a antibodies were generated. An IgG2c 
response was evident at day 35.
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Figure 6.5 Immune response generated in group C (Crry-Fc).
A. ELISA result showing the antibodies generated to Crry-Fc in the day 35 
serum samples. All animals (C0-C4) mounted an IgM response, class 
switching was seen to all isotypes. IgG2a was not included in the ELISA due 
to cross reactivity of the detection antibody with the coat.
B. Representative ELISA result (animal C3) showing the antibody class 
switching within the Crry-Fc group. The IgM response increased over the 35 
days of the experiment. Class switching to IgG2b was evident at day 28, this 
response decreased by day 35. IgGl and IgG2c responses increased from day 
28.
C. ELISA result showing the specificity of the antibodies in the day 35 serum 
samples from one of the group C animals. The antibodies equally recognised 
Crry-Fc, Crry-cys and CD59-Fc revealing that the response was to the whole 
molecule rather than the join between the Crry and Fc or one particular part 
of the molecule.
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62.2.2 Clearance of Crry-Fc
The antibodies generated recognised the whole of the Crry-Fc protein but did the 
immune response cause clearance of the protein from the circulation? To answer this 
question an ELISA was carried out to quantify the amount of Crry-Fc in the serum 
taken from the animals at different time points (method 2.6.3.2). All post-injection 
serum samples contained Crry-Fc, the concentration was highest on day 7 as two 
Crry-Fc injections were administered in the first week, the concentration decreased 
to 7pg/ml on day 35 (table 6.1). This demonstrated that the response had not caused 
clearance of the protein from the circulation.
Day 7 14 21 28 35
Cone, (pg/ml) 10.4 7.3 4.3 4.6 6.8
Table 6.1 Serum concentrations of Crry-Fc
Concentrations of Crry-Fc within the serum taken from group C animals during the 
immune response study. Animals were injected day 0, 3, 7, 14, 21 and 28. Blood 
was collected prior to administration of reagent.
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6.2.23 Function-blocking study
To assess whether the antibodies inhibited the function of Crry-Fc, CHO cells 
expressing rat Crry on their cell surface were utilised in a series of flow cytometry 
experiments (method 2 . 6 3 . 2 ) .  First, deposition of the antibodies from the immune 
sera on the CHO cells was measured. All the immune sera caused a shift compared 
to the secondary only control and incubation with normal rat serum revealing that 
anti-Crry antibodies were deposited on the CHO cells (figure 6.6).
Secondly, the ability of these deposited antibodies to inhibit the function of Crry was 
assessed following method 2.6.3.2. Crry expressing CHO cells were initially pre­
incubated with heat inactivated rat or rabbit serum prior to C deposition using rat 
serum to reveal if the positive control, rabbit polyclonal anti-Crry antiserum, could 
be directly compared to the immune sera (rat) in the subsequent assay. Pre­
incubation with the rat or rabbit serum did not alter C3b deposition compared to pre­
incubation in buffer only revealing that antibodies or CReg present in the sera would 
not interfere with the subsequent assay and that the two sera types could be directly 
compared (figure 6 .1  A ) .  Following incubation with anti-CHO antiserum, the CHO 
cells were incubated with the immune sera or rabbit polyclonal anti-Criy antiserum 
to deposit the anti-Crry antibodies. This was followed by incubation in rat serum to 
deposit C3b. The immune sera all showed equivalent C3b deposition which was not 
enhanced compared to incubation with buffer only, the antibodies did not inhibit the 
function of Crry. On the other hand, incubation with the rabbit polyclonal anti-Crry 
antiserum did cause enhanced C3b deposition as the function of Crry was inhibited 
resulting in less regulation of C and more C3b deposition (figure 6.7B). The 
difference in C3b deposition between CHO cells incubated with the polyclonal anti- 
Cny antiserum and the immune sera was further evident when the CHO cells were 
not incubated with the anti-CHO antiserum. In this assay C activation proceeds via 
the AP resulting in a lower level of C activation and revealing a greater difference in 
C deposition between the Crry inhibiting polyclonal antiserum and the non-Crry 
inhibiting immune sera (figure 6.7C)
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Figure 6.6 Deposition of anti-Crry antibodies from immune sera onto Crry 
expressing CHO cells.
CHO cells expressing rat Crry on their surface were incubated with normal rat 
serum or with the immune serum from each animal. The deposition o f anti-Crry 
antibodies was detected using anti-mouse IgG RPE (cross reactive with rat 
antibodies) by flow cytometry. Normal rat serum (black) caused a shift in 
comparison to the secondary only control; however, all immune sera (purple, light 
blue, green, yellow and dark blue) produced a greater shift showing that anti-Crry 
antibodies were deposited on the CHO cells. The amount o f deposition varied 
between animals but all produced a shift in comparison to normal rat serum.
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Figure 6.7 Inhibition of Crry function by anti-Crry antibodies.
A. Deposition of C3b on rat Crry CHO cells pre-incubated with rat serum (heat 
inactivated), rabbit serum (heat inactivated) and buffer prior to incubation 
with rat serum as a source of C. Incubation with rat and rabbit serum before 
C deposition did not cause any difference in C3b deposition on the CHO cells 
compared to pre-incubation with buffer. Hence, incubation with the immune 
sera could be directly compared to incubation with the rabbit polyclonal 
antiserum in figure B.
B. Deposition of C3b on rat Crry CHO cells incubated with anti-Crry antibodies 
following sensitisation to C activation with anti-CHO antiserum. Prior to C 
activation the cells were incubated with immune sera, buffer or rabbit 
polyclonal anti-Crry antiserum. No difference in C3b deposition was seen for 
the cells incubated with the immune sera or buffer only. Enhanced C3b 
deposition was seen for the cells incubated with the polyclonal antiserum as 
the function of Crry had been inhibited.
C. Deposition of C3b on rat Crry CHO cells proceeding via the alternative 
pathway. CHO cells that had not been incubated with anti-CHO antiserum 
were incubated with the immune sera, buffer or rabbit polyclonal anti-Crry 
antiserum followed by deposition of C using rat serum. As above, the 
immune sera did not result in enhanced C3b deposition while the polyclonal 
antiserum inhibited Crry resulting in enhanced C3b deposition.
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6.2.3 In vivo C inhibitory capacity (CH50)
The ability of 4SCR and 4SCR-Fc to inhibit C in vivo was assessed in the animals 
with EAMG (see section 6.2.4). The animals in the therapeutic study were tail bled 
pre-disease induction and then at different time points post-induction (method 2.6.4). 
Following isolation of the serum, the amount of serum necessary to bring about 50% 
lysis of antibody-coated sheep erythrocytes was compared, this is the CH50 (figure 
6.8A). The PBS control group showed an increase in haemolytic activity in their 
serum compared to the pre-bleed due to an acute phase reaction in the model 
resulting in an increase on C components from the liver. The 4SCR treated group 
showed a similar increase in haemolytic activity, although this increase was not to 
the same extent during the first few hours, up to 24 hours post-induction. The 4SCR- 
Fc group showed a marked reduction in C activity, significant inhibition was evident 
up to 6 hours post-induction (p<0.05 compared to 4SCR lysis at 6 hours by an 
ANOVA test). The haemolytic activity then increased gradually to its pre-bleed 
level by 24 hours post induction; it never reached the levels of increased haemolytic 
activity seen in the PBS or 4SCR groups.
To clarify the CH50 data, mainly to normalise for the increase in haemolytic activity 
in the PBS and 4SCR groups, the haemolytic activity of the serum was expressed as 
a percentage of the 4SCR serum haemolytic activity (figure 6.8B). The 4SCR group 
was used for this, not the PBS group as the PBS group were sacrificed 52 hours post­
induction so not all the time points are present. Other than the first few hours the 
4SCR group response overlaid the PBS group response. Using this approach the 
PBS group showed an increase in haemolytic activity in the first few hours, 
presumably due to low levels of 4SCR remaining in the circulation causing a small 
amount of C inhibition or the acute phase reaction being reduced in the 4SCR group. 
The 4SCR-Fc protein caused a decrease in haemolytic activity of the serum 
throughout the 96 hours of the therapy experiment assessed here, at 2 hours post 
induction lysis was inhibited by 50% in serum isolated from the 4SCR-Fc animals. 
At 96 hours post-induction the lysis caused by the serum had increased to 75% of the 
pre-bleed level.
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Figure 6.8 CH50 of 4SCR and 4SCR-Fc.
A. Graph showing the CH50 from the PBS group (blue), 4SCR group (pink) and 
4SCR-Fc group (aqua) in diseased animals. The haemolytic activity of the 
serum from the PBS group increased, the 4SCR group also showed an 
increase in haemolytic activity although this was to a lesser extent during the 
first few hours. The 4SCR-Fc group had a marked reduction in haemolytic 
activity of the serum compared to the PBS and 4SCR groups.
B. The haemolytic activities of the serum from the diseased animals were 
expressed as a percentage of the 4SCR level and plotted against time. The 
PBS group (blue) had an increase in haemolytic activity compared to the 
4SCR group (pink) during the first few hours. The 4SCR-Fc group (aqua) 
had reduced haemolytic activity.
Data points on both graphs are the average for the animals in each group, +/- 1
SD.
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6.2.4 Therapeutic efficacy of 4SCR-Fc and 4SCR
The therapeutic efficacy of 4SCR-Fc and 4SCR was tested in a rat model of EAMG. 
This work was carried out in collaboration with Dr Jayne Chamberlain-Banoub, Dept 
of Medical Biochemistry and Immunology, who administered the i.p. injection of 
mAb35, took the tail bleeds, carried out the assessment of clinical score and weight 
change and did the histology, and Dr Anwen Williams, Dept of Rheumatology, who 
administered the i.v. injections. EAMG was induced in three groups of six normal 
female Lewis rats following method 2.6.5.1. In brief, the disease was induced using 
an i.p. injection of mAb35, a rat monoclonal anti-acetylcholine receptor (AChR) 
antibody. Group A was simultaneously injected with PBS, group B with 4SCR and 
group C with 4SCR-Fc. All these reagents were administered intravenously. The 
clinical score (see 2.6.5.1, an increasing score corresponded to increasing muscle 
weakness and paralysis) and weight were assessed daily for the duration of the 
experiment. At 52 hours post induction group A (PBS control) was sacrificed due to 
the severity of the disease (defined method 2.6.5.1) along with one animal from each 
of group B and C to enable comparative histology. For histology, the soleus muscles 
from the hind limbs were taken, these were processed following method 2.6.5.2. At 
the end of the experiment, 183 hours, the remaining animals were sacrificed and the 
soleus muscles taken for histology. For immunohistochemistry muscle sections were 
stained for C3b deposition, C9 deposition, AChR using bungarotoxin, a compound in 
snake venom that binds the receptor, and inflammatory infiltrates to complement the 
H&E staining. The extent of inflammatory infiltrate was scored by Dr Jim Neal, 
Dept of Pathology, as a percentage of the muscle that was infiltrated with 
inflammatory cells.
The PBS control group (Group A) showed an increasing clinical score from 6 hours 
post-induction corresponding to increasing muscle weakness and paralysis. The 
score increased to 3.5 at 52 hours post-induction when they were sacrificed due to 
disease severity, from this point on the score was taken as 4. The 4SCR group 
(group B) had a clinical score which also increased from 6 hours post-induction, 
although the severity of disease was not equivalent to that in the PBS group. The 
m axim um  clinical score was 1.5 at 52 hours post-induction. The animals then began 
to recover from the disease. The 4SCR-Fc group showed no clinical signs of the
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disease throughout the experiment, figure 6.9A. These clinical signs of the disease 
were also manifest in the change in weight seen in the animals throughout the 
experiment. The PBS group had a marked reduction in weight from 6 hours post 
induction; throughout the experiment the animals lost an average of 28g, around 15 %  
of their starting body weight. These animals were sacrificed at 52 hours post­
induction so from that point on the weights of these animals were regarded as being 
unchanged. The 4SCR group also lost weight in a manner which mirrored their 
clinical scores, the animals progressively lost weight from 6 hours post-induction 
until 52 hours post-induction when they began to recover and gain weight. The 
4SCR-Fc group on the other hand showed no weight loss during the experiment, they 
progressively gained weight, figure 6.9B.
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Figure 6.9 Clinical score and weight assessment of 4SCR-Fc, 4SCR and PBS- 
treated animals in the EAMG model.
A. Graph showing clinical scores of the animals. The clinical score 
corresponding to muscle weakness and paralysis increased in the PBS group 
(blue) from 6 hours post induction until it reached 3.5 at 52 hours post 
induction. At this point the animals were sacrificed. The 4SCR group (pink) 
showed an increasing clinical score from 6 hours post-induction to 1.5 at 52 
hours post-induction at which point the animals began to recover and the 
clinical score decreased. The 4SCR-Fc group (yellow) showed no clinical 
score throughout the experiment. Each data point represents the average of 6 
animals +/-1 SD.
B. Graph showing weight change throughout the therapy experiment. The PBS 
group (blue) lost weight through the experiment in line with their increase in 
clinical score. The 4SCR group (pink) lost weight until 52 hours post­
induction when they began to recover and progressively gained weight. The 
4SCR-Fc group (yellow) gained weight throughout the experiment. Each 
data point represents the average of 6 animals +/- 1 SD.
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The histology from one animal from the PBS group and a representative animal from 
the other two groups sacrificed at 52 hours post-induction is shown in figures 6.10- 
6.12. At 52 hours post-induction group A (PBS) showed C3b deposition which 
merged with the bungarotoxin staining revealing that there was C activation and 
deposition at the AChR. Group B (4SCR treated group) also showed C3b deposition 
at this time point localising with the AChR, the 4SCR-Fc treated group (group C) 
had minmal C3b deposition at 52 hours post induction (figures 6.10). At 52 hours 
post-induction C9 deposition was also present at the acetylcholine receptors in the 
PBS treated and 4SCR treated animals. C9 staining was absent in the 4SCR-Fc 
treated group (figure 6.11). H&E staining along with staining for macrophages 
revealed that inflammatory infiltrates were present in the PBS treated animals, up to 
40% of the whole muscle was infiltrated. The 4SCR treated group also had 
inflammatory infiltrates within the muscle, at 52 hours post induction 20-40% of the 
muscle was infiltrated. No inflammatory infiltrate was evident in the 4SCR-Fc 
treated group (figure 6.12).
At the end of the experiment when the remaining animals treated with 4SCR and 
4SCR-Fc were sacrificed, group B (4SCR) demonstrated C3b and C9 deposition at 
the AChR (figure 6.13). There was no marked difference between the two time 
points for C3b and C9 deposition, there was however a difference in inflammatory 
infiltrate (figure 6.14). There was more infiltrate in the muscle taken at the end of 
the experiment, 40-60% of the whole muscle was infiltrated, compared to 20-40% of 
the whole muscle taken at 52 hours post-induction. The 4SCR-Fc treated group still 
had minimal C3b deposition but no C9 deposition in the muscle taken at the end of 
the experiment (figure 6.13). In the 4SCR-Fc treated group the muscle taken at 52 
hours post induction showed no inflammatory mfiltrate (figure 6.11), however, the 
muscles taken at the end of the experiment did have a low level of inflammatory 
infiltrate when investigated by H&E staining and immunohistochemical analysis 
staining for macrophages (figure 6.14).
242
AChR C3b Merged
Figure 6.10 Immunohistochemical analysis of C3b deposition in all groups at 52 
hours post-induction.
A, D and G are bungarotoxin stained sections; B, E and H are stained for C3b 
deposition while C, F and I are the merged bungarotoxin and anti-C3b stained 
sections. In the PBS treated group (A, B and C) C3b deposition was evident at the 
AChR. In the 4SCR treated group (D, E and F) C3b deposition was also found at the 
AChR. In the 4SCR-Fc treated group (G, H and I) minimal C3b deposition was seen 
at the AchR, it was limited compared to the 4SCR and PBS treated animals.
All images were taken at 400x magnification and cropped to focus on an area 
containing acetylcholine receptors. Bar in I represents 100pm. Representative 
images are shown here.
AChR C9 Merged
Figure 6.11 Immunohistochemical analysis of C9 deposition in the muscles 
taken at 52 hours post-induction.
A, D and G are bungarotoxin stained sections, highlighting the acetylcholine 
receptors present in the tissue. B, E and H are stained for C9. C, F and I are the 
merged images o f the bungerotoxin and anti-C9 stained sections. The PBS-treated 
group (A, B and C) showed C9 deposition merging with the bungarotoxin stain 
revealing that C9 deposition was at the AChR. The 4SCR-treated group (D, E and 
F) also had C9 deposition at the AChR. The 4SCR-Fc treated group (G, H and I) 
had no C9 deposition at the AChR or elsewhere in the tissue.
All images were taken at 400x magnification and cropped to focus on an area 
containing acetylcholine receptors. Representative images are shown here. Bar in 
I represents 100pm.
Figure 6.12 Histological analyses of inflammatory infiltrates within the 
muscles taken at §2 hours post-induction.
The immunohistochemical analysis is shown in A-I. A, D and G show the 
bungarotoxin stained sections. B, E and H show the sections stained for 
macrophages using anti-CD68. C, F and I are the merged images. Group A 
(PBS treated) show marked inflammatory infiltrates within the sections, this 
staining was evident throughout the muscle, not just at the AChR (A, B and C). 
Group B (4SCR treated) showed some inflammatory infiltrate throughout the 
muscle, 20-40% of the muscle was infiltrated (D, E and F). Group C, those 
treated with 4SCR-Fc, showed no inflammatory infiltrate (G, H and I). The 
immunohistochemical analysis was supported by H&E staining (J, K and L). 
The PBS-treated group (J) showed a high level of inflammatory infiltrate 
within the muscle. The 4SCR-treated group (K) showed some inflammatory 
infiltrates while there was none present in the muscle of the 4SCR-Fc treated 
group (L).
All immunohistochemical images were taken at 400x magnification. Bar in 
figure I represents 400pm. H&E stained images were taken at lOOx 
magnification.
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Figure 6.13 Immunohistochemistry of C deposition within the muscles taken 
at the end of the experiment.
A, D, G and J are the bungarotoxin stained sections. B and E are stained for C3b 
deposition while H and K are stained for C9 deposition. C, F, I and L are the 
merged images of the anti-AChR stain and the respective anti-C component stain. 
The 4SCR treated animals sacrificed at the end of the experiment demonstrated 
both C3 (A, B and C) and C9 (G, H and I) deposition which merged with the 
AChR. On the other hand, the 4SCR-Fc treated animals had minimal C3b 
deposition (D, E and F) and no C9 deposition (J, K and L) at the AChR or present 
elsewhere in the tissues.
All images were taken at 400x magnification and cropped to focus on an area 
containing acetylcholine receptors. Bar in L represents 100pm.
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Figure 6.14 Histochemical analyses of inflammatory infiltrates within the 
muscles taken at the end of the experiment.
A-F show the immunohistochemical analysis o f  the inflammatory infiltrate. A and 
D show the bungarotoxin stained sections highlighting the acetylcholine receptors. 
B and E show the anti-CD68 staining demonstrating macrophage infiltration. C 
and F show the merged images o f the bungarotoxin staining and the anti-CD68 
staining. The H&E stained sections are in G and H. The 4SCR treated animal 
showed inflammatory infiltrate throughout the muscle when investigated by both 
immunohistochemical analysis (A, B and C) and H&E staining (G). The 4SCR-Fc 
treated animal showed an increased amount o f inflammatory infiltration compared 
to the muscles at 52 hours post induction but the amount was still low when 
analysed by immunohistochemistry (D, E and F) and H&E staining (H).
All immunohistochemical images were captured at 400x magnification while all 
H&E sections were captured at lOOx magnification. Bar in F represents 400pm.
6.3 Discussion
In this chapter I have described the in vivo characterisation of the therapeutic 
reagents, 4SCR-Fc and 4SCR. The proteins were characterised in terms of their
■ in vivo half-life,
■ immunogenicity,
■ ability to inhibit C in vivo
■ and therapeutic efficacy.
One of the limitations of anti-C therapeutics has been the short half-life of the 
reagents resulting in their rapid clearance from the circulation. Previous studies have 
documented a strategy to increase the half-lives of anti-C therapeutics by fusing the 
active agent to the Fc of an antibody. In 1998, a mouse Crry-mouse Ig fusion protein 
was generated that had a p-phase half-life of 40 hours, although a comparison with a 
non-Fc fusion protein was not demonstrated (Quigg, Kozono et al. 1998). 
Comparison of a rat DAF-human Fc fusion protein with sDAF (non-Fc fusion 
protein) showed that the DAF-Fc had an increased p-phase half-life, 33 hours 
compared to 20 minutes for the non-fusion protein (Harris, Williams et al. 2002). 
This approach of increasing the half-life of a therapeutic by creating Fc fusion 
proteins is not limited to anti-C therapeutics but has been used widely including the 
generation of IFN-y receptor, CTLA-4 and TNF-a receptor fusion proteins 
(Kurschner, Ozmen et al. 1992; Linsley, Wallace et al. 1992; Pugsley 2001).
The Crry-Fc fusion protein generated here had an increased p-phase half-life of 53 
hours compared to 7 minutes for the non-Fc fusion protein, 4SCR. This increase in 
half-life was due to several factors including the increase in size of the protein taking 
the protein above the filtration limit of the kidney. Fc fusion proteins are also 
actively retained in the circulation due to the interaction of the Fc with Fc receptors 
such as the Brambell receptor which acts to retain immunoglobulins in the 
circulation by binding to the Fc domain (Telleman and Junghans 2000). Brambell 
receptors (FcRn) are widely expressed on vascular endothelial cells and can prevent 
IgG catabolism by directing the release of IgG into extracellular fluid following 
endocytosis (Telleman and Junghans 2000).
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Another limitation of anti-C therapeutics has been their immunogenicity in animals. 
A number of anti-C reagents have been based upon human regulators, for example 
sCRl is based upon human CR1. Use of this reagent is limited in animal models as 
long-term administration results in neutralising antibodies being generated 
(Piddlesden, Storch et al. 1994). To enable the long-term C inhibition in chronic 
disease models to be investigated the fusion proteins generated here consisted of a rat 
regulator, Crry, fused to a rat Fc domain. To investigate if this chimeric molecule 
was immunogenic an immune response study was carried out. Antibodies were 
generated to the Cny-Fc although further investigation revealed that these antibodies 
caused neither the Crry-Fc to be cleared from the circulation nor its function to be 
inhibited. This immune response may have been caused by altered glycosylation, 
folding or other post-translational modifications of the protein. Some CHO cell lines 
do not cany out N-linked glycosylation, although the cell line used here does carry 
out this glycosylation (Raju, Briggs et al. 2000). It is still possible that the protein 
differed from its native conformation in some way as CHO cells carry out altered 
glycosylation under high ammonium ion concentrations (Chen and Harcum 2005). 
While the high expression systems used to generate these proteins (see chapter 5) 
appeared not to alter the proteins, perhaps high ammonium ion content within the 
cell culture may have altered glycosylation. Recombinant follicle-stimulating 
hormone (FSH) expressed in CHO cells has been shown to differ from native FSH, 
recombinant FSH contained less heavily sialylated carbohydrates as CHO cells differ 
from native cells in their ability to sialyte carbohydrates (Loumaye, Dreano et al. 
1998). Species specific glycosylation of immunoglobulins has also been 
demonstrated, the glycosylation of Fc and proteins in general may differ in Chinese 
hamsters from the glycosylation of proteins in rats (Raju, Briggs et al. 2000). Similar 
immune responses have been noted to other therapeutic proteins. Patients on sCRl 
have been noted to produce antibodies to the reagent, although similarly the 
antibodies neither enhanced clearance nor reduced the protein’s function (personal 
communication Prof. B. P. Morgan). In the clinical trials of etanercept, a TNF 
receptor Fc fusion protein, 2% of patients produced antibodies to the reagent, these 
antibodies were non-neutralising (Anderson 2005). Although the immune response 
study was carried out using 5SCR-Fc, it is reasonable to assume that an equivalent 
response would be generated to 4SCR-Fc, which was used in the therapy experiment. 
The antibodies were generated to the whole molecule and not a neoepitope at the
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join, which would differ between 5SCR-Fc and 4SCR-Fc. Both 5SCR-Fc and 
4SCR-Fc were produced using the same cell line under the same conditions and 
therefore have the same potential to be immunogenic due to altered glycosylation, 
folding or other post-translational modifications.
While the immune response has not altered the function and clearance of the protein 
within the time period of this experiment (35 days), there is no guarantee that long 
term treatment with this reagent will not drive the immune response to cause 
enhanced clearance or function inhibition. This result highlights the need to select an 
appropriate cell line in which to produce recombinant proteins. Perhaps generation 
of this protein in a rat or mouse cell line would have resulted in a non-immunogenic 
protein being produced. The immune response within the negative control group, 
those treated with sCrry-cys, was surprising. The response was not due to the 
cysteine residue but the Criy itself. The generation of antibodies may have been 
driven by lipopolysaccharide contamination of the protein as this was a bacterially 
expressed protein. Also, as discussed previously bacteria do not fold and carry out 
glycosylation of proteins, while this protein has been refolded and shown to have no 
change in function, slight changes in folding and differences in glycosylation may 
have resulted in this native protein becoming immunogenic.
Anti-C therapeutics have been tested in a wide range of animal models including 
antigen and collagen induced arthritis, glomerulonephritis and ischaemia-reperfusion 
injuries (for more information see section 1.5). In particular, administration of Crry 
has proved to be a viable therapeutic strategy in glomerulonephritis where 
administration of mouse Crry-Ig in a murine model substantially reduced renal injury 
(Quigg, Kozono et al. 1998). Crry-Ig has also been used in a model of airway hyper­
responsiveness where it was proven to be protective (Taube, Rha et al. 2003), in a 
mouse model of lupus where it decreased inflammation (Alexander, Bao et al. 2003) 
and in mesenteric ischaemia-reperfusion where it decreased intestinal mucosal injury 
(Rehrig, Fleming et al. 2001). Studies of transgenic mice over expressing soluble 
Crry have also shown the therapeutic potential of Crry. These animals are protected 
from antibody-induced acute renal failure (Schiller, Cunningham et al. 2001), 
experimental allergic encephalomyelitis (Davoust, Nataf et al. 1999), membrane
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proliferative glomerulonephritis (Muhlfeld, Segerer et al. 2004) and collagen- 
induced arthritis (Banda, Kraus et al. 2003).
Here, Crry was proven to be protective against EAMG. Two recombinant forms of 
Crry, 4SCR-Fc and 4SCR, were used to treat EAMG in rats. Both reagents reduced 
the clinical severity of disease with the long-lived 4SCR-Fc reagent having the most 
profound effect. Animals treated with 4SCR-Fc did not develop a clinical score or 
have the weight loss associated with the disease. Histological analyses revealed that 
these animals had low levels of C3b deposition but no C9 deposition at the AChR or 
elsewhere on the motor end plate. Low levels of inflammatory infiltrate within the 
muscle were also noted; less than 20% of the muscle was infiltrated. These 
beneficial clinical effects of 4SCR-Fc were due to its ability to inhibit C in vivo as 
seen by the measurement of haemolytic activity in the serum from these animals. 
The haemolytic activity of the serum collected from the 4SCR-Fc group was reduced 
by 50%. This 50% reduction was sufficient to prevent disease as the level of C was 
taken below the threshold required to bring about the damage associated with 
EAMG. The detection of C3b deposition by immunohistochemistry demonstrates 
that the C system was still active but the level of C3b deposition required for C to 
cause damage to the motor end plate was never achieved. It is possible that the C3b 
detected has been inactivated by Crry acting as a cofactor for factor I. Therefore the 
C3b staining identified may actually be iC3b staining, iC3b no longer participates in 
the C cascade.
The 4SCR reagent also reduced clinical signs although not to the same extent as 
4SCR-Fc, the clinical scores peaked at 52 hours post-induction. The reduction in 
clinical score after this point may be due to the 4SCR reagent inhibiting C enough so 
that only minor damage occurred at the motor end plate. Clearance of the anti-AChR 
antibody from the circulation prevented continued C activation so the clinical score 
decreased. The weight loss of the animals also peaked at 52 hours post-induction 
after which the animals gained weight. Histological analyses revealed C3b and C9 
deposition at the AChR and inflammatory infiltrate. The haemolytic activity of the 
serum from the animals treated with 4SCR was the same as the PBS treated group 
except for the first few hours where the serum from the 4SCR treated animals had a 
reduced haemolytic activity compared to the PBS group. In both the PBS treated
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animals and 4SCR treated animals an increase in haemolytic activity was observed 
presumably due to an acute phase response caused by EAMG resulting in increased 
synthesis of a number of proteins in the liver including many C components. During 
the first few hours, the haemolytic activity of the serum from the 4SCR treated 
animals did not increase to the same extent as the PBS treated animals; this may be 
due to C inhibition caused by the 4SCR reagent present in the serum although given 
the p-phase half-life of the protein this is unlikely. It is more likely that the presence 
of the 4SCR reagent during the initial C activation, immediately following mAb35 
administration, lessened the initial injury delaying the acute phase response. The 
presence of 4SCR at this early time point preventing massive C attack following the 
initial activation may also be the reason for the decreased disease profile in terms of 
histology, clinical scores and weight loss seen in these animals. As previously 
discussed, both 4SCR-Fc and 4SCR inhibited C in vivo when assessed in diseased 
animals. This assessment of in vivo activity was complicated by the acute phase 
response in the disease resulting in enhanced production of many C components. 
Assessment of the in vivo C inhibitory activity of these proteins in non-diseased 
animals would clarify the ability of the proteins to inhibit C in vivo.
In conclusion, 4SCR-Fc and 4SCR are therapeutically active in EAMG with the 
4SCR-Fc reagent being most efficient at inhibiting the clinical signs of disease. This 
enhanced therapeutic effect of 4SCR-Fc is a consequence of its increased P-phase 
half-life compared to the 4SCR reagent and therefore its ability to inhibit C in vivo 
for a longer period than the 4SCR reagent.
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Chapter 7: Final discussion.
The overall aim of this study was to design and develop better inhibitors of C for use 
in rats. The specific aims of this study were:
1. To generate a totally rat CReg-Fc fusion protein using rat Crry and rat Fc,
2. To carry out functional analysis of rat Crry to locate functional domains 
within Crry and enable the generation of a rat Crry ‘prodrug’,
3. To test both the Crry-Fc and ‘ prodrug ’ in rat models of disease.
In this study I have generated a variety of recombinant forms of rat Crry, the 
following proteins were made: 5SCR-Fc, 4SCR-Fc, 3SCR-Fc, 4SCR and 3SCR 
Functional characterisation of these recombinant proteins identified a functional 
Crry-Fc, 4SCR-Fc, but a ‘prodrug’ was not identified as functional domains within 
Crry were deleted before steric hindrance sufficient for the ‘prodrug’ was achieved. 
4SCR-Fc was compared with 4SCR (non-Fc fusion protein) in a rat model of EAMG 
where it reduced clinical severity and C deposition in vivo.
7.1 Current anti-C therapeutics and their limitations
The C system has been heavily implicated in the pathogenesis of a number of 
inflammatory diseases. Among these diseases is rheumatoid arthritis where C 
activation products have been found in the synovial fluid and on the synovial 
membrane (Brodeur, Ruddy et al. 1991; Kemp, Spragg et al. 1992). In 
glomerulonephritis, C activation products are deposited in the glomeruli and in MG, 
C activation products are detected on the post-synaptic membrane (Davis and 
Cavallo 1976; Engel, Lambert et al. 1977; Adler, Baker et al. 1984; Engel and 
Arahata 1987). Due to the implication of C in such diseases, C became a therapeutic 
target and anti-C therapy was bom. Anti-C therapy began with cobra venom factor. 
This reagent was a useful proof-of-principle demonstrating that anti-C therapy could 
successfully reduce disease severity in a number of animal models (Morgan and 
Harris 2003). However, its in vivo use was limited as it is strongly immunogenic 
resulting in the generation of neutralising antibodies. Over the years, many different 
anti-C therapeutics have been tested, these include a number of peptides. FUT-175, 
one such peptide is a broad spectrum serine protease inhibitor that acts as an inhibitor
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of Cls, factor D and the C3/C5 convertases. FUT-175 was effective at treating 
glomerulonephritis patients (Fujita, Inoue et al. 1993). Compstatin a synthetic 
peptide that prevents the cleavage of C3 inhibits C activation in extracorpeal circuits 
(Sahu, Kay et al. 1996; Nilsson, Larsson et al. 1998). Several antibodies that block 
the activity of C components have been used in therapeutic models. Anti-C5 
monoclonal antibodies have been tested in models of immune complex nephritis and 
collagen-induced arthritis, and has reached clinical trials in myocardial infarction 
patients and patients undergoing cardiopulmonary bypass (Wang, Rollins et al. 1995; 
Wang, Hu et al. 1996; Granger, Mahaffey et al. 2003; Sheman, Fitch et al. 2004). 
Finally, recombinant forms of the membrane regulators have been used 
therapeutically. Soluble CR1, the most studied, consists of the extracellular domains 
of human CR1 and has been tested in various animal models including models of 
MG, multiple sclerosis, rheumatoid arthritis and I/R injures (Weisman, Bartow et al. 
1990; Piddlesden, Storch et al. 1994; Piddlesden, Jiang et al. 1996; Goodfellow, 
Williams et al. 1997; Goodfellow, Williams et al. 2000). This reagent is still 
undergoing development for clinical use, having been tested in adults with ARDS 
and in cardiopulmonary bypass where it effectively inhibited C activation 
(Zimmerman, Dellinger et al. 2000; Rioux 2001).
Despite the success of many of the anti-C therapeutics described above in animal 
models, their uses in humans have been limited. Many of the peptides have broad- 
spectrum activities and as a result act non-specifically. They are also small 
molecules which are rapidly cleared in vivo meaning that effective anti-C therapy 
requires regular administration. Soluble recombinant forms of the membrane 
regulators are also limited by rapid in vivo clearance. A number of different 
approaches have been employed to extend the in vivo half-life of recombinant CReg. 
Soluble CR1 has been expressed as a form containing the albumin binding site from 
streptococcal protein G at the C-terminus. This resulted in an increased half-life, as 
the reagent bound albumin in the circulation, whilst not inhibiting function 
(Makrides, Nygren et al. 1996). Addition of targeting domains has also been used to 
increase the in vivo efficacy of sCRl. Addition of Sialyl Lewis X tetrasacchande 
groups to sCRl created a molecule that localised to sites of inflammation by binding 
P-, E- and L- selectins. Through this interaction the molecule also inhibited selectin- 
dependent leukocyte adhesion (Mulligan, Warner et al. 1999; Rittershaus, Thomas et
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al. 1999). Recombinant CReg have also been targeted to membranes. In this 
approach a lipid targeting peptide was attached to the C-terminus. The peptide 
contained positively charged amino acids that bound the phospholipids in the 
membrane and a terminal myristoyl group that inserted into the membrane bilayer 
(Smith and Smith 2001). This technology has been applied to a truncated form of 
sCRl, rat Crry and rat CD59. It extended the circulating half-life of rat Crry from 15 
minutes to 50 minutes although the true half-life is likely to be much greater than this 
as the targeted Crry would no longer be in the plasma but bound to cell surfaces 
(Fraser, Harris et al. 2002). The final approach used to extend the circulating half- 
life of recombinant CReg is the generation of CReg-Fc fusion proteins. The CReg 
replaces the Fab arms of an antibody while the Fc increases the plasma half-life by 
increasing the protein size and by interacting with Fc receptors retaining the proteins 
in the circulation. This interaction with Fc receptors serves to increase the plasma 
half-life as binding to Fc receptors prevents protein catabolism (Telleman and 
Junghans 2000). Comparison of a DAF-Fc fusion protein with sDAF (non-Fc) 
revealed that utilising the Fc increased the circulating half-life from 20 minutes to 33 
hours (Harris, Williams et al. 2002).
A further disadvantage of anti-C therapy is the tendency of the therapeutics to 
systemically inhibit C, that is they inhibit all the roles of C rendering an individual 
susceptible to bacterial infections. Targeting C therapeutics to sites of inflammation 
has been used to overcome the problems of systemic C inhibition. As discussed 
above, sCRl was targeted to sites of inflammation by adding Sialyl Lewis X 
tetrasaccharide groups. Complement receptor 2 (CR2) binds C3 activation fragments 
present at sites of C activation and has been used to target CReg to sites of C 
activation and inflammation. A DAF-CR2 fusion protein targeted to sites of C 
activation in a model of lupus nephritis and a Crry-CR2 fusion protein significantly 
reduced C-mediated injury in an intestinal I/R injury model whilst also reducing 
susceptibility to infection compared to an untargeted Crry-Fc protein (Song, He et al. 
2003; Atkinson, Song et al. 2005). Further engineering of CReg-Fc to bring the 
active site of a CReg in to close proximity to the Fc had resulted in steric hindrance 
of the CReg by the Fc and the creation of the ‘prodrug’. Insertion of a short enzyme 
target site, for enzymes at high levels at sites of inflammation, between the CReg and 
Fc resulted in the generation of a CReg-Fc that could be activated at sites of
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inflammation. Activation of this CReg-Fc at sites of inflammation unleashed 
powerful anti-C activity from a reagent that otherwise had negligible activity (Harris, 
Hughes et al. 2003).
A final limitation of anti-C therapeutics is the fact that many reagents created to date 
are based on human regulators so their use is limited in rat models of disease by their 
immunogenicity. The testing of sCRl in rat models has been limited to short term 
therapy due to the generation of neutralising antibodies (Piddlesden, Jiang et al. 
1996). To date the CReg-Fc proteins generated in our laboratory contain a human Fc 
domain so their use is limited to acute studies in the rat. As rat models of chronic 
diseases offer a way of testing the potential of anti-C therapeutics, particularly CReg- 
Fc fusion proteins, in chronic diseases efficient rat anti-C therapeutics are needed.
In this study various recombinant forms of rat Crry were generated in order to 
identify two different Crry-Fc fusion proteins both with long circulating half-lives 
but different functional characteristics. One would be fully active as a fusion protein 
so could enable the testing of rat CReg-Fc in models o f chronic disease. The other 
would be functionally inactive as a fusion protein but could be further engineered 
into a ‘prodrug’ to overcome the problems of systemic C inhibition and enable this 
novel anti-C therapeutic to be tested in vivo.
7.2 Effective C inhibition by Crry-Fc
Recombinant forms of rat Crry were generated by amplifying and ligating DNA 
encoding the 5, 4 or 3 N-terminal SCRs into an appropriate vector. To create the Fc 
fusion proteins the Crry-encoding DNA was ligated in frame with DNA encoding the 
Fc of rat IgG2a. Transfection of CHO cells with the generated vectors resulted in 
production of five different proteins: 5SCR-Fc, 4SCR-Fc, 3SCR-Fc, 4SCR and 
3 SCR. These proteins were purified from cell culture supernatant using a 
monoclonal anti-Crry affinity column.
To identify the two different Crry-Fc required for this project the function of the 
purified proteins was compared. All the proteins inhibited CP-mediated lysis with 
the 3SCR-Fc protein being the least effective comparison with 3 SCR and 4SCR 
revealed that this was due to steric hindrance imparted by the Fc on the 3 SCRs
258
within this protein. Both 3 SCR and 3SCR-Fc had reduced abilities to inhibit AP- 
mediated lysis due to the removal of an active site in SCR4. The reduced ability of 
the 3 SCR reagents to inhibit the AP was also seen using surface plasmon resonance 
to compare the ability of the proteins to decay the AP C3 convertase. Steady state 
affinity analysis revealed that the reduced ability of the 3 SCR reagents to inhibit C 
was partly due to a drastically reduced affinity for C3b. A decrease in binding to Bb 
was not investigated in this project and cannot be ruled out. Further work could be 
carried out looking at the affinity of the recombinant forms of Crry for Bb as well as 
for CP components such as C4b and C2a. All the proteins had cofactor activity, 
although this function was reduced in the 3 SCR proteins. The functional analysis 
revealed that it was not possible to generate a Crry ‘prodrug’ as active domains in 
Crry were deleted before steric hindrance sufficient for the ‘prodrug’ was achieved. 
4SCR-Fc was fully active as a fusion protein and was therefore the focus of the 
project as an active Crry-Fc reagent.
In addition to identifying two categories of Crry-Fc fusion protein, the functional 
characterisation shed additional light on the function of the SCRs within Crry. 
Previous knowledge of the function of rat Crry came from observation of the mouse 
homologue, mouse Crry, and the related human protein, CR1, as well as the use of 
recombinant forms of rat Crry. The five N-terminal SCRs of rat Crry have been 
expressed recombinantly and were shown to have the ability to regulate both the CP 
and AP (He, Alexander et al. 1997). A later study where the four N-terminal SCRs 
were expressed recombinantly revealed that CP regulation and cofactor activity lay 
within these four SCRs (Fraser, Harris et al. 2002). The functional characterisation 
carried out in this project revealed that the ability to regulate the CP lay within the 
SCRs 1-3. Steric hindrance of the 3SCR-Fc reagent suggested the site or sites 
required for function lay close to the Fc. Removal of SCR4 decreased the ability of 
Crry to regulate the AP although removal of this SCR did not entirely remove this 
function. In particular removal of this SCR reduced the ability of Crry to accelerate 
the decay of the AP convertase. Removal of the SCR4 also reduced cofactor activity 
and the affinity for C3b. Through removal of SCR4 and a reduced binding of Crry to 
C3b, Crry had a weaker interaction with the convertase and is therefore less efficient 
at decaying the convertase. The reduction of Crry binding to C3b also reduced the 
ability of fl to cleave C3b. Figure 7.1 summarises the functional data. The function
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of the related human protein, CR1, has been located to SCRs 1-3, 8-10 and 15-17 
(Klickstein, Bartow et al. 1988; Krych, Clemenza et al. 1994; Krych-Goldberg, 
Hauhart et al. 1999). These SCRs in CR1 are homologous to SCRs 1-3 in rat Crry, 
indeed a study which carried out phylogenetic analysis of SCRs and classified them 
into 11 sub-families classified the first four SCRS of CR1 and Crry into the same 
sub-families (McLure, Dawkins et al. 2004). This homology and conservation 
between different regulators in different species suggests that these SCRs may be 
crucial for function. Crry also shows similarities to DAF as the AP regulation 
carried out by DAF has been mapped to the SCRsl-4 while the SCRsl-3 are 
sufficient to regulate the CP (Coyne, Hall et al. 1992).
The attachment of the Fc domain to the 4SCRs of rat Crry significantly increased the 
half-life of the reagent. The 4SCR-Fc reagent had a p-phase half-life of 53 hours 
compared to 7 minutes for the 4SCR reagent. This approach has been used to 
increase the in vivo half-life of a number of therapeutics, not solely anti-C 
therapeutics, including CTLA-4 and a TNF receptor (Linsley, Wallace et al. 1992; 
Pugsley 2001). Within the field of anti-C therapeutics a mouse Crry-Fc fusion 
protein and a rat DAF- human Fc fusion protein have been made (Quigg, Kozono et 
al. 1998; Harris, Williams et al. 2002). Both these reagents also had long p-phase 
half-lives of over 30 hours. Generation of Fc fusion proteins is not the only approach 
used to increase the half-life of anti-C therapeutics, discussed previously. The 
generation of Fc fusion proteins has the advantage over other methods to extend 
circulating half-lives as a native molecule is used to increase the half-life reducing 
the potential immunogenicity of the therapeutic.
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► Classical pathway regulation
C3b binding, removal reduces AP 
regulation and cofactor activity
Figure 7.1 Functional domains of rat Crry
Diagram summarising the functional characterisation carried out within this project. 
CP regulation lies within the three N-terminal SCRs while SCR4 binds C3b and is 
involved in the regulation of the AP, cofactor activity.
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I have shown that a Crry-Fc reagent did cause the generation of an immune response 
in vivo as detected by antibody generation. The antibodies were to the entire protein 
and not just to the join in between the Crry and Fc domains. Further investigation of 
the antibody response revealed that the antibodies did not enhance the clearance of 
the protein or inhibit its function. The CHO cells, used to produce the proteins, 
carrying out different post-translational modifications compared to native proteins 
may have caused the immune response. The immune response may be reduced or 
prevented altogether by using an alternative cell line, such as a rat or mouse cell line. 
Immune responses to other anti-C therapeutics have been noted, in particular, 
antibodies against sCRl have been produced in human trials although similarly these 
antibodies did not result in clearance of the protein or inhibition of function (personal 
communication, Prof. B P Morgan). Non-neutralising antibodies have also been 
detected against other therapeutic Fc fusion proteins. In clinical trials of etanercept, 
a TNF receptor Fc fusion protein, 2% of patients produced antibodies against the 
therapeutic although these were not neutralising and did not effect therapeutic 
efficacy (Anderson 2005).
In a rat model of EAMG both 4SCR-Fc and 4SCR reduced the clinical severity of the 
disease. 4SCR-Fc prevented any clinical signs developing, animals did not lose 
weight and C deposition and inflammatory infiltrate within the muscle was reduced. 
The short-lived 4SCR reagent inhibited C sufficiently during the initial disease 
induction phase such that the clinical severity and weight loss were reduced. Soluble 
CR1 has also been shown to reduce muscle weakness and weight loss in EAMG 
(Piddlesden, Jiang et al. 1996).
7.3 Future work
The aim of this project was to generate two different Crry-Fc. One that would be 
fully active and could be tested in models on chronic disease and the other would be 
further engineered to form a ‘prodrug’. The functional analyses revealed that it was 
not possible to generate the ‘prodrug’ as active sites within Crry were deleted before 
sufficient steric hindrance was achieved. The flexible nature of the SCRs within 
Crry meant that it was difficult to sterically hinder its function. Perhaps a better 
candidate for a ‘prodrug’ is CD59. CD59 is a small regulator, 20-28 kDa, with a 
large multimolecular substrate, the MAC, suggesting that steric hindrance would be
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easier to achieve. A rat CD59- human Fc fusion protein has been made and shown to 
have drastically decreased function compared to the non-Fc fusion protein (Harris, 
Williams et al. 2002). As CD59 only inhibits the terminal pathway, a CD59-Fc 
‘prodrug’ also has the advantage of still allowing C to opsonise pathogens and 
immune complexes with C3b and thereby further limiting systemic C inhibition. 
Disruption of the terminal pathway of C has been shown to be effective against 
disease in studies using animals deficient in certain terminal pathway components. 
For instance, C5 deficient mice are protected from EAMG and C6 deficiency 
protects against glomerulonephritis and graft rejection (Christadoss 1988; Brauer, 
Baldwin et al. 1995; Brandt, Pippin et al. 1996). Inhibition of the terminal pathway 
with anti-C5 monoclonal antibodies protects against rheumatoid arthritis and aids 
recovery following myocardial infarction (Wang, Rollins et al. 1995; Vakeva, Agah 
et al. 1998). Finally, administration of CD59 has proved successful in a model of 
rheumatoid arthritis where membrane targeted CD59 decreased disease severity and 
in experimental nephritic syndrome antigen-targeting of CD59 to membranes proved 
protective (Fraser, Harris et al. 2003; He, Imai et al. 2005).
The fully active Crry-Fc reagent was made and tested in EAMG. The reagent was 
effective at protecting rats from this disease and 4SCR-Fc now needs to be tested in a 
chronic model of disease such as collagen-induced arthritis. Mice transgenic for 
Crry were protected from disease as were mice treated with an anti-C5 monoclonal 
antibody (Wang, Rollins et al. 1995; Banda, Kraus et al. 2003). Soluble CR1 was 
also protective against collagen-induced arthritis although the treatment was 
temporally limited by the immunogenicity of the reagent (Goodfellow, Williams et 
al. 2000). The use of Crry-Fc reagent in collagen-induced arthritis will address 
whether the reagent is effective in a chronic model of disease.
Longer term, human analogues of this reagent have to be considered. Crry is such a 
potent regulator of C as it possesses both decay acceleration activity and cofactor 
activity but it is not present in humans. The only human regulator to possess both 
decay accelerating and cofactor activities is CR1. The attachment of functional 
SCRs from CR1 to a human Fc may result in a human analogue of equivalent 
function. Another alternative is the generation of a DAF-MCP hybrid Fc fusion 
protein. Previously sDAF and sMCP have been produced but their function is
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reduced compared to sCRl (Christiansen, Milland et al. 1996). Generation of a 
hybrid DAF-MCP molecule with the reagents arranged C-terminus to C-terminus 
resulted in an increase of function as both decay acceleration and cofactor activity 
were present (Higgins, Ko et al. 1997). Previously a hybrid Fc fusion protein has 
been created with DAF on one arm and CD59 on the other, such technology could be 
employed to generate an Fc fusion protein containing DAF on one arm and MCP on 
the other as a human analogue of Crry-Fc (Harris, Williams et al. 2002).
7.4 Final conclusion
The role of C in a number of inflammatory diseases has been well established. As a 
result C has become a therapeutic target. A number of different anti-C therapeutics 
have been tested in in vivo models as well as in clinical trials. Amongst these 
approaches are small peptides, however, these are limited by their broad spectrum 
activities and short in vivo half-lives. While the problems of their broad spectrum 
activities can be overcome by further engineering to generate peptides with specific 
activities, their short circulating half-lives limit their use to acute conditions such as 
I/R injuries, haemodialysis and cardiopulmonary bypass. The most promising way 
of treating chronic conditions is with therapeutic antibodies, such as the anti-C5 
monoclonal antibody, or with soluble recombinant forms of the membrane 
regulators. Recent disappointing results in the treatment of myocardial infarction 
with the anti-C5 antibody have raised questions about its potential therapeutic 
efficacy in chronic conditions (Granger, Mahaffey et al. 2003; Mahaffey, Granger et 
al. 2003; Sheman, Fitch et al. 2004). The approach used in this study to engineering 
soluble recombinant membrane regulators to contain Fc domains or targeting 
domains offers the most promising method for treating chronic conditions. Here, one 
such reagent has demonstrated therapeutic efficacy in an acute disease model. 
Further studies to investigate the efficacy of such reagents in chronic disease models, 
as well as identifying the ideal regulator and targeting strategy will enable such 
therapeutics to reach the clinic.
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